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1.1 Introduction 
This chapter gives an outline of sex determination, sex differentiation, and gonadal 
development in mammalian species. In most studies described herein, rats and mice 
were used. 
During embryonal development in mammals, sex differentiation is preceded by a 
bipotential stage. Indifferent gonads are formed that can develop into eilher testes or 
ovaries. The anlagen of the male and female intemal genitalia, which are both present 
in embryos of either chromosomal sex, are called the wolffian and the mOlierian ducts, 
respectively. The extemal genitalia are bipotential (Fig.1). 
Male sex is determined in a subpopulation of somatic cells in the indifferent 
gonads. The presence of an intact Y chromosome initiates development of these cells 
along the male pathway. Further sex differentiation of the gonad into a testis is 
achieved via processes that involve cell-cell communication. All subsequent 
morphological differences between male and female eutherian mammals are 
hormonally regulated. The testis starts to synthesize two hormones that are essential 
for correct sex differentiation. The first hormone, anti-mOlierian hormone (AM H) 
induces degeneration of the mOlierian ducts. The second hormone, testosterone, 
stimulates development of the wolffian ducts into epididymides, vasa deferens and 
seminal vesicles. The testosterone metabolite dihydrotestosterone is essential for the 
development of the prostate and external genitalia from their respective primordia: 
urogenital sinus (prostate), genital tubercle (penis, urethra), and labioscrotal swellings 
(scrotum). 
In the female, ovary differentiation takes place in the absence of an intact Y 
chromosome, and, in the absence of AMH which is not produced by fetal ovaries, the 
mOlierian ducts develop into the fallopian tubes, the uterus and the upper part of the 
vagina. Moreover, in the virtual absence of testosterone, the wolffian ducts 
degenerate and the external genitalia develop along the female pathway. 
The above described processes, dependent on either the presence or absence 
of AMH and testosterone, are described in detail in the first part of this chapter. An 
overview of the regulatory mechanisms in the gonads by which these hormones act, 
is given in the second part of this chapter, followed by the scope of this thesis. 
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Fig. 1,1: Schematic representation of sexual differentiation of male and female internal genitalia during 
embtyonic development (from Wilson et a/. 1981). 
During the indifferent stage, the gonads and the anlagen of the male and female internal genitalia, the 
wolffian and mOllerian ducts, respectively, are formed, In the male embryo, the gonads develop info 
testes; the mOl/erian ducts degenerate, and the wolffian ducts develop into the epididymides, vasa 
deferens and semina! vesicles, In the female embryo, the indifferent gonads follow the ovarian 
differentiation pathway; the wolffian dUcts degenerate, and the mOl/erian ducts develop into the fallopian 
tubes, uterus and upper part of the vagina. 
3 
Chapter 1 
1.2. Sex determination and differentiation 
Many species exhibit an extensive range of dimorphic characteristics that 
distinguish the two sexes, when adult. Among different mammalian and non-
mammalian species, various mechanisms have evolved that control the switch that 
initiates either the male or the female sex differentiation pathway. The signal for sex 
determination that precedes sex differentiation is environmental (temperature) in some 
species such as reptiles (reviewed by Crews et al. 1994), but the signal is 
chromosomal in mammals (reviewed by Goodfellow and Lovell-Badge, 1993; and 
George and Wilson, 1994), and in many other animal species. In the well studied 
species Drosophila me/anogaster and Caenorhabditis e/egans, sex determination is 
controlled by the ratio of the number of X chromosomes to the number of sets of 
autosomes (reviewed by Hodgkin, 1985; Cline, 1993; and Parkhurst and Meneely, 
1994). This is referred to as the X:A ratio. The X:A ratio is counted in each individual 
cell of the developing organism. In the XX females, the ratio is 1, whereas the XV (D. 
me/anogastel) or XO (C. e/egans) males have an X:A ratio of 0.5 (for review see 
Parkhurst and Meneely, 1994). Sex determination in D. me/anogaster is coupled to 
the mechanism that regulates dosage compensation. Dosage compensation corrects 
for the fact that males have only one copy of X-chromosomal genes, whereas females 
have two copies, and is achieved by doubling the level of X-chromosomal gene 
expression in males. 
Mammalian sex determination depends upon the presence or absence of a V 
chromosome, irrespective of the number of X chromosomes. Dosage compensation, 
an earlier and seemingly independent event, is achieved by inactivation of one X 
chromosome in females. If, in the case of chromosomal aberrations, more X 
chromosomes are present in males or females, all but one X chromosome are 
inactivated. 
A single factor, encoded by the V chromosome, dominantly induces the 
formation of a testis from the indifferent gonad, which otherwise would develop into 
an ovary. This factor is called the testis determining factor (TDF) (reviewed by 
Goodfellow and Lovell-Badge, 1993; and Bogan and Page, 1994). 
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1.2.1 Genetic sex determination in mammals: TDF 
Identification of TDF 
The region on the human Y chromosome that encodes TDF was defined 
through extensive analysis and comparison of the sex chromosomes of XX males 
containing small fragments of the Y chromosome, and XY females lacking fragments 
of Y. Finally, a single gene, named SRY (sex determining region Y) in human (Berta 
et al. 1990; Sinclair et al. 1990) and Sry in mouse (Gubbay et al. 1990; Sinclair et al. 
1990), has been identified. Direct evidence that SRY/Sryis a primary sex determinant 
was obtained when the mouse Sry gene with its flanking sequences was shown to 
induce male sex differentiation, when introduced as a transgene into XX mouse 
embryos (Koopman et al. 1991). Furthermore, SRY point mutations have been 
detected in several human XY females (reviewed by GOOdfellow, 1993). 
SRY; structure and function 
SRYencodes a protein of the high mobility group (HMG) family of DNA binding 
proteins. This family of proteins is characterized by a so-called HMG box. The HMG 
box of SRY can bind DNA in a sequence specific manner, and is predicted to bend 
the target DNA to perhaps as much as 1300 (Nasrin et al. 1991; Giese et al. 1992; 
Harley et al. 1992). SRY binds also to cruciform DNA structures, but in a non 
sequence-specific manner (Ferrari et al. 1992). 
None of the SRY point mutations reported in human XY females is located 
outside the HMG domain (Goodfellow and Lovell-Badge, 1993). This indicates that 
the biochemical functions of SRY mainly reside in the HMG domain. However, the 
human SRY gene with flanking sequences is incapable of inducing sex-reversal when 
expressed as a transgene in XX mice, despite the similar DNA binding characteristics 
of SRY and Sry in vitro (Koopman et al. 1991; Goodfellow and Lovell-Badge, 1993). 
Outside the HMG domain, there is little sequence conservation among mammals. 
Thus, the significance of the amino acid sequences outside the HMG domain is still 
unclear. Also the exact mechanism of action of the SRY protein needs further 
investigation, to determine whether SRY can actually induce transcription, perhaps 
through interactions with cofactors. It remains possible that SRY acts solely by 
inducing a change in chromatin structure and/or combining distant DNA sequences, 
allowing other transcription factors to bind (Bogan and Page, 1994). 
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Sex determining genes other than SRY 
It is most likely that SRY function depends upon interactions with other 
aulosomal or X-chromosomal genes involved in sex determination. Indications for the 
existence of such downstream genes come from the finding that ovotestes in mice are 
formed when the Y chromosome from Mus musculus (ydOm) is placed onto the 
C578U6J (86) background (Eicher and Washburn, 1983). Genetic evidence indicates 
Ihat the interaction between tdydom and 86 autosomal or X-linked alleles involved in 
sex determination, may result in a delay of the onset of testis differentiation beyond 
a critical time point, allowing partial ovary differentiation to take place (Taketa et al. 
1991). It has been found that Ihe presence of a polymorphism of a CAG trinucleolide 
repeat in the SI}' gene on the ydom chromosome correlates with the 86ydom partial sex 
reversal (Coward et al. 1994). The functional significance of this finding remains to 
be established. 
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Fig. 1.2: Regulation of seX determinatfon and differentiation in mammals (mouse). 
The formaUon of the indifferent gonad depends on the action of at least two genes, Wilms' tumor locus-
I ('NT-I) and Ftz-FI (SF-I). In the male embtyos (upper part olthe ligure) a Single gene named Sty 
Is able to induce testis differentiation, and to prevent the activation of ovary determinIng genes. If Sry 
is not present, as is the case In female embryos (lower part of the figure), ovary determining genes are 
activated, such as the gene located on the X-chromosomal Dosage Sensitive Sex reversal locus (OSS), 
and a possible negative regulator of male sex differentiation (Z). All other aspects of sex differenUation 
are regulated by gonadal hormones. An increase in SF- 1 expression possibly results in a stimulation 
of AMH expression in the fetal SertoN cells of the testis. AMH subsequently induces mOllerian duct 
degeneration. The tesUcular Leydig cells start to synthesize testosterone, which stimulates the 
development of the wolman duct. In the developing ovary, SF·t expression decreases, and AMH is 
not expressed, allowing mOllerian duct development. The wolman duct degenerates, due to a lack of 
androgens. 
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In humans, certain chromosomal aberrations such as deletions (Bennett et al. 
1993; Wilkie et al. 1993) or reciprocal translocation (Tommerup et al. 1993) may lead 
to XY female development. One such an autosomal sex reversal locus, SRA 1, is 
associated with the skeletal malformation syndrome campomelic dysplasia (CMPD1). 
Recently, it has been shown that haploinsufficiency (deletion or mutation of only one 
allele) of the SRY-related gene SOX9, can cause both XY sex reversal and CMPD1 
(Wagner et al. 1994; Foster, 1994). It is thought that SOX9 acts very early in the sex 
determination pathway. Although nothing is known about the nature of the function 
of SOX9 in sex determination, it is suggested that gene dosage may be involved in 
the mechanism of sex reversal in the case of haploinsufficiency of SOX9 (Wagner et 
al. 1994; Foster, 1994). The dosage sensitivity of genes involved in sex determination 
may be a remnant of a primordial sex determination system, which has evolved into 
a dominant induction system, with Sry being the dominant inducer of the male 
phenotype (Foster, 1994; King et al. 1995). 
The female pathway of mammalian sex differentiation is considered the default 
pathway. Development of the indifferent gonad into an ovary takes place when 
SRY/Sry is absent. To date, no genes that are involved in the genetic cascade that 
leads to ovary differentiation in the female have been identified. Studies of XX male 
individuals that lack SRY have led to the hypothesis that these individuals carry a 
recessive autosomal mutation in a gene named Z (McElreavey et al. 1993). In 
females, this gene could normally act as a negative regulator of male sex 
determination, and expression of Zwould be repressed by SRY in males (McElreavey 
et al. 1993). Evidence for the existence of so-called ovary determining genes, comes 
from studies of several XY female patients with an intact SRY gene, carrying 
duplications of fragments of Xp (Bernstein et al. 1980; Scherer et al. 1989; Bardoni et 
al. 1994). Recently, it has been determined that a double active dosage of a locus at 
chromosome Xp21 is a cause of male to female sex reversal (Bardoni et al. 1994). 
This locus has been named DSS (Dosage Sensitive Sex reversal). 46,XY patients 
with deletions in this region have male external genitelia, suggesting that DSS is not 
required for testis differentiation. It is thought that in normal males, ovarian 
development and DSS function are repressed, thus allowing testis formation. 
Somehow, a double dosage of DSS in XY female patients hampers repression of the 
ovarian pathway, or activation of testis differentiation, although a normal SRY gene is 
present (Bardoni et al. 1994). Adjacent to, or overlapping with, DSS, a locus is 
mapped that is involved in adrenal gland development. Deletions in this region cause 
X-linked adrenal hypoplasia congenita (AHC) and also hypogonadotropic 
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hypogonadism (HHG). Mutations in a newly identified gene, called DAX-1 (for DSS-
AHC critical region on the X-chromosome, gene 1), give rise to both AHC and HHG 
(Zanaria et al. 1994; Muscatelli et al. 1994). Since this gene maps within the DSS 
critical interval, DAX-1 is also a candidate gene underlying DSS (Zanaria et al. 1994). 
DAX-1 encodes a new member of the nuclear hormone receptor superfamily, but 
displays a novel DNA-binding domain (Zanaria et al. 1994). 
1.2.2 Development of the indifferent gonads 
Morphological aspects 
The indifferent gonad develops along the ventral cranial part of the 
mesonephros, which is the second of the three consecutive nephric structures (pro-, 
meso-, and metanephros). The primordial germ cells are first detected in the 
extraembryonic mesoderm at 7.5 days of embryonic development (E7.5) (days post 
coitum) (Ginsberg et al. 1990). Later during embryonic development, these cells 
migrate from the yolk sac into the developing gonads (reviewed by Byskov and Hoyer, 
1994). The early nondifferentiated gonad consists of loose mesenchymal tissue, 
covered by the coelomic epithelium and supported by the developing mesonephric 
tissue (Byskov and Hoyer, 1994). 
Genetic aspects 
Before Sty can induce testis differentiation, genes common to both sexes have 
to regulate the formation of the indifferent gonad, and induce an intracellular 
environment in gonadal cells that allows the correct initiation of Sty expression. 
Two such genes have recently been identified. Gene targeting experiments in 
mice have shown that the Wilms' tumor associated gene (WT-I), and a locus that is 
called Ftz-FI that encodes steroidogenic factor 1 (SF-1; also called adrenal 4-binding 
protein, Ad4BP), are both essential for development of intermediate mesoderm and 
formation of indifferent gonads (Kreidberg et al. 1993; Luo et al. 1994). 
Targeted inactivating mutation of WT-I, resulted in a failure of kidney and 
gonad development. WT-1 is a tumor suppressor gene that encodes a transcription 
factor that has four (Cys),-(His), DNA-binding zinc fingers (Call et al. 1990). 
In Ftz-FI null animals, gonad development is arrested at a very early stage, and 
also the adrenal glands are absent (Luo et al. 1994). Furthermore, SF-1 regulates the 
expression of several genes involved in steroid hormone biosynthesis, that are 
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essential for sexual differentiation of the internal and external genitalia (Lala et al. 
1992; Honda et al. 1993; Shen et al. 1994) (see paragraph 1.1.4). SF-1 is an orphan 
nuclear receptor that shows the structural and functional characteristics of members 
of the steroid hormone receptor superfamily (see Chapter 2). 
Thus, both WT-1 and SF-I encode zinc-finger containing transcription factors 
that contribute to the establishment of the bipotential gonad. In the developing gonad 
of normal mouse embryos, the temporal and spatial expression patterns of these two 
genes overlap (Luo et al. 1994). However, it is not known whether WT-1 and SF-1 
functionally interacl. 
1.2.3 Gonadal sex determination and differentiation 
Differentiation of the gonadal cells 
The first morphological sign of testis differentiation in the rat is the formation of 
testicular cords at the end of E13 (Jost et al. 1973). Cord formation depends upon 
interactions between the fetal Sertoli cells and the precursors of the peritubular myoid 
cells (Buehr et al. 1993). The testicular cords contain the prespermatogonia (also 
called gonocytes) and the fetal Sertoli cells, which regulate and support 
spermatogenesis in the adult testis. Differentiation of the steroid producing Leydig 
cells, located in the interstitium, is induced around E14 in the rat (Tapanainen et al. 
1984). 
Mesenchymal tissue, located between the outermost testicular cords and the 
coelomic epithelium develops into the tunica albUginea. Furthermore, the testis 
becomes rounded, thus minimizing further contact with the mesonephros (Byskov, 
1986). 
In the female gonad, the absence of Sry leads to ovary differentiation, which 
becomes morphologically visible at E 16 in the rat, two days after testis formation is 
apparent in the male. The germ cells differentiate into oogonia that continue to divide 
mitotically. Subsequently, at E17.5 in the rat, meiosis is induced in cells that are 
located at the inner part of the cortex (Beaumont and Mandl, 1962). Many oocytes 
degenerate at different stages of meiosis, often in zygotene or pachytene. The 
oocytes become arrested in the diplotene stage of the prophase of meiosis I (dictyate). 
Then, folliculogenesis takes place, which depends upon the migration of mesonephros-
derived cells, which surround the centrally placed oocytes and differentiate into 
granulosa cells (reviewed by Hirschfield, 1991, and Byskov and Hoyer, 1994). 
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Granulosa cells and Sertoli cells share many structural and functional characteristics, 
which supports the notion of their common embryonic origin. However, it has not been 
unequivocally established whether mesonephros-derived cells and cells from the 
coelomic epithelium both contribute to granulosa and Sertoli cell formation. Possibly, 
granulosa and Sertoli cells are solely mesonephros-derived in certain species (Patek 
et al. 1991; reviewed by Byskov and Hoyer, 1994). Mesonephros-derived cells have 
been shown to contribute also to the interstitial mesenchymal cell population from 
which Leydig cells and peritubular myoid cells differentiate in the mouse (Buehr et al. 
1993). 
Timing of Sry expression 
Although genetic sex is set at fertilization, the first time point of Sry action that 
marks the onset of male sex determination and differentiation is not fully clear. Initial 
stUdies concerning the temporal mRNA expression pattern of Sry suggested that this 
gene is transcribed for only a very brief period starting at E10.5 in the mouse gonad, 
two days before testis formation becomes morphologically apparent (Koopman et al. 
1990). However, recent studies have detected Sry mRNA expression in the mouse 
preimplantation embryo (Zwingman et al. 1993). Whether this pre gonadal mRNA 
expression results in formation of functional protein remains to be established. After 
E12.5 in the mouse, Sry mRNA expression is detected only in the adult testis, in 
differentiating spermatids (Rossi et al. 1993). Most of this Sry mRNA is a circular 
transcript, and there is no evidence that it is actually translated into protein (Capel et 
al. 1993). 
Cellular localization of Sry action 
Since absence of germ cells from the indifferent gonad does not interfere with 
the formation of testis in XY individuals or ovaries in XX individuals (reviewed by 
Mclaren, 1991), sex determination must unfold in the somatic cell lineages of the 
gonad. Because Sry most likely functions in the cell nucleus, Sry is thought to act cell 
autonomously. Studies in chimeric XX/XV embryos have shown that in chimeras with 
testes, most, but not all, Sertoli cells are XV, whereas the proportions of XX and XY 
cells in the Leydig cell popUlation are similar to those seen outside the gonad. In 
chimeric embryos with ovaries, the granulosa cells were predominantly XX (>90%) 
(Patek et al. 1991). These results indicate that the initial steps that commit the gonad 
to male or female differentiation occur in the pre-Sertoli or -granulosa cells. However, 
cell-autonomous action of Sry must be supplemented by non-autonomous Sry-induced 
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factors, because some XX Sertoli cells and XV granulosa cells have been observed 
in chimeric gonads (Patek et al. 1991). Consequently, factors that are involved in cell-
to-cell communication must be expressed very early in the sex differentiation pathway 
of the gonad. 
1.2.4 Endocrine differentiation of the gonads 
The absence or presence of two fetal testicular hormones, AMH and testosterone, is 
essential for sex differentiation of all other internal genitelia, as well as the external 
genitalia. 
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linked (A). Plasmin cleavage between arginine 427 and serine 428 (Indicated by the small arrows) 
generates N· and C-terminal subunits of 110 and 25 kDa, that remain noncovafently associated (B). 
The actual location of the disulfide bonds and the sites of N- and C-terminaf interaction afe currently 
unknown, Acid·dlssociation generates the two separate subunits. Full bioactivity is obtained only 
when the cleaved subunits are associated, The C-terminus alone displays approximately 50% of the 
maximal bioactivity (e). 
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Structural and functional aspects of AMH 
AMH is the first known product secreted by fetal Sertoli cells (Tran and Josso, 1982), 
and was identified as a member of the activinfTGFp family of peptide growth and 
differentiation factors (Cate et al. 1986; Haqq et al. 1992) (see also Paragraph 1.2.3 
and Chapter 2). In general, most members of this family are synthesized as large 
precursor molecules that form homodimers or heterodimers (Massague, 1990). Each 
chain of the dimer is cleaved at approximately 110 amino acids from the C-terminus, 
generating the mature growth factor (the C-terminal subunit) and an N-terminal product 
(Massague, 1990). AMH is a 140 kDa dimeric glycoprotein, which can be cleaved by 
plasmin to generate a 110 kDa N-terminal and a 25 kDa C-terminal subunit (Pepinsky 
et al. 1988). The C-terminal domain alone is biologically active. However, AMH 
differs from the other family members in that the N-terminus can potentiate the activity 
of the C-terminal domain, and appears to be required in order to obtain full bioactivity 
of AMH (Wilson et al. 1993) (see Fig. 3). The N-terminus possibly plays a role in 
maintaining the proper conformation of the C-terminus of AMH, and in preventing the 
formation of inactive aggregated C-termini (Wilson et al. 1993). Unlike AMH, 
reassociation of the N- and C-terminal domains of TGFp results in latency, 
characterized by the inability of the C-terminus to bind to its receptor (Gentry and 
Nash, 1990). 
Regulation of AMH expression during sex differentiation 
It has been suggested that Sry directly regulates AMH expression through 
binding to the AMH gene promoter (Haqq et al. 1993). However, recent results (Shen 
et al. 1994; Haqq et al. 1994) indicate that Sry dependent activation of the AMH gene 
promoter is indirect. Shen et al. (1994) and Hatano et al. (1994) suggest that the 
expression of AMH is regulated by SF-1. This hypothesis is based on the observation 
that, after formation of the indifferent gonad, SF-1 expression decreases in the female 
and increases in the developing testis, which correlates with the absence of AMH from 
the fetal ovary and the onset and increase of AMH production by the testis (Shen et 
al. 1994; Ikeda et al. 1994). Indeed it has been shown that SF-1 binds to a conserved 
element in the AMH gene promoter (Hatano et al. 1994; Shen et al. 1994). 
Furthermore, activation of the AMH promoter in 15-day-old rat Sertoli cells in vitro 
required an intact SF-1 binding site (Shen et al. 1994). In order to stimulate AMH 
transcription, SF-1 most likely needs to be activated by an as yet unknown cofactor 
or ligand (Shen et al. 1994). This agrees very well with the structural similarity of SF-1 
with members of the steroid hormone receptor family. Whether SF-1 actually 
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regulates AMH gene expression during sex differentiation remains a matter of debate, 
since in an in vitro assay system, in which Sry dependent transcription from the AMH 
gene promoter was operative, SF-1 acted as a transcriptional repressor (Haqq et al. 
1994). 
Regulation of testosterone synthesis during sex differentiation. 
The other important testicular hormone, the steroid hormone testosterone, is 
synthesized by developing Leydig cells of the fetal testis. Several steroidogenic 
enzymes are involved in the steps that lead to the conversion of cholesterol into 
testosterone (see FigA). These enzymes are present in both male and female 
gonads. However, differences in the activity of only a few enzymes leads to 
testosterone synthesis in the male and estrogen synthesis in the female gonad. In the 
testis, the activity of 3~ hydroxysteroid dehydrogenase activity (3~-HSD) increases, 
whereas in the ovary the aromatase activity increases (Wilson et al. 1981). This 
regulation can occur In vitro, independently of exogenous hormones or growth factors, 
in steroidogenic cells from rabbit testes (George et al. 1978; George and Wilson, 
1980). SF-1 binding sites are present in the promoters of the genes encoding several 
steroidogenic enzymes, including P-450scc, P-450c17 and P-450 aromatase (Lala et 
al. 1992; Morohashi et al. 1992; Honda et al. 1993; Lynch et al. 1993). This implies 
that SF-1 may be involved not only in the regulation of AMH expression, but also in 
the regulation of expression of steroidogenic enzymes. The fetal production of 
testosterone reaches its maximum in rats at E18.5-E19.5, followed by a gradual 
decline (Warren et al. 1975). 
Regulation and functions of the androgen receptor 
Testosterone acts via the androgen receptor, a member of the steroid hormone 
receptor family (see also Chapter 2). The androgen receptor is a nuclear protein that 
specifically binds testosterone and dihydrotestosterone. After binding the ligand, the 
androgen receptor can regulate gene transcription through binding to an androgen 
response element (ARE) in the promoter of androgen regulated genes. The androgen 
receptor is involved in the regulation of many processes. Its function is crucial for the 
development and maintenance of internal and external sex organs. 
Testosterone can down-regulate transcription of the gene encoding its own 
receptor in a number of tissues, including ventral prostate, kidney, epididymis, brain 
and coagulating gland (Shan et al. 1990; Quarmby et al. 1990; Blok et al. 1992a). 
However, in cultured immature Sertoli cells, testosterone did not affect androgen 
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receptor mRNA levels, whereas FSH stimulated androgen receptor expression 
(Verhoeven and Cailleau, 1988; Siok et al. 1989; Siok et al. 1992b). Testosterone 
deprivation in vivo resulted in up-regulation of testicular androgen receptor mRNA 
expression in one case (Sanborn et al. 1991), but no effect was observed in another 
study (Slok et al. 1992a). Thus, it is not clear whether downregulation of androgen 
receptor mRNA expression by androgens is operative in the testis. 
Although it has been shown for many genes that their expression is up- or 
down regulated by androgens, it has been proven for only a few genes that this 
regulation is directly at the level of gene transcription (Riegman et al. 1991; Celis et 
al. 1993; Murtha et al. 1993; Rennie et al. 1993). Since primary androgen responsive 
genes in the testis have not been described, little is known about the mechanism by 
which testosterone exerts its effects on testicular functions. 
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Fig, 1.4: Regulation of testosterone and estrogen synthesis during sex differenUalion. 
Four different enzymes are necessary to convert cholesterol into testosterone. One additional enzyme, 
aromatase, converts testosterone into estradiol. The enzymes of which it is known that the gene 
transcription Is regulated by SF·! are underlined, It Is presently unknown whether 3f3-HSD and 17P-
HSD are also regulated by SF-to In male embryos the activity of 3f3-HSD in the testis Increases during 
sex differentiation (indicated by d'), whereas in the fetal ovary, aromatase activity increases (indicated 
by ~). 
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Possible functions of AMH and testosterone in testis differentiation 
AMH and testosterone are not essential for the differentiation of the testis itself. 
Mutations in the gene that encodes AMH in humans result in a phenotype that is 
characterized by the presence of a uterus and fallopian tubes in otherwise normally 
virilized males, a syndrome known as persistent mOlierian duct syndrome (PMDS) 
(Josso et al. 1991; Josso et al. 1993; Imbeaud et al. 1994). The testes develop 
normally in these patients, but do not descent, resulting in infertility, which precludes 
conclusions about the role of AMH in spermatogenesis (see also Chapter 2). 
Similarly, mutations that disrupt the function of the androgen receptor in mice or man 
do not affect testis formation (Griffin and Wilson, 1989), and androgens cannot induce 
the formation of testicular tissue in differentiating ovaries during embryonic 
development (Jost, 1947a). 
Contrary to the implications of these observations, there are some experimental 
results that indicate that AMH may perform certain functions during testis 
development. AMH can induce the formation of testis cord-like structures and 
endocrine sex reversal in ovaries cultured in vitro (Vigier et al. 1987; Vigier et al. 
1989). Similarly, when AMH is ectopically expressed as a transgene in female 
embryos, testis cord-like structures occur in the developing ovaries (Behringer et al. 
1990). Furthermore, in male mice that express extremely high levels of AMH, Leydig 
cell function is impaired (Behringer et al. 1990), and in the opposite situation, in AMH 
knock-out male mice, Leydig cell hyperplasia is observed (Behringer et al. 1994). 
Possible role of estrogen in sex differentiation 
In reptiles and birds, aromatase activity, and hence the level of estrogens, is 
a critical determinant in the regulation of gonadal sex differentiation (Elbrecht and 
Smith, 1992; Crews et al. 1994). In the mouse, estrogen receptors are present in 
male and female gonads throughout gonadal sex differentiation (Greco et al. 1993). 
Furthermore, fetal rat ovaries and testes can produce estrogens in vitro after 
gonadotropic stimulation (Weniger et al. 1993a; Weniger et al. 1993b). On the other 
hand, estrogen receptor (ER) knock-out mice show no abnormalities with respect to 
gonadal sex determination and differentiation (Lubahn et al. 1993). This may indicate 
that estrogens are not essential for correct gonadal sex differentiation. The fact that 
residual estrogen binding, to about 5% of the normal level and with normal binding 
affinity, could be detected in the ER-disrupted animals (Lubahn et al. 1993) implies 
that some reservation should be made. However, recent results suggest that this 
binding is due to either the presence of a non-ER estrogen-binding protein, or an 
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altered protein product transcribed from the disrupted ER gene that is biologically 
inactive (Korach, 1994). 
1.2.5 The roles of AMH and testosterone In sexual differentiation of the genital 
ducts 
The wolffian and the mOlierian ducts are the anlagen of respectively the male 
and female reproductive tracts, but are present in the embryos of either sex. The 
wolffian duct is the excretory duct of the mesonephros. The mOlierian duct, also called 
the paramesonephric duct, develops around E14 in the rat (Trelstad et al. 1982), as 
an invagination of the coelomic epithelium that starts lateral to the cranial end of the 
wolffian duct and develops in a cranial caudal direction along this duct (Byskov and 
Hoyer, 1994). 
The wolffian ducts 
The wolffian ducts become dependent on testosterone during the period immediately 
after gonadal sex differentiation. Further development of the wolffian ducts into 
epidydimides, vasa deferens and seminal vesicles is controlled by testosterone (Jost, 
1947b; Jost, 1947a; Josso, 1970), although some action of dihydrotestosterone cannot 
be excluded (Tsuji et al. 1991; Tsuji et al. 1994). Initially, the mesenchymal cells 
surrounding the wolffian ducts are the testosterone target cells. During later stages 
of wolffian duct development, the epithelial cells also start expressing the androgen 
receptor (Cooke et al. 1991). This indicates the importance of mesenchymal/epithelial 
interactions during differentiation of the wolffian ducts (Cunha and Lung, 1979). In the 
female, the wolffian ducts regress due to the absence of testosterone. 
The mOl/erian ducts 
The mOlierian ducts are sensitive to the degenerative action of AMH during a 
critical period that comprises E14.5-E15.5 in the rat (Picon, 1969; Donahoe et al. 
1977; Tsuji et al. 1992). The first morphologic change that marks the beginning of 
mOlierian duct regression, is the dissolution of the basement membrane that separates 
the epithelial cells, which form the actual duct, from the surrounding mesenchymal 
cells. Subsequently, contacts between the mesenchymal cells and the epithelial cells 
are frequently observed (Trelstad et al. 1982). Migration of both cell types takes 
place, which finally results in the formation of a circular whorl of cells at E 16 in the rat 
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(Trelstad et al. 1982). Although some cells die during this process, mOlierian duct 
degeneration seems to involve reorganization and functional changes of cells rather 
than programmed cell death (Trelstad et al. 1982). In analogy to the actions of 
testosterone on the wolff ian ducts, AMH seems to act on the mOlierian ducts via the 
mesenchymal cells that surround the ducts, rather than acting directly on the epithelial 
cells themselves. Evidence in support of this hypothesis comes from experiments on 
isolated epithelial and mesenchymal cells during mOlierian duct regression in the rat 
(Tsuji et al. 1992). Using cells isolated from E15.5 fetuses, it was shown that AMH 
could reduce [3H]-thymidine incorporation by mOlierian duct mesenchymal cells, but 
not by epithelial cells (Tsuji et al. 1992). 
If exposure of explanted rat mOlierian ducts to AMH in vitro is delayed until after 
E 15.5, mOlierian duct regression does not occur (Picon, 1969; Donahoe et al. 1977; 
Tsuji et al. 1992). However, AMH induced the formation of linear bulges in the 
mOlierian duct of urogenital ridges isolated from 17.5 to 18.5-day-old rat fetuses. This 
indicates that the mOlierian ducts can still respond to AMH after the critical period, 
albeit in a different way (Tsuji et al. 1992). 
In the female, the mOlierian ducts develop into the fallopian tubes, the uterus 
and the upper part of the vagina. Early development and growth of the mOlierian 
ducts are generally considered to occur autonomously (Jost, 1953; Lubahn et al. 1993; 
Byskov and Hoyer, 1994). 
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1.3 Gonad development and function 
1.3.1 Testis development 
Development of the testicular cell types 
The neonatal testis consists of seminiferous tubules in which the 
prespermatogonia and Sertoli cells are located, and an intertubular space with Leydig 
cells and blood vessels. A basal membrane is located between the Sertoli cells and 
the peritubular myoid cells surrounding the tubules. The fetal and neonatal Leydig cell 
population differs from the adult Leydig cells in several aspects, illustrated by a much 
higher steroidogenic capacity of the fetal testis, which is important for the androgen 
dependent genital differentiation (Huhtaniemi et al. 1982; Tapanainen et al. 1984; 
Huhtaniemi, 1994). Fetal Sertoli cells divide rapidly, with their highest proliferative 
activity occurring on E16 in the mouse, followed by a gradual decline (Vergouwen et 
al. 1991). The Sertoli cells stop dividing around postnatal day 15 in the rat (van 
Haaster et al. 1992). A Sertoli cell can only support the development of a limited 
number of germ cells. Thus it is the number of Sertoli cells that is present at day 15 
that determines the maximal output of sperm during adult life, and hence the final 
testis size (Orth et al. 1988; reviewed by Sharpe 1994). Sertoli cell maturation is 
characterized by a number of biochemical and morphological changes. A marked 
structural change is the formation of tight junctional complexes between adjacent 
Sertoli cells, which results in the formation of the so-called blood-testis barrier. Thus, 
a separated inner part of the testicular tubules is formed (the adluminal compartment) 
in which the meiotic and postmeiotic development of the germ cells takes place. 
Formation of the blood-testis barrier and cessation of Sertoli cell divisions occur more 
or less coincident (Russell et al. 1989). 
The prespermatogonia have undergone series of mitotic divisions until E18 in 
the rat after which they enter a phase of mitotic arrest (Byskov and Hoyer, 1994). 
Between postnatal days 3 and 8 in the rat, reinitiation of prespermatogonia divisions 
marks the onset of the first wave of spermatogenesis (van Haaster and de Rooij, 
1994). Subsequently, the first germ cells enter the prophase of meiosis and are 
translocated to the just formed adluminal compartment when they are in the 
pre leptotene stage. The complete process of spermatogenesis, from undifferentiated 
spermatogonia into spermatocytes, that undergo two meiotic divisions, followed by the 
development of the haploid spermatids into mature sperm, culminates in the release 
of the first spermatozoa into the tubular lumen around day 45 in the rat (Clermont and 
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Perey, 1957). 
The spermatogenic cycle 
The location of all spermatogenic cell types within the seminiferous epithelium 
of the adult rat is highly organized. A single Sertoli cell is always associated with one 
of fourteen defined sets of spermatogenic cells. The regular occurrence of these 
fourteen cell associations is called the spermatogenic cycle. In the adult rat, waves 
of differentiating spermatogonia enter the cycle at regular time intervals (see Fig 1.5). 
II 111 IV V VI VII VIII IX X XI XII XIII XIV 
STAGES OF THE CYCLE 
Fig. 1.5: Germ cell associaUons at the different stages of the spermatogenic cycle In the rat (adapted 
from Sharpe, 1994). 
Each vertical column or stage describes the fixed complement of germ cells associated with Sertoli cells 
at that particular stage, with the rumen of the tubule to the top and the basement membrane to the 
bottom of the diagram. Each Stage of the cycle fasts for a fixed period of time. A single germ cell 
goes through each step of spermatogenic development from fefl to right and bottom to top through the 
diagram until it reaches Step 19 of spermatid development at Stage VIII and is released as mature 
sperm. Thus, each germ cell from A, passes through the cycle 4.5 times before it is released. The 
complete process of spermatogenesis can be divided into phases based on the major developmental 
events that occur. A"A,21A3JA4: spermatogonia type A; In: intermediate spermatogonia; B 
spermatogonia type B; PL: preleptotene spermatocytes; L: leptotene spermatocytes; P: pachytene 
spermatocytes; 01: diplotene spermatocytes; II: secondary spermatocyte undergoing meiotic division 
II; 1-19: steps of spermatid differentiation. Note: The undifferentiated spermatogonia are not 
represented in this diagram. The undifferentiated spermatogonia are named according to their 
topographical arrangement in the seminiferous tubules. Clones of one cell are named As,hg!(I (AJ, two 
cells Apa:re<j (Apr), and four or more cells AlI1,gned (AaJ. The As cells are the stem cells of spermatogenesIs 
and are present during aft stages of the cycle. Stem cell renewal and differentiation take place in a 
cyclic manner. A period of active proliferation spans Stages X-II, whereas during Stages III-IX the 
stem cell proliferation is inhibited and the All! enter the spermatogenic cyefe as spermatogonia type A 1 
during Stage VII (Huckins, 1971). 
Hormonal regulation of testis development and function 
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FSH and LH are the most important regulators during prepubertal testis 
development. LH stimulates Leydig cell development and steroidogenesis, while FSH 
stimulates the proliferation of Sertoli cells and also regulates Sertoli cell maturation 
(reviewed by Sharpe, 1994). Leydig cell development and Sertoli cell development are 
interactive processes. FSH receptor binding can be detected at E17.5 in the rat, and 
increases parallel to the degree of testicular growth, indicating that the number of FSH 
receptors per Sertoli cell is relatively constant (Warren et al. 1984). 
Leydig cells secrete large amounts of testosterone around the time of birth, 
followed by a rapid decrease which is due to changes in the steroidogenic pathway 
(Warren et al. 1984; Huhtaniemi, 1994). Full length mRNA encoding the LH receptor 
can be detected from E16 in the rat (Zhang et al. 1994). However, it is thought that 
the peak of testosterone synthesis in the rat during fetal/early postnatal life is not 
caused by LH, since levels of LH in the rat are too low during this period (Huhtaniemi, 
1994). The level of LH receptor mRNA expression is maximal at E21.5 and decreases 
after birth (Zhang et al. 1994). 
After an initial decline in testosterone synthesis shortly after birth, the levels of 
testosterone rise again around puberty, resulting in high adult levels (Podesta and 
Rivarola, 1974). Testosterone is absolutely required for maintenance of 
spermatogenesis (reviewed by Sharpe, 1994), but no androgen receptor, essential for 
testosterone action, is expressed in the spermatogenic cells of the testis (Grootegoed 
et al. 1977; Buzek and Sanborn, 1988; Bremner et al. 1994). Therefore, testosterone 
must exert its effects through the androgen receptor positive peritubular myoid cells 
and Sertoli cells. There is an increase in testicular androgen receptor levels during 
sexual maturation in the rat (Buzek and Sanbom, 1988). This increase may be partly 
caused by FSH, which has been shown to up-regulate androgen receptor expression 
in immature Sertoli cells in vitro (Verhoeven and Cailleau, 1988; Blok et al. 1989; Blok 
et al. 1992b). Total testis androgen receptor mRNA expression (per given amount of 
total RNA) decreases from postnatal day 26 onwards, but this is most likely due to the 
increasing amount of androgen receptor negative germ cells (Lubahn et al. 1988). 
The role of FSH in adult male animals is not clear, and seems to be species 
dependent. In the rat, conflicting results have been reported. On the one hand, there 
is an age dependent decline in responsiveness of Sertoli cells to FSH in terms of 
secretion of several FSH regulated proteins, which appears to result from an increased 
activity of cAMP phosphodiesterase activity (Rilzen et al. 1989). On the other hand, 
studies using hypophysectomized rats substituted with FSH and/or androgen, indicate 
that the combination of the two hormones is necessary to maintain normal testicular 
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weight (Bartlett et al. 1989). Also, in Sertoli cells isolated from 20-day-old rat testis 
and adult testis, similar levels of FSH receptor mRNA are detected (Heckert and 
Griswold, 1991). Furthermore, the expression in adult Sertoli cells of both FSH 
receptor and cAMP phosphodiesterase is strictly regulated during the spermatogenic 
cycle (Kangasniemi et al. 1990; Heckert and Griswold, 1991; PalVinen, 1993). The 
highest responsiveness of Sertoli cells to FSH during Stages XIV to VI (PalVinen, 
1993) of the spermatogenic cycle, is consistent with the hypothesis that FSH plays a 
role in the regulation of sUlVival of differentiated spermatogonia that undergo the last 
four mitotic divisions during this period (Sharpe, 1994). 
1.3.2 Ovary development 
Follicle growth 
Primordial follicles, which are all formed around birth in the rat, consist of an oocyte 
surrounded by a single layer of pregranulosa cells, that form the precursors of the 
granulosa cells that will finally populate the follicle. From the pool of primordial 
follicles, groups of follicles will enter the growing phase throughout life. The 
pregranulosa cells that surround the oocyte in the primordial follicle cease to divide 
and enter a period of quiescence. Theca cells are not immediately obselVed, but 
differentiate during early stages of follicle growth in the rat and arise from the 
undifferentiated mesenchymal interstitial cells throughout reproductive life (reviewed 
by Hirschfield, 1991). 
Each follicle that begins to grow either goes on to OVUlate or degenerates, a 
process which is called atresia. Follicular atresia can occur at all stages of follicle 
development (Fig. 6A). When follicle growth is initiated, the oocyte, still arrested in the 
late prophase of meiosis I (dictyate), grows rapidly in size. The granulosa cells of 
these small preantral follicles (Fig. 1.6A) proliferate extensively, also after the oocyte 
has ceased to grow. A basement membrane separates the granulosa cells on the 
inside from the theca interna (steroidogenic cells) and theca externa (connective tissue 
cells) outside. During the following phase of growth, fluid-filled spaces appear 
between the granulosa cells, eventually merging into a single large antral cavity; these 
follicles are called antral follicles (Fig 1.6A) (reviewed by Hirschfield (1991), and 
Byskov and Hoyer, 1994). The complete process of follicle development from a small 
preantral follicle into a preovulatory follicle takes approximately 15-17 days (Hage et 
al. 1978). During the final steps of follicle differentiation (follicle maturation), the 
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granulosa and theca cells diHerentiate further and the antral cavity enlarges. After the 
LH surge, resumption of oocyte-meiosis takes place (oocyte meiotic maturation), 
resulting in formation of the first polar body and arrest of meiosis in metaphase II. 
Then, ovulation occurs. 
The estrous cycle 
In the adult rat, the surge of FSH at estrus stimulates a group of preantral follicles to 
become antral. Subsequently, 12-14 of these follicles are selected, reach the 
preovulatory size, and ovulation is induced by the LH surge at proestrus. This 
process, which is called the estrous cycle, repeats every 4-5 days depending on the 
strain. After ovulation the remaining follicle luteinizes and develops into a corpus 
luteum. The corpus luteum will degenerate after 4-5 days unless the ovum is 
fertilized; then the corpus luteum is rescued from luteolysis. 
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A) Schematic representation of hormone concentrations in serum during the rat estrous cycle. E: 
Estrus; M: Metestrus,' 01;02: Diestrus 1 and 2; Pr; Proestrus. 
B) (next page) Schematic illuslration 01 lolliculardevelopmenl and alresia (adapled Irom Findlay (/994). 
The amount of primordial folNcles ;s set during the first days of postnatal development when follicle 
formation fakes place. Primordial follicles consist of an oocyte surrounded by a single layer of 
pregranulosa cells. Once follicle growth is initiated, the committed follicles either go on to ovulate or 
become atretic. In a committed follicle, the oocyte grows rapidly, and the granulosa cells proliferate 
extensively. These follicles are surrounded by a basement membrane and a theca cell layer. Small 
antra! follicles develop fluid-filled spaces between the granulosa cells, and they become responsIve to 
gonadotropins, and large antral follic/es are gonadotropin dependent. The preovulatory follicles are 
mature and ovulate in response to the LH surge. Atresia can take place during all steps of follicle 
development. The highest rate of atresia occurs In the populaUon of large antral follicles. 
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Primordial follicles 
Committed follicles 
Smalillarge antral follicles 
Pre-ovulatory follicles 
Ovulation 
Hormonal regulation of ovaty development and function 
During the prepubertal period, follicle growth occurs, but this does not lead to 
formation of mature preovulatory follicles, and the follicles slowly degenerate_ 
Ovulation does not occur until after the first LH surge (35-45 days after birth, reviewed 
by Ojeda and Urbanski, 1994)_ During the prepubertal period, establishment of the 
hypothalamus-pituitary-gonad axis takes place, and negative and positive feedback 
mechanisms develop_ 
The level of circulating FSH in the rat increases after birth to a maximal value 
at day 12, after which there is a gradual decline (Ojeda and Ramirez, 1972; 
Meijs-Roelofs et al. 1973)_ Also LH levels are higher during the first two weeks of 
postnatal development than during later phases of prepubertal development (Ojeda 
and Ramirez, 1972; Meijs-Roelofs et al. 1973)_ Binding of FSH and LH to their 
respective receptors cannot be detected until postnatal day 7 in the rat (Smith-White 
and Ojeda, 1981; Sokka et al. 1992)_ During the second week of postnatal ovary 
development their is an increase in sensitivity of the growing follicles to FSH and LH 
which is illustrated by a concomitant increase in gonadotropin receptor numbers 
(Smith-White and Ojeda, 1981; Uilenbroek and van der Linden, 1983; Sokka and 
Huhtaniemi, 1990)_ In the female, granulosa cells specifically express FSH receptors 
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(like Sertoli cells in the male). LH receptors are expressed by theca cells and, during 
the final phases of follicle development, also by granulosa cells (Zeleznik et al. 1974). 
The initiation of follicular growth does not depend on gonadotropins, FSH is required 
for continued follicle growth and development (reviewed by Hirschfield, 1991). 
In the adult cycling female rat, the elevated level of FSH at estrus stimulates 
growth and differentiation of the granulosa cells. FSH induces aromatase activity 
(Dorrington et al. 1975; Fitzpatrick and Richards, 1991) and LH receptors (Piquette et 
al. 1991) in granulosa cells of maturing follicles. An important functional characteristic 
of these follicles is the increased output of estrogens. The theca cells are stimulated 
by LH to produce androgens. In granulosa cells, these androgens are subsequently 
converted to estrogens by aromatase. This is known as the "two-cell, two-
gonadotropin" model (reviewed by Hillier et al. 1994). FSH secretion is decreased by 
the increased estrogen output and also by inhibin, a member of the activinrrGFp 
family of growth/differentiation factors (see also Paragraph 1.2.3). The decrease in 
FSH secretion results in atresia of large follicles that are in less than optimal condition, 
and thus in selection of follicles that can reach the final stages of follicle maturation 
and will OVUlate at estrus. The high estrogen levels eventually elicit the FSH and LH 
surges (Fig. 1.6B) that result in ovulation and subsequent luteinization of the remaining 
follicle (positive feedback mechanism). A secondary FSH surge starting at early estrus 
recruits follicles that will undergo the final stages of follicle maturation in the next cycle. 
Estrogens are not only important as a feedback regulator, but are thought to act as 
an autocrine/paracrine factor as well. For example, estrogens have been reported to 
stimulate granulosa cell proliferation and to prevent follicular atresia (reviewed by 
Hirshfield, 1991). 
1.3.3 local regulatory actions In the gonads 
During the last decade, it has become more and more obvious that besides 
gonadotropins and steroids, local growth factors also play important roles in the 
regulation of gonadal functions. Many different growth factors have been reported to 
be locally expressed, and/or to have effects upon gonadal functions. These include 
fibroblast growth factors, transforming growth factor-a, insulin-like growth factors I and 
II, nerve growth factor, interleukins, and members of the activinrrGF-p family of 
growth/differentiation factors (reviewed by Adashi et aI., 1991; Lamb, 1993; 
Spiterigrech and Nieschlag, 1993; Findlay, 1993 and 1994; and Tsafriri and Adashi 
24 
Introduction 
1994). 
In general, the actions of growth factors may nol be as marked as the effects 
of gonadotropins and steroid hormones. In many cases, their major role seems to be 
local fine-tuning of hormone action. Several features, inherent to local regulatory 
mechanisms, complicate the assignment of specific gonadal functions to a certain 
growth factor. First, these factors often function in many extragonadal processes that 
are essential for the overall viability of the organism, thus making it impossible to study 
the effect of their absence. Second, if the absence of a factor is not lethal, 
redundancy phenomena may hide the physiologic function of that factor, for example 
in gene knock-out experiments (Shastry, 1994). Third, species-specific effects and/or 
species-specific expression patterns of growth factors may preclude the development 
of general hypotheses. Finally, the interpretation of in vitro experiments that address 
the effects of exogenously added growth factors, may be complicated if these factors 
are also produced by the isolated cell types or tissues in culture; local production may 
result in high local levels. Thus, although many results on expression and effects of 
growth factors have been reported, liltle progress has been made concerning their 
actual functions in vivo. This paragraph focusses on the available data concerning the 
gonadal expression and effects of some members of the activinlTGFp family of growth 
factors. The existing concepts on their in vivo actions in the gonads will be described. 
TGFJ3s 
The synthesis and effects of the three known mammalian TGFps (TGFp1, 
TGFp2 and TGFP3) in the gonads vary depending on the species (reviewed by 
Benahmed et aI., 1993). It is not known whether the different TGFps each perform 
specific functions, or whether their functions overlap. Many cell types in the rat ovary 
and testis have been reported to express protein or mRNA representing one or more 
of the TGFps (Skinner and Moses, 1989; Mullaney et al. 1991; Benahmed et al. 1993; 
Schmid et al. 1994; Gautier et al. 1994). Gonadotropins most likely control TGFp 
expression in their target cells (Benahmed et al. 1993; Mullaney and Skinner, 1993). 
During the estrous cycle in the ovary, interstitial cell TGFp production varies liltle, 
whereas the granulosa cells start expressing TGFp 1 and 2 at the preovulatory stage 
of follicle development (Teerds and Dorrington, 1992). Mullaney and Skinner (1993) 
report marked changes in the TGFp expression patterns in the somatic cells of the 
testis around puberty. During adult spermatogenesis, there are different levels of 
TGFp expression also in spermatogenic cell types (Teerds and Dorrington, 1993). 
Receptors for TGFp have recently been cloned (see Chapter 2). However, liltle 
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is known about their expression in the gonads. TGFp type II receptor mRNA has been 
detected mainly in the theca cells of preantral and antral follicles of the mouse ovary 
(Schmid et al. 1994), and in the peritubular myoid cells of the rat testis, with much 
lower levels in the other somatic cell types, and being not detectable in spermatogenic 
cells (Le Magueresse et al. 1994). TGFp type III receptor is expressed in all testicular 
cell types. In addition, spermatogenic cells express high levels of an abberrant mRNA 
of 3.5 kb (Le Magueresse et al. 1994). 
All these expression data have not led to a comprehensive model that fits all 
the effects of TGFp in a general mechanism by which TGFp might influence the 
regulation of gonadal functions. It is clear that most forms of TGFp are locally 
synthesized in the gonads. Also, TGFp can regulate important functions of most 
gonadal cell types in vitro (Hutchinson et al. 1987; Morera et al. 1988; Skinner and 
Moses, 1989; Hernandez et al. 1990; Dorrington et al. 1993; Hakovirta et al. 1993). 
Yet, it is not clear whether these actions are important in vivo. 
A step towards the development of a general concept was made by Dorrington 
et al. (1993), who have proposed that FSH, estradiol and TGFp positively interact to 
stimulate cell proliferation and differentiation, both in granulosa and Sertoli cells. In this 
model, TGFp is thought to mediate the stimulatory actions of estradiol. 
AMH 
AMH is one of the very few factors whose functions during postnatal development are 
most likely restricted to the gonads (see also Chapter 7). In females, AMH is 
synthesized only by the granulosa cells of preantral and antral follicles, but not by 
large preovulatory follicles, in rat (Hi robe et al. 1994) and mouse (MOnsterberg and 
Lovell-Badge, 1991; Hirobe et al. 1992) (see also Chapter 4). In males, the Sertoli 
cells specifically express AMH, of which the level decreases after birth, but low levels 
of AMH mRNA can be detected throughout adult life in various species (Kuroda et al. 
1990; Baker et al. 1990; Lee et al. 1992; Lee et al. 1994) (see also Chapter 5). No 
convincing binding data of AMH to potential target cells in the gonads have been 
reported (see also Chapters 3 and 7). Several effects of AMH on gonadal cell 
functions have been described. AMH represses the biosynthesis of aromatase, 
decreases the number of LH receptors (di Clemente et al. 1994), and opposes 
induction of progesterone biosynthesis by epidermal growth factor, in granulosa cells 
from several species (Kim et al. 1992). It has also been reported that bovine AMH 
can inhibit meiotic maturation of both denuded and cumulus-enclosed rat oocytes in 
vitro (Takahashi et al. 1986). However, Tsafriri et al. (1988) have not been able to 
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reproduce these results. In the male, AMH has been postulated to cause mitotic 
arrest of prespermatogonia (MOnsterberg and Lovell-Badge, 1991). This hypothesis 
is based on prenatal and neonatal expression of AMH, which is high around the time 
of mitotic arrest and decreases during the first 2-3 weeks in rat and mouse, 
concomitant with the first wave of spermatogenesis (Kuroda et al. 1990; MOnsterberg 
and Lovell-Badge, 1991). Also, there is a strong correlation between germ cell arrest 
at the prespermatogonia stage and the expression of AMH in adjacent somatic cells 
in the ovotestis of B6ydom mice (Taketo et al. 1991). However, results from in vitro 
culture experiments of neonatal mouse testes in the presence or absence of AMH, 
showed no inhibitory effects of AMH on spermatogonial numbers, but instead indicated 
that differentiation of prespermatogonia into spermatogonia A requires AMH (Zhou et 
al. 1993). 
Experiments using transgenic mice (overexpression of AMH and AMH knock-
out) indicate that AMH may regulate Leydig cell development (Behringer et al. 1990; 
Behringer et al. 1994). Thus, although numerous observations suggest that AMH 
functions in the testis during fetal and neonatal development, the nature of this 
function remains to be established. No effects of AMH on the adult testis have been 
reported. 
Activins and inhibins 
Similar to TGFI3 and AMH, activins and inhibins are dimeric proteins. Inhibin consists 
of an inhibin-a and an inhibin-I3A or -I3B subunit, named inhibin A and inhibin B, 
respectively, whereas inhibin-13 subunits (A or B) dimerize to form activin A, B or AB 
(see also Chapter 2). The fact that inhibin-13 subunits contribute to both inhibin and 
activin formation, complicates the interpretation of inhibin subunit immunohistochemical 
and mRNA expression data. 
The inhibin subunits are expressed in many ovarian and testicular cell types in 
the rat (Meunier et al. 1988; Kaipia et al. 1992; Klaij et al. 1994). Bioassays and! or 
selective immunoassays that specifically identify inhibin and!or activin are important 
tools in determining the cell types that produce these growth factors (Eddie et al. 1979; 
Robertson et al. 1988; Grootenhuis et al. 1989; Shintani et al. 1991; de Winter et al. 
1994). Synthesis and possible functions of inhibins and activins in the gonads have 
recently been reviewed (Findlay, 1993; Hillier and Mir6, 1993; Moore et al. 1994). 
Based upon the expression of inhibin subunits in granulosa cells during follicle 
development, follicular activin production is thought to increase during early stages of 
follicle development, followed by an inhibition of activin secretion during follicle 
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maturation (Woodruff et al. 1988; Meunier et al. 1988; Findlay, 1993; Hillier and Mira, 
1993), whereas inhibin production by granulosa cells increases when follicles reach 
the preovulatory size, but decreases again after the LH surge (Woodruff et al. 1989; 
Hillier and Mira, 1993). 
In the testis, Sertoli cells produce both inhibin and activin. Immature Leydig 
cells produce activin, whereas adult Leydig cells produce only free a-subunits (de 
Winter et al. 1992b; de Winter et al. 1993; Moore et al. 1994). Immature peritubular 
myoid cells have also been reported to produce activin in vitro (de Winter et al. 1994). 
The expression of the inhibin subunits varies during the spermatogenic cycle 
(Kaipia et al. 1992; Klaij et al. 1994). Furthermore, germ cell preparations enriched 
in early spermatids have been found to increase the level of a-subunit mRNA 
expressed in cultured Sertoli cells isolated from 20-day-old rats (Pineau et al. 1990). 
These results indicate that the relative levels of inhibin and activin secreted by Sertoli 
cells depend upon interactions with specific spermatogenic cell types. 
Two activin receptor type II genes (ActRil and ActRIIB) and two activin receptor 
type I genes (Alk-2 and Alk-4) have recently been identified (see Chapter 2). Inhibin 
can bind to the ActRilB with approximately ten-fold lower affinity than activin. Whether 
there exists a separate inhibin receptor remains an enigma, because most effects of 
inhibin can be explained by neutralization of activin actions. However, recent binding 
experiments indicate that Leydig cells may express specific inhibin receptors, whereas 
activin was shown to bind specifically to cells in the basal compartment of the 
seminiferous tubules and to Step 7 and 8 round spermatids (Krummen et al. 1994). 
In the testis, ActRil mRNA is expressed in Sertoli cells, peritubular myoid cells, 
pachytene spermatocytes, round spermatids and also, albeit at a very low level, in 
Leydig cells (de Winter et al. 1992a; Cameron et al. 1994). ActRilB mRNA is 
expressed in interstitial cells including Leydig cells (Cameron et al. 1994). mRNAs 
encoding type I receptors for activin are found in Sertoli cells (Alk-2 and Alk-4), Leydig 
cells (Alk-2), spermatocytes and spermatids (Alk-4) (de Jong et aI., personal 
communication). Less is known about activin receptor expression in the ovary. Actrll 
mRNA is detected at high levels in oocytes and at a low level in corpora lutea 
(Cameron et al. 1994). Granulosa cells express low levels of ActRil and ActRilB 
mRNAs (Cameron et al. 1994). 
Follistatin is a protein that is functionally, but not structurally, related to inhibin 
and activin (reviewed by Michel et aI., 1993). Follistatin is expressed in the gonads 
and can bind inhibin and activin, and thereby acts as an inhibitor of their actions. 
In the ovary, most data concerning the expression of activin and inhibin and 
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their receptors, as well as reported effects on cell functions, seem to fit in a model that 
implicates activin in the stimulation of early follicular development, and inhibin in 
preovulatory follicle selection and maintenance of follicle dominance. It is postulated 
that activin is involved in inducing FSH sensitivity, by increasing FSH receptor 
numbers, in undifferentiated granulosa cells from preantral follicles (Findlay, 1993), 
whereas the increasing levels of inhibin during the late phases of follicular 
development may stimulate the LH-induced androgen synthesis in theca cells, thereby 
positively influencing the final follicular estrogen output. However, this model of activin 
and inhibin action is not supported by Woodruff et al. (1990), who found that inhibin 
stimulated follicular growth, whereas activin had atretogenic effects in vivo. In a more 
recent report, Li et al. (1995) show that activin promotes ovarian follicle development 
in vitro, and these authors suggest that the findings of Woodruff et al. (1990) might be 
explained by an activin-induced overproduction of follistatin, which counteracts activin. 
Several effects of activin and inhibin on spermatogonial cell proliferation, Leydig 
cell steroidogenesis and Sertoli cell functions have been reported (van Dissel-Emiliani 
et al. 1989; Lin et al. 1989; Mather et al. 1990; Mauduit et al. 1991; Hakovirta et al. 
1993; de Winter et al. 1993). However, there is no model that could explain effects 
of activin and inhibin on testicular cell types. One important function of activin and 
inhibin could be the maintenance of a constant rate of spermatogonial proliferation 
during the spermatogenic cycle in adult animals, as suggested by Moore et al. (1994). 
Furthermore, inhibins and activins are likely to be involved also in the control of 
somatic cell growth in the gonads, since transgenic mice that carry a targeted deletion 
in the a-inhibin gene develop gonadal stromal tumors (Matzuk et al. 1992) (see also 
Chapter 2). 
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1.4 Scope of this thesis 
Gonadotropins (LH and FSH), together with steroid hormones (in particular estradiol 
and testosterone), are the principal regulators of gonadal development and function. 
Members of the activinrrGFj3 family of growth and differentiation factors, including 
AMH, are probably some of the most important local factors that affect gonadal 
functioning. Of the different growth factors of this family, only AMH functions are 
specifically restricted to sex differentiation and the gonads. This thesis is focussed on 
the regulation of the postnatal functions of AMH and testosterone in the gonads, and 
on the interactions of these two hormones with other regulators of gonadal function. 
Chapter 2 describes the mechanism of action of steroid hormones, 
gonadotropins, and members of the activinrrGFj3 family. Furthermore, the importance 
of these regulatory hormones and their receptors is illustrated by the disturbances in 
sex differentiation and/or gonadal functioning, caused by mutations that disrupt their 
functioning. 
Due to the fact that no good binding assays for AMH could be developed 
(Donahoe et al. 1977), the receptors that bind AMH have remained elusive. In 
Chapter 3, the first cloning of a receptor for AMH is described. The levels of AMH and 
AMH receptor mRNA in gonads before and after birth were studied using sensitive 
molecular techniques (in situ hybridization and RNase protection). In the male rat, the 
testicular levels of AMH and AMH receptor mRNAs were determined during postnatal 
testis differentiation and also in the adult rat. Regulatory effects of certain germ cell 
types upon AMH and AMH receptor mRNA expression in Sertoli cells of adult rats 
were determined by elimination of germ cells that are at specific steps of 
spermatogenesis (Chapter 4). In Chapter 5, AMH and AMH receptor expression is 
studied in ovarian follicles of different stages, during postnatal development of the 
ovary and during the estrous cycle, and the effect of various hormonal treatments was 
evaluated. 
Chapter 6 describes the first cloning of the androgen receptor promoter from 
the rat. The availability of this genomic DNA region that determines the expression 
of the androgen receptor has led to important advances in understanding the control 
mechanisms of this key regulator of testicular function. 
In the General Discussion (Chapter 7), a hypothesis concerning the postnatal 
functions of AMH is presented. The current knowledge on the AMH receptor(s) and 
related receptors is integrated, to discuss the mechanism of action of AMH. An 
overview of recent results concerning regulation of the androgen receptor promoter is 
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presented, and the functional implications of these data are described. Finally, some 
directions are given for future research. 
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2.1 Introduction 
This chapter describes structural and functional aspects of gonadotropins, steroid 
hormones, and members of the activinfTGFp family of growth and differentiation 
factors (which also can be considered as hormones). These three groups of 
hormones and their receptors each display specific structural characteristics that allow 
for their biological functions (see Figs. 2.1, 2.2). Clinical and experimental data 
concerning mutations in some of these hormones or their receptors illustrate their 
importance in sex differentiation and/or gonadal development and function (see Table 
2.1). 
2.2 Gonadotropins 
2.2.1 Hormone and receptor structure. 
LH and FSH are large heterodimeric glycoprotein hormones that consist of a common 
a-subunit and a hormone specific p-subunit (Gharib et al. 1990). They are members 
of a distinct family of glycoprotein hormones which also includes thyroid-stimulating 
hormone (TSH) and chorionic gonadotropin (CG), and their receptors have a similar 
overall structure (Frazier et al. 1990; McFarland et al. 1989; Sprengel et al. 1990) (Fig. 
2.2A). A large extracellular domain encompasses the ligand binding domain, followed 
by a transmembrane domain that contains seven membrane-spanning segments. The 
short intracellular C-terminal domain and the intracellular loops can interact with G 
proteins. 80th LH and FSH receptors couple to adenylyl cyclase through G" although 
it has been found in in vitro studies that coupling to phospholipase C, resulting in 
phosphoinositide breakdown, is also possible (Gudermann et al. 1992). The LH and 
FSH receptors belong to the large family of G protein-coupled receptors (Segaloff and 
Ascoli, 1992), but the presence of the large extracellular domain places the LH and 
FSH receptors together with the TSH receptor in a separate subfamily. Another 
difference is that, while most G protein-coupled receptors are encoded by a single 
exon, the extracellular domains of the LH and FSH receptors are encoded by 
respectively 10 and 9 exons (Tsai Morris et al. 1991; Heckert et al. 1992). These 
exons contain several "leucine-rich repeats", that occur in a large and diverse group 
of functionally non-related proteins, collectively known as leucine rich glycoproteins 
(Leong et al. 1992). The leucine rich repeats are probably involved in formation of 
amphipatic helices that may contact other proteins. 
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Fig. 2. 1: Schematic drawing of a Sertoli cell expressing three receptor types that are essential for correct 
sex differentiation and/or gonadal development. 
FSHR and AMHR are specifically expressed only In Sertoli cells (or in granulosa cells in females), 
whereas the AR is also expressed in a number of other cell types. The FSHR is a member of the large 
family of G protein-coupled receptors. It contains a farge extracellular ligand binding domain. The 
transmembrane domain contains seven membrane spanning regions. The intracellular loops, together 
with the G-terminal Intracellular domain, interact with intracellular G proteIns. G proteins (G), when 
bound to GTP, activate adenylyl cyclase (AC), which converts ATP into the second messenger cAMP. 
AMH most likely binds to a receptor complex that contains two different receptor types (I and /I). Both 
receptors are members of the family of transmembrane serine/threonine kinase receptors (see also 
Chapter 7). Probably, the type" receptor binds AMH, then recruits the type I receptor into the complex, 
and subsequently the constitutively active Idnase domain of the type /I receptor phosphorylates the GS 
domain of the type I receptor. ThIs results in further propagaUon of the signal to unknown downstream 
substrates. Testosterone (T) enters the cell through diffusion and binds to the AR that Is located in the 
nucleus. T binding to the AR results In dissociation of heat-shock profeins, and binding of the AR to 
specific response elements in the DNA Certain regions of the AR are capable of interacting with other 
transcription factors (TF), and components of the basic franscripUon machinery, contaIning RNA 
polymerase 1/ (Pol). Together, these events lead to transcription of androgen responsive genes. 
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The transmembrane and intracellular domains of the LH and FSH receptors are 
encoded by a single exon, and are homologous to the other members of the G 
protein-coupled receptor family. 
The deduced molecular weight from the cDNA of the FSH receptor is 
approximately 75 k. Using a polyclonal antibody to a synthetic peptide derived from 
the rat FSH receptor, and a mammalian cell line transfected with an FSH receptor 
cDNA construct, Quintana et al. (1993) detected the FSH receptor on Western blots 
as a 58-83 k protein or a 69-81 k protein, under non-reducing and reducing conditions, 
respectively. However, a solubilized, isolated membrane FSH receptor complex of 
approximately 240 k, that dissociates into four subunits upon exposure to dithiothreitol, 
has also been described (Dattatreyamurty et al. 1992; Sperbeck et al. 1993; 
Dattatreyamurty and Reichert Jr, 1993). Thus, some controversy exists about whether 
the FSH receptor forms large (possibly FSH dependent) homomeric complexes in vivo, 
or whether it exists as a single peptide in the membrane. 
The predicted molecular weight of the LH receptor is 75 k and the difference 
between this calculated number and the apparent molecular weight (93 k) on SDS-
PAGE gels is thought to be due to the glycoprotein nature of the molecule (Segaloff 
and Ascoli, 1993). Multiple species of LH and FSH receptor mRNAs have been 
reported. Many of these are the result of differential splicing, often resulting in mRNAs 
that encode truncated proteins. Whether these receptor forms have any functional 
significance is not clear and needs further investigation (reviewed by Themmen et aI., 
1994). It has been suggested that alternative splicing of gonadotropin receptor pre-
mRNAs is used as a means to regulate the expression of the receptors in the fetal 
gonads (Huhtaniemi, 1994) 
After binding of gonadotropin, the receptor changes its conformation, and starts 
to activate G proteins. The receptor does not stay in this activating conformation, but 
mechanisms such as phosphorylation by kinases acting on the receptor, will lead to 
a process called desensitization, resulting in lower ligand affinity, less efficient coupling 
to G proteins, and a lower receptor number at the plasma membrane (LaPolt et al. 
1991; Themmen et al. 1991; Heckert et al. 1992). 
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2.2.2 Mutations In LH, FSH, and their receptors 
FSH deficiency is an uncommon cause of infertility, producing amenorrhoea and 
hypogonadism in women, and oligo- or azoospermia with normal testosterone levels 
in men. In one such case, a woman with primary amenorrhoea and infertility, a 
frame-shift deletion in both genes encoding the p-subunit of FSH has been reported 
(Matthews et al. 1993). Homozygeous mutation of the p-subunit of the LH gene 
(single amino acid substitution) has been reported in one case (Weiss et al. 1992). 
This male patient failed to undergo spontaneous puberty, and testicular biopsy 
revealed an arrest of spermatogenesis and absence of Leydig cells. 
The clinical symptoms of other patients, with hypogonadism and Leydig cell 
hypoplasia, and certain forms of pseudohermaphroditism, suggest that in some cases 
the defect may be caused by a loss-of-function mutation of the LH receptor (David et 
al. 1984; Wu et al. 1984). Kremer et al. (1995) have recently identified a mutation in 
the LH receptor of 2 siblings who presented with female external genitalia and a 46,XY 
karyotype. In vitro expression studies showed that this mutated receptor binds hCG 
with a normal Kd. However, in contrast to the wild type receptor, ligand binding did 
not result in increased production of cAMP (Kremer et al. 1995). 
Several constitutively activating mutations of the LH receptor have been 
reported in man (Kremer et al. 1993; Shenker et al. 1993). These mutations lead to 
a syndrome that is called familial male-limited precocious puberty. This gonadotropin-
independent disorder is inherited in an autosomal dominant manner, and thusfar no 
female phenotype has been described. It is thought that constitutive cyclic AMP 
production in Leydig cells of the affected boys causes Leydig cell hyperlunction, and 
subsequently increased testosterone production, and signs of puberty at a very young 
age. The male-limited inheritance pattern of precocious puberty may be explained by 
the fact that in females FSH is required for LH receptor expression in the postpubertal 
cycling ovary, and thus for subsequent ovarian steroidogenesis (Shenker et al. 1993). 
No naturally occurring mutations of the FSH receptor have been reported yet, 
but are expected to be present in the human popUlation. Constitutively activating 
mutations might lead to Sertoli and granulosa cell hyperplasia. Loss of function 
mutations may be found in infertile males and females with supranormal FSH levels. 
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Hg. 2.2: (Next page) Unear representation of gonadotropin receptors, steroid receptors, and 
transmembrane serinelthreonine kinase receptors, 
A) Both the rat FSHR and LHR contain a large extracellular ligand binding domain that consists of 14 
imperfect leucine-rich repeats of approximately 20 aa each (1-14). The transmembrane domain 
contains seven membrane spanning segments (I-VII), followed by the short intracellular C·terminal 
domain. Regions that show a high degree of sequence similarity are denoted by the lines below the 
figure; the numbers indicate the percentage similarily between the two receptors. Regions in which 
more than 90% of the aa residues Is conserved are indIcated by black boxes, The numbers of aa 
residues of Ihe ral FSHR (Sprengel el al. 1990) and LHR (McFarland el al. 1989) are indicaled (Fig. 
adapled from Sprengel el al" 1990). 
B) The general structural domains of steroid receptors are shown. The N-terminal domain contains 
regions that are essential for transcn'ption activation, the DNA binding domain contains the two zinc 
fingers, and the C-termlnalligand binding domain contains several conseNed aa residues that form a 
hydrophobic hormone bInding pocket. The numbers in the DNA binding domain and hormone binding 
domain indicate the percentage of sequence similarity of the ER compared to the AR In these domains. 
The number of aa residues of the human AR (Chang et al. 1988) and ER (Green et al. 1986) are 
indicated. 
C) Members of the transmembrane serine/threonIne kinase receptor family show a simifar overall 
structure. The extracellular ligand binding domain contains a cysteine rich regIon; the location of most 
cysteines is conseNed. A single transmembrane domain is followed by a large intracellular domain that 
consists almost entirely of a kinase domain, that contains two inserts that are characteristic for 
members of the family (shown as black boxes). The transmembrane serine/threonine kinase receptor 
family can be divided in two subfamilies, based on structural and functional characteristics of the 
receptors. The type 1/ receptors contain a longer C-terminal tail than the type I receptors, and lack the 
GS domain that is present in type I receptors. The GS domain is a conseNed region of approximately 
29 aa residues that contains a GSGBG sequence. The numbers in the cysteine rich domaIn and in the 
kinase domain indicate the percentage of sequence simifarity of the receptor domain compared to the 
corresponding domain of Ihe AclRIl (Iype II receplors) or AclRI (type I receplors). The number of aa 
residues of Ihe mouse AclRIl (Malhews and Vale, 1991), human TGFfjRII (Un el al. 1992), ral AMHRII 
(see Chapler 3), human AclRI (AIIisano el al. 1993), and human TGFfjRI (Franzen el al. 1993) are 
indicated. 
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2.3 Androgen and estrogen receptors 
2.3.1 Functional and structural aspects of members of the steroid receptor 
superfamily 
Estrogens and androgens can enter the cell through diffusion and act via intracellular 
receptors (the existence of active transport systems and/or plasma: membrane 
receptors is not excluded). The ER and the AR belong to a large family of receptors 
that exert their regulatory effects by acting as ligand-activated transcription factors 
(Evans, 1988; Beato, 1991). Members of this family include the receptors for all 
steroid hormones, thyroid hormone, retinoids, vitamin 03, and an increasing number 
of orphan receptors. The human AR gene contains 8 exons (Kuiper et al. 1989; Faber 
et al. 1991), and is transcribed into a mRNA of approximately 11 kb which encodes 
a protein of 902 amino acids (Chang et al. 1988; Lubahn et al. 1988; Tilley et al. 1989; 
Trapman et al. 1988). The relative molecular weight on SDS-PAGE is approximately 
110 k. The estrogen receptor (ER) is encoded by 9 exons, and the 6 kb mRNA 
encodes a 595 aa protein of 66 k (Green et al. 1986). 
The members of the steroid hormone receptor family show a similar overall 
structure with several functional domains (Fig. 2.2B). First, the C-terminal region of 
the receptors constitute the hormone binding domain. Several conserved amino acids 
in this region are essential for the formation of a hydrophobic pocket (Evans, 1988). 
Second, the zinc finger-containing DNA binding domain, which is the most 
conserved domain, is located N-terminal to the ligand binding domain. Zinc-fingers are 
present in the DNA binding domain of many transcription factors (Schwabe and 
Rhodes, 1991). In the steroid hormone receptor superfamily, the C-terminallocated 
zinc-finger is assumed to be involved in protein-protein interactions, whereas the N-
terminal zinc finger is able to recognize and interact with specific DNA sequences 
(Freedman and Luisi, 1993). These DNA sequences are so-called hormone response 
elements (HREs), and are located in the promoters or enhancers of the genes that are 
regulated by the steroid hormone receptors. Both the ER and the AR bind as 
homodimers to HREs consisting of two halfsites, that are inverted repeats separated 
by a 3 base pair gap. The consensus androgen response element is 
5'AGAACAnnnTGTICT3', whereas the ER binds to the 5'AGGTCAnnnTGACCT3' 
consensus sequence (Forman et al. 1992; Freedman and Luisi, 1993). 
Finally, the N-terminal domain is highly variable in size and amino acid 
composition among the different family members. It contains regions that are 
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essential for transcription activation (Jenster et al. 1991). The N-terminal domain of 
the AR is relatively long, whereas the ER has a much shorter N-terminal domain (see 
Fig.2.2B). 
In the absence of hormones, the AR and the ER are bound to so-called heat-
shock proteins. Heat-shock proteins are important for several cellular house-keeping 
functions. Their expression is enhanced under stress conditions, and they are thought 
to function as molecular chaperones (Craig et al. 1993). When a steroid receptor is 
complexed with heat-shock proteins, it is unable to bind DNA. Binding of a steroid 
hormone to its receptor results in dissociation of heat-shock proteins and other 
changes that result in transformation of the receptor to the tight nuclear binding form 
(Veldscholte et al. 1992; Smith and Toft, 1993). An increase in the degree of receptor 
phosphorylation is one of the changes that occur after ligand binding. Several 
possible physiological roles of phosphorylation, conceming the capacity of the 
receptors to act on gene transcription, have been suggested (reviewed by Kuiper and 
Brinkmann, 1994). 
2.3.2 Mutations in the AR and ER 
Mutations that disrupt AR function will affect male but not female individuals, due to 
the X chromosomal localization of the AR gene (Lubahn et al. 1988). Depending on 
the degree of AR functional impairment, a partial or complete androgen insensitivity 
syndrome (pAIS or cAIS) is observed (Griffin and Wilson, 1989). Patients with cAIS 
(sometimes called testicular feminization), are 46,XY females with undescended 
testes instead of ovaries, and lacking fallopian tubes, uterus and upper part of the 
vagina. 
Many naturally occurring mutations of the AR have been described, varying 
from single base pair mutations to complete deletion of the AR gene (Quigley et al. 
1992). Single base pair mutations can lead to either amino acid substitutions, the 
introduction of premature stopcodons or an aberrant pre-mRNA splicing pattern (for 
examples see McPhaul et aI., 1993). All these mutations result in complete or partial 
AIS. Allhough in vitro mutagenesis studies have shown that truncated AR receptors, 
from which the hormone binding domain is deleted, can activate gene transcription 
independent of androgens (Jenster et al. 1991), naturally occurring mutations, leading 
to such constitutively active receptors, have not been reported. 
The human ER gene has been localized to chromosome 6 (Waller et al. 1985). 
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It has been described that estrogens may perform essential functions during blastocyst 
implantation (George and Wilson, 1978), and that this function of the ER precludes the 
existence of an estrogen insensitivity syndrome analogous to AIS. However, one 
recent report indicates that an estrogen insensitivity syndrome exists in man (Smith 
et al. 1994). Analysis of the ER genes of this individual revealed a homozygous 
mutation in exon 2, resulting in a premature stop codon. The phenotype of this male 
patient indicated the importance of estrogen in the pubertal growth spurt, maturation 
of the epiphyses, and mineralization of the skeleton. 
Furthermore, it has been shown that targeted disruption of the ER gene in the 
mouse is not lethal (Lubahn et al. 1993). These ER knock-out mice showed no 
abnormalities with respect to sex differentiation, but the females were infertile and had 
hemorrhagic cystic ovaries. Fertility of the males also was much reduced; less than 
10% of the normal sperm count was detected. Although residual estrogen binding 
could still be detected in the ER knock-out mice, no ER protein could be detected by 
Western blot using a monoclonal antibody that recognizes an epitope in the C-
terminus, near the ligand-binding domain of the receptor (Korach, 1994). There are 
currently two possible explanations for the observed residual estrogen binding; the 
presence of a non-ER estrogen-binding protein, or the presence of an altered protein 
product, transcribed from the disrupted ER gene which is biologically inactive (Korach, 
1994). 
ER mutations leading to constitutive activity have been reported to exist 
together with expression of a wild type ER gene in human breast cancer tissue (Fuqua 
et al. 1991). 
Table 2.1: (Next page) Schematic OV8Niew of several hormonelreceptor mutations that cause aberrant 
sexual differentiation. 
All mutations are complete loss of function mutations, unless otherwise indicated. Symbols and 
abbreviations: AR,androgen receptor; ER,estrogen receptor; AMH,anti-mOflerian hormone (receptor); 
LH,luteinizing hormone,' LHR,LH receptor; FSH,fo/licfe-sUmulating hormone; FSHR,FSH receptor; 
cAts, complete androgen insensitivity syndrome; EIS,es(rogen insensitivity syndrome (presumably 
complete); PMOS,persistent mOl/erian duct syndrome; LCH,Leydig cell hypoplasia; FMPP,famifial male 
precocious puberty,' Chromos. sex,chromosomal sex,' Phenol. sex,phenotypic sex; Int. Genit.,internal 
genitalia; WD, wolffian duct; MD,mOllerian duel; Fert.,fertilily; cJ',male external genilalia; !j! ,female external 
genitalia; -,absent,' +,presenl; T,tesles; O,ovaries. 
50 
'" ~ 
Mutated 
gene 
AR 
ER 
AMH 
AMHRII 
LH 
FSH 
LHR 
FSHR 
Syndrome Genet. sex 
cAIS XV 
EIS XV 
XX 
PMOS XV 
XX 
LCH XV 
Unknown XX 
Unknown XV 
Amenorrhoea XX 
LCH XV 
XX 
FMPP XV 
(constitutive 
LHR) 
- ------
Phenot.sex Int. genit. 
derived from 
MO WO 
~ - -
d" - + 
d" + + 
~ + -
Unknown 
d" - + 
~ + 
-
~ - +/-
~ + -
d" - + 
Unknown 
Gonads Puberty 
T Normal breast dev. Sparse 
pubic and axillary hair 
Primary amenorrhea 
T No pubertal growth spurt 
No maturation of epiphyses 
Unknown 
T Normal puberty 
0 Unknown 
T No puberty 
Unknown 
Unknown 
0 Primary 
amenorrhoea 
T No breast dev. 
Primary amenorrhoea 
0 Primary amenorrhoea 
T Precocious puberty 
Fert. 
-
? 
-
-
-
-
-
+ 
".. 
o 
~ g 
Q) 
til 
n {g 
Q 
:3 
\? 
'" ::. 
*. 
Chapter 2 
2.4 Structural and functional aspects of TGFps, activins, inhibins, AMH and 
their receptors 
2.4.1 General structure of the activin and TGF-p family of growth/differentiation 
factors 
All activin and TGFp family members are synthesized as large precursors, that form 
disulphide linked dimers which are subsequently cleaved. This results in an N- and 
a C-terminal domain (each composed of two subunits), the latter being the active 
hormone (AMH has somewhat different characteristics, see Paragraph 1.1.4). The 
spacing of seven cysteines in both chains of the active C-terminal domain is the most 
conserved feature among the different family members (Massague, 1990). The 
elucidation of the crystal structure of TGFp2 has revealed that six of these cysteines 
form a rigid central structure known as the cysteine knot. The seventh cysteine forms 
a disulphide bridge with the other folded chain of the dimer (Daopin et al. 1992; 
Schlunegger and GrOtter, 1992). 
In mammals, three closely related genes are known that encode respectively 
homodimeric TGFpl, 2, and 3. As mentioned in Paragraph 1.1.4, AMH is also a 
homodimeric protein. Activins consist of two inhibin-p subunits (PA or pB, forming 
activin A,B, or AB), whereas inhibin is a heterodimer of an inhibin-o; and an inhibin-pA 
or PB subunit. 
2.4.2 Serine/threonine kinase transmembrane receptors 
Members of the activinlTGFp family of growth and differentiation factors act through 
heteromeric receptor complexes. For TGFp, type I, type II and type III receptors 
(TGFpRI, TGFpRII, TGFpRIII) have been defined, based upon their relative molecular 
weights of 55,80 and 230 k, respectively (Mass ague, 1990). This nomenclature is also 
used for receptors of the other family members. Genetic evidence from cell mutants 
resistant to TGFp actions suggests that TGFp binding to receptor type I requires the 
presence of receptor type II. Furthermore, both receptors are required for signalling 
of any response (Laiho et al. 1991). Expression cloning was used to identify the 
genes encoding the human TGFpRIl and TGFpRIII, and mouse activin receptor type 
II (mActRII) (Wang et al. 1991; Mathews and Vale, 1991; Lin et al. 1992). The 
TGFpRll1 is a betaglycan that has no signalling motive, and is thought to be involved 
in presenting the ligand to the type I and II receptors (Lopez-Casillas et al. 1993). The 
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type II receptors for TGFp and activin are structurally similar and, together with the C. 
elegans orphan receptor Daf-1 (Georgi et al. 1990), they were the first identified 
members of a new family of transmembrane serine/threonine kinase receptors (Lin et 
al. 1992). Subsequently, PCR-strategies resulted in the cloning of similar receptors 
from other species (Donaldson et al. 1992; Hemmati-Brivanlou et al. 1992; Legerski 
et al. 1992; Matzuk and Bradley, 1992; Ohuchi et al. 1992; Shinozaki et al. 1992; 
Childs et al. 1993; Tsuchida et al. 1993a; Barnett et al. 1994), a second type II 
receptor for activin (ActRIIB) from mouse (Attisano et al. 1992), and a number of 
orphan receptors from rat (R1-4) and human (Alk-1-5 and SKR1) (He et al. 1993; 
Matsuzaki et al. 1993; ten Dijke et al. 1993). In later studies, type I receptors where 
identified for TGFp (Alk-5, TSR-I/Alk-1), activin (ActR-1/Alk-2/R1ITsk-7L, Alk-4/R2), 
and bone morphogenetic proteins (ALK-3 and Alk-6) (Attisano et al. 1993; Ebner et 
al. 1993; Franzen et al. 1993; Tsuchida et al. 1993b; Koenig et al. 1994; ten Dijke et 
al. 1994b; ten Dijke et al. 1994c). Some of these receptors were initially called orphan 
receptors, due to their inability to bind ligand in the absence of type II receptors. 
Genetic studies combined with PCR-based strategies, have led to the identification of 
a type II receptor in C. elegans that can bind bone morphogenetic proteins (Daf-4) 
(Estevez et al. 1993), and of two receptors for the decapentaplegic gene product, 
which also is a member of the activinITGFp family, from D. melanogaster (Brummel 
et al. 1994; Nellen et al. 1994; Xie et al. 1994). 
Both inhibin and AMH are notorious for loss of binding and bioactivity upon 
iodination. This has made it extremely difficult to develop good binding assays for 
these hormones, so that specific inhibin and AMH receptors have remained elusive. 
General structure of serine/threonine kinase receptors 
This large family of transmembrane serine/threonine kinases consists of 
receptors that have the following overall structure: an extracellular ligand-binding 
domain with conserved cysteine residues, a single hydrophobic transmembrane 
domain, and an intracellular domain with intrinsic serine/threonine protein kinase 
activity, containing two inserts that are characteristic for the family (Fig.2.2C). The 
degree of sequence similarity between the kinase domains is higher among the type 
I receptors compared to the type II receptors (ten Dijke et al. 1994a). The type I 
receptors have a distinct distribution of the cysteine residues in the extracellular 
domain and a shorter C-terminal tail compared to the type II receptors. Furthermore, 
the kinase domain of type I receptors is preceded by a so-called GS domain which 
contains a short glycine/serine repeal. This domain is highly conserved among type 
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I receptors (Attisano et al. 1994; Lin and Moustakas, 1994; Massague et al. 1994). 
Mechanism of receptor activation 
Type II receptors can bind hormone in the absence of type I receptors, but both 
receptor types are needed for transduction of the signal (Laiho et al. 1991; Wrana et 
al. 1992). In the case of the TGFp receptors, the mechanism of signal transduction 
has been elucidated (Fig. 2.3) (Wrana et al. 1994). The kinase domain of TGFpRIl 
is constitutively active, and the receptor exists as an autophosphorylated protein. 
Autophosphorylation of TGFpRIl increases two-fold upon hormone binding, but this is 
not the receptor activating evenl. Hormone binding to type II receptor is followed by 
recruiting a type I receptor molecule, and the formation of a highly stable heteromeric 
complex. Subsequently, the type II receptor phosphorylates the GS domain of the 
type I receptor, which results in activation of the kinase domain of the type I receptor. 
This series of events allows the signal to be propagated to downstream substrates 
(Wrana et al. 1994). Thus, the nature of the biological response to ligand is specified 
by the type I receptor that is engaged in the complex (Carcamo et al. 1994; Wrana et 
al. 1994). Homo-oligomers of TGFpRI, TGFpRIl and TGFpRll1 have also been 
observed in transfected cells in vitro (Henis et al. 1994; Yamashita et al. 1994). This 
may indicate that TGFp induces formation of heterotetrameric, rather than 
heterodimeric complexes, containing two type I and two type II receptor molecules 
(Yamashita et al. 1994; Okadome et al. 1994). Whether the above described 
mechanism of receptor activation applies to the receptors for all members of the 
activinffGFp family awaits further study. 
Transfection studies have shown that one species of type I receptor may 
interact with different species of type II receptors, but it is unclear whether this also 
occurs in vivo {Attisano et al. 1993; ten Dijke et al. 1994b). The high level of receptor 
expression in transfected cells may lead to aberrant interactions. However, recent 
experiments using non-transfected cell lines, in which receptor levels are more 
physiological, have shown that ALK-2 can be detected in a heteromeric complex with 
a type II receptor for bone morphogenetic proteins, and also, in a different cell line, 
can form a heteromeric activin binding complex with ActRIl (ten Dijke et al. 1994c). 
This indicates that some type I receptors may function together with different type II 
receptors, depending on the hormone, cell type or cell differentiation state, in vivo. 
Thusfar, ligand-activated signalling of receptor complexes could only be shown with 
specific type I and type II receptors in combination with one specific ligand (Attisano 
et al. 1993). 
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Fig. 2.3: Mechanism of activation of the TGFP receptor complex 
A general model fOf the Initiation of signalling by the TG,Fp receptor complex. The type /I receptor is 
a constitutively active serine/threonine kinase that recruifs the type I receptor by means of bound TGFJ3 
(diamond). Subsequent phosphorylation of the GS domain (striped circle) by the type II receptor allows 
the kinase of the type I receptor to propagate the signal to downstream substrates (Fig. adapted from 
Wrana et al., 1994) 
2.4.3 Functional disruption of members of the activin and TGFp family of 
growth/differentiation factors 
No natural occurring mutations of genes encoding members of the TGFp and activin 
family of growth factors or their receptors in mammals have been reported, with the 
exception of mutations in the gene encoding AMH (see below). In mice, targeted 
disruption of genes encoding several of these growth factors and of the ActRIl has 
provided some information on their functioning. 
The TGFp1 gene was the first member of the family, for which genetic knock-
out mice Were generated (Shull et al. 1992; Kulkarni et al. 1993). Based on the 
embryonal expression pattern of TGFp1, it was expected that this protein would have 
a vital role during embryogenesis. However, TGFp 1 null neonates were 
indistinguishable from heterozygous or wild type IIttermates. Soon after birth, the 
absence of TGFp1 led to diffuse and lethal inflammation. The animals died before 
breeding age, and this precluded thorough investigation of gonadal function. It is 
thought that redundancy in the expression of the various isoforms of TGFp, and 
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maternal support lead to fetal rescue of the TGFp1 null mice (Letterio et al. 1994). 
Dexamethasone treatment of the TGFp 1 null animals allowed prolonged survival and 
a successful pregnancy of a single homozygous null female. Pups homozygous for 
the mutated allele showed a much more impaired phenotype than TGFp null pups that 
were derived from heterozygous mothers, and died within one day (Letterio et al. 
1994). 
Targeted disruption of the o:-inhibin gene in mice leads to the development of 
mixed or incompletely differentiated gonadal stromal tumours (Matzuk et al. 1992). 
However, in these homozygous o:-inhibin deficient animals (males and females), initial 
gonadal development seems to have occurred in a normal manner, since mature 
oocy1es and spermatozoa were initially present. There is an arrest of 
spermatogenesis and folliculogenesis as the tumours grow and become more 
destructive. The interpretation of these resulls is complicated by several factors. 
First, all homozygous animals were derived from heterozygous mothers, thus maternal 
sources of o:-inhibin may (partially) rescue the o:-inhibin null fetuses, as has been 
shown in the case of targeted disruption of the TGFp1 gene. Second, the absence 
of o:-inhibin may have an effect on the synthesis of activins, either through the 
presence of excess p-inhibin subunits, incapable of forming inhibin, or through a 
disturbance of the regulatory mechanisms that may result in changes in the level of 
p-inhibin subunit expression. Recent results have shown that this is the case. The 
mRNA of pB-inhibin is increased more than 200-fold in the testes of o:-inhibin deficient 
mice compared to wild type controls (Trudeau et al. 1994), and the serum levels of 
activin are 1 O-fold elevated in the mutated animals (Matzuk et al. 1994). Togetherwith 
the report that the growth of gonadal tumour cell lines derived from mice deficient in 
both o:-inhibin and p53 depends on activins (Shikone et al. 1994), these results 
indicate that overexpression of activin significantly contributes to the observed 
phenotype in o:-inhibin deficient mice. 
Taking these considerations into account, it is clear that the balance between 
inhibins and activins is a critical determinant in the control of Sertoli cell and granulosa 
cell proliferation. Indications for direct effects of the absence of inhibin, or the 
presence of excess activin, on spermatogenesis come from the observation that in 
some male o:-inhibin knock-out mice there is an arrest of germ cell maturation in the 
contralateral gonad, where tumours have not appeared (Matzuk at al. 1992). 
Mice homozygous for a null mutation of pB-inhibin are viable and fertile 
(Vassalli at al. 1994; Schrewe et al. 1994). These mice have a defect in eyelid 
development, and homozygous mothers neglect and consume their progeny. Tissue 
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sections of the gonads of mutated and wild-type animals at six weeks of age did not 
reveal any significant differences (Schrewe et al. 1994). pA-inhibin gene knock-out 
mice develop to term, but die within 24 h of birth (Matzuk et al. 1995b). These mice 
have a number of defects, that are all different from those observed in pB-inhibin gene 
knock-out mice. The phenotype of mice deficient in both PA- and pB-inhibin show the 
defects of both individual mutants, but no additional abnormalities (Matzuk et al. 
1995b). This does not exclude the possibility that inhibin A and activin A may partially 
compensate for the absence of inhibin Band activin B proteins in the PB gene knock-
out transgenic mice, since the synthesis of pA-inhibin subunit was upregulated in the 
PB deficient animals (Vassalli et al. 1994). If the gene encoding one of the known 
activin type II receptors, ActRII, is disrupted, a phenotype unlike that of any of the 
inhibin subunit deficient mice develops (Matzuk et al. 1995a). The observed 
phenotypes suggest a role for ActRIl signalling during embryonic mandible 
development, through a mechanism that does not involve action of activin A or B. The 
recently cloned pC-inhibin gene (Hotten et al. 1995) might playa role in this process. 
The observed reduced fertility in ActRIl gene knock-out males, and infertility in females 
(Matzuk et al. 1995a) are consistent with the known gonadal ActRIl expression 
patterns (de Winter et al. 1992; Cameron et al. 1994), but mainly concern the reported 
stimulatory effect of activin on FSH secretion (reviewed by Oe Kretser and Robertson, 
1989). 
Although the gene knock-out experiments have provided new insights into the 
functions of TGFps, activins and inhibins, redundancy phenomena might mask 
additional functions of these proteins. 
In the case of AMH, the situation is slightly different, at least during embryonic 
development where redundancy cannot compensate for loss of AMH, since it is known 
that lack of AMH function leads to the persistent mOlierian duct syndrome (PMOS) in 
humans. This is a rare form of inherited male pseudohermaphroditism, characterized 
by the presence of a uterus and fallopian tubes in otherwise normally virilized males. 
The molecular basis for PMOS is heterogenous. AMH positive and AMH negative 
cases have been described (Guerrier et al. 1989). In the latter case, mutations in the 
gene encoding AMH have been identified in several patients as the cause of the 
syndrome (Guerrier et al. 1989; Imbeaud et al. 1994). AMH positive cases of PMOS 
could be caused by a receptor defect, although mutations in downstream genes 
cannot be excluded. Targeted disruption of the gene encoding AMH leads to the 
development of mOlierian duct derived female reproductive organs in males (Behringer 
et al. 1994), similar to the above described phenotype in human PMOS patients. 
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Apart from the degenerative effect of AMH on mOlierian duct development, the 
phenotype of the AMH knock-out mice points to a possible role of AMH in testis 
development (Behringer et al. 1994). The AMH-deficient males had testes that were 
fully descended and produced functional sperm. However, some testes showed 
Leydig cell hyperplasia, suggesting that AMH is a negative regulator of Leydig cell 
proliferation. The combined presence of male and female reproductive organs 
interfered with sperm transport, rendering most of these males infertile. In human 
PMOS patients the testes do not descent, which results in infertility. There are no data 
on the numbers of Leydig cells in the testes of these patients. Female AMH knock-out 
mice showed no abnormalities and were fertile. Thus, the phenotype of the AMH 
knock-out mice is in agreement with impairment of mOlierian duct regression, the 
classical function of AMH. However, some of the possible functions of AMH may be 
shared with other members of the activin and TGF~ family, and consequently may not 
be apparent from the phenotype of the AMH knock-out mice. Generation and analysis 
of mice that have mutations in more than one member of the activinrrGF~ family, may 
provide more information about possible functional overlaps between the different 
hormones. 
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SUMMARY 
The actiyin and TGF-p type II receptors afe members of a 
separate subfamily IIf transmembrane receptors with 
htlrinsit,-' protein kinase acthity, which also includrs the 
recently cloned TGF-p type I receptor. We haYe isolated 
lind characterized a cDNA clone (Cl4) encoding a new 
member of this subfamily. The domain stl"Ucture of the 
C14-encoded protein COlT~sponds with the structure of the 
other known transmembrane serine/threonine kinase 
receptors. It also contains the two inserts in the kinase 
domain that are characteristic fOl' this sUbfamily. Using in 
situ hybridization, C14 mRNA was detected in the mes-
enchymal cells 10CClted ndjacent to the mlilJerian duct ... of 
males and females at day 15 (1<:15) of emhryonic dewloJl· 
menl. Marked Cf4 mRNA expression was also detected in 
the female gonads. In female EI6 embryos, the Cl4mHNA 
expression pattern remained similar to that in E15 
embr~'os, However, in male El6 embryos Cl4 mRNA was 
detected in a circular area that includes the degenerating 
mlillerian duel. The expression of C14 mRNA was alsu 
studied using RNase protection assa~'s, At ElS and E16, 
CI4 mRNA is expressed in Ihe female as well as in the male 
urogenital ridge. Howen;'I', at El9, a high C14 mRNA leYeI 
in the female urogenital ridge contmsts with a lack of C14 
INTRODUCTION 
The cloning of receptors for the peptide growth factors activin 
(Mathews and Vale, 1991; Attisano et al., 1992) and TGP-p 
(Lin et a\., 1992, Ebner el aI., 1993) has provided information 
about their overall structure and the molecular mechanism of 
signal transduction. The activin re,:eptor types II and lIB and 
the TGF-p receptor types I and II, together with the C. e/egons 
orphan receptor Daf-I (Georgi et aI., 1990) and .~e\'eral 
recently cloned rat orphan receptors (He et ai., 1993), mllsti-
lute a new subfamily of transmembrane protein killa~e 
receptors. Based upon its primary structure, the kinase domain 
has a predicted speciJicity for serine und threonine residues. 
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mRNA in the male urogenital ddge, This cOl'relates with 
the almost complete degelleration of the l11ullerian ducts In 
male elubQ'os at )<;19, Cl4 I11RNA expression \HIS also 
detected in emiJl')'onie testes at E15, E16 and El9 using 
RNase IH'ofection assays, but at much I()\\'('l' lewis than 
those found in the dew loping ovaries, In ele\'en other 
tissues no CI4 mRNA was obsened, 
The results Jloint to antl·mUlierian honnolle (AMH) 
being the lUost likely candidate IiRand for C14, The 
embryonic C14 mRNA expression pattern in the urogeni-
tal ridge correlates \\ith the expected site of AMH action, 
Hnd C14 mRNA expression in the fetal m'ar)' is in 
agreen1l'nt with known effects or AJ\IH on gonadal differ-
entiation, 
Postnatal C14 mRNA expn'ssioll in I'ats was found to he 
confined mainly to thc gonads, In the testis, C14 I11RNA 
expression occurs in Sertoli cells. This testicular expression 
markedly increases during the first 3 week. .. after birth, 
concurrent with the onset of sllennaltJgellesis, 
Key wonk unti-mU!lerian hormone, ao.:livin, TGF-p, receptor, ~ex 
differentiation, (c,lb, ovary 
However, the mouse activin receptor Iype rlR has been shown 
to contain serine, threonine anu tyrosine kinase activity 
(Nakamura et al., 1992). 
The tenns type II and type I refer to the nomenclature that 
is used for the different TGF-p receptors that have been 
described (Cheifetz et al., 1987). Crusslinking of radio labelled 
TGF-p to cellular proteins allowed the identification of at least 
three different TGF-~ binding proteins at the cell surface, 
named TGI-'-p receptor types I, II and III according to their 
relative l110lecular masses of 55, 80 and 2H()x 10', respectively. 
The type III receptor is a betaglycan without a signalling motif 
(Wang et aI., 1991), and is thought to playa role in the pre-
sentation and binding of TGF-p to the other receptor types 
(Lopez-Casillas et aL, 1993). The TGF-p type 1 receptor cannot 
bind TGF-p in the absence of the type II receptor (\Vrana et 
aI., 1992, Ebner et aI., 1993), and association with the type r 
receptor is essential for the TGF-p type II receptor to signal 
growth inhibition (\Vrana et aI., 1992). It is thought that this 
obligatory association between type I and type II receptors is 
a functional characteristic for all members of the 
serine/threonine kinase receptor family (Wrana et aL, 1992). 
However, there arc also indications that for sOllie cellular 
responses to TGF-p the presence of only the type I or type II 
TGF-p receptor might be sufficient (Chen et aI., 1993). 
In this report, we describe the cloning and characterization 
of a rat eDNA, termed C14, which encodes a new member of 
the serine/threonine kinase receptor family. Based upon the 
ccll-Itisslle-specific CI4 mRNA expression pattem, described 
herein, it will be discussed that the 1110st likely candidate ligand 
of Cl4 is anti-mUlIerian hormone (Ar-.-IH) (also called 
mUlierian inhibiting substance; MIS). 
Ar>.HI is a member of the activin and TGF-p family of 
peptide growth factors (Cale et al., 1986). These signalling 
molecules share numerous structural similarities. They are syn-
thesized as large precursor molecules that form homo- or 
hetero-dimers. Each chain of the dimer is cleaved at approxi-
mately 110 amino acids from the C tcnninus, which generates 
the mature subunit and an N-terminal proregion. Sequence 
identity between members of this growth factor family is found 
mainly in the C-terminal mature subunits (2S-80%; for review 
see: Massague et aI., 1990). 
The known action of AMH in sex differentiation is very 
spedlk, when compared with the variety of functions that arc 
performed by most other growth factors of the same family. 
For example, activin Illay regulate the secretion of follicle-
stimulating hormone (FSH) by the pituitary gland (Vale et al., 
1988), but also plays different roles in erythroid cell differell-
tiation (Yu el al., 1987), neural cell survival (Schubert et aI., 
1990), and during embryogenesis (Thomsen et aI., 1990; 
Hemmati-Drivanloll and Melton, 1992). 
AMH is the earliest protein product known to he .~ecreted by 
Sertoli cells in the fetal testis (Tnln and Josso, 1982). Around 
day IS of embryonic development in the male rat, AMH 
induces the regression of the miiUerian duels, which forlll the 
anlagen of the uterus, oviducts, and upper vagina. The Leydig 
cells in the developing testis produce testosterone, which stim-
ulates the differentiation of the wolffian ducts into epi-
didymides, va~a deferens and seminal vesicles. The window of 
sensitivity of the miillerian duct to A~vIH in the rat has been 
shown to be between- EI4.S-ElS.S. After E16, exposure to 
Ar>.·1H does not result in mUlIerian duct regression (Josso et al., 
1977; Tsuji et aI., 1992). In female embryos, the lack of 
nndrogcns leads to wolffian duct regression, and the mUllerian 
duct persists because the ovarian cells do not produce AivlH. 
All these events form part of the earliest steps in sex differen-
tiation following gonadal sex determination. In addition to its 
effect upon the miillerian duct, A~'lH may have a role to play 
in the development of ovaries and testes (Miin.~terberg and 
Lovell-Badge, 199 I; Hirobe et aI., 1992). The cellular 
mechanism by which Ai\'lH induces mlillerian duel regression 
is poorly understood. Recent results show that At\'lH elicits its 
effect upon the mOllerian duct epithelium most likely via the 
surrounding mesenchymal cells (Tsuji et aI., 1992). 
The expre~sion of CI4 mRNA during embryonic sex differ-
candidate AMH type /I receptor 
entiation, described in the present report, is in accordance with 
the hypothesis that C14 encodes a type un receptor for AMH. 
MATERIALS AND METHODS 
Tissue and RNA preparations 
Sertoli cells and peritubular myoid cells were isolated from 21-day-
old rats and cuhuri'd as described previously (Themmcn et aI., 1991; 
llIok et aI., 1992). Round spennatids were isolated from 35-day-old 
rats as described by Grootegoed et al. (1986). Total tissues, isolated 
cell fractions, or cultured cells were snap frozen in liquid nitrogen and 
stored at -70'C until used for RNA isolation. Total RNA wa.~ isolated 
using the UCllurea method (Aufray and Rougeon, 1980). 
Isolation of C14 from a rat Sertol! cell eDNA library 
Sertoli cells were cultured for 6 hours without (-T) or with 0.6 I-lM 
testosterone (+ T), in the presence of 50 pglml cycloheximide. These 
cells were u~ed to prepare -T and +T cDNA libraries in Lambda 
ZAPII (Stratagene, Westburg, Leusden, The Netherlands), using 
standard molecular biology techniques (Sambrook et al., 1989). All 
radiolane1led agents were frum Amersham ('S Hcrtogenbosch, The 
Netherlands). A + T-enriched subtracted probe wa~ prepared (Sive and 
St John, 198~), using in vitm synthesized cRNA from the - T cDNA 
library a~ driver RNA. RNA was synthesi7ed using an in vitro RNA 
transcription kit (Stratagene) according to the illstruction~ of the man-
ufacturer. Clones from the +T cDNA library that ~howed a stronger 
hybridi7ation signal with the subtracted pwhe than with a -T cDNA 
probe were iwlated, and pos,ible induction by androgens wa, tcsted 
on northern blots containing +T and -T total RNA. Northern blotting 
and random-primed labeHing of the CI4 cDNA with 132p]dATP was 
performed according to Sambrook et al. (1989). CI4 mRNA 
expres,ion initiaHy seemed 10 be andwgen re~ponsive, but this wa.' 
not eonfinned in later experiments (Fig. I). 
Sequencing 
The complete 1.9 kb C14 cDNA clone wa, sequenced on both strands 
using the dideoxy chain termination mcthod (Sangere! al., 1977). The 
sequence wa.' analyzed using the sequence analysis program Micro-
genie (Beckmann. l\lijdrecht, The Netherland.,). Computer searches 
were l'arried out llsing the UWGCG program (Devereu)(, 1992). 
RNase protection assay 
A PstI fragment containing bp 1243-1640 frolll Cl4 wa.' subcloned 
in pBluescript KS (Striltagene) and med to generate [32p]UTP_ 
labelled anti-sense transcripts in vitro. TIle foHicle-~timulating 
hormuae receptor (FSHR) RNA probe was obtained using a 386 bp 
Hil1dIII/Pl'lli1 frngnlent from the rat cDNA (Sprengel et aI., 1990). 
The aetivin receptor type II (ActRIl) RNA probe was obtained using 
a 569 bp rat ActRII eDNA fragment (de Winter et al., 1992). The 
control glyceraldehyde 3-pho~phate dehydrogcnlhe (GAPDH) RNA 
probe wa~ "ynthe'ii7ed ming a cumtruel containing a 291 bp 
XbaUSal/3AI fragment fWllI rat GAPDH eDNA (Fort et al., 1985). 
Approximately 5x10~ cb/minute of C14, FSHR, or ActRII prnhe, 
tugether with 5xlet1' ets/minute of GAPDH probe, \Va, mixed with 5 
or 10 ~lg uftotal RNA in a total volume of 30 ~tl hybridi7ation mixture 
containing 40 lllftl Pipes pH 6.4, I mM EDTA, 0.4 M NaCi and RO% 
(v/v) fumlamide. TIle hybridizations were performed overnight at 
55'C. TIle RNa"e proll'Clion H"qy \Va., perfomll'd as de'icribed by 
Sambrook et al. (19&9). 
In situ hybridization 
The Cl4 suhclone that was used for RNa,e protection assays was also 
used to prepare sense and anti-~eme 35S·UfP-labelled transcripts in 
vitro. The probes were diswlved in 5 ~ll n.2 M OTT. Immediately 
priur to use, the prohe solution was mixed with 5 ~IJ of 30 pglpl S-
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ATP (Calbiochcm, Omnilabo, Breda, The Netherlands), incubated at 
IOO'C for 1 minute and diluted in prewanned (55'C) hybridization 
mixture to a final concentration of approximately 2xlO5 cIs Iminute 
per ~tl. The hybridization mixture contained: 50% (v/v) deionised 
fomwmide, 0.3 }'1 NaCl, 10 mM Tris pH 8, I nL\1 EDTA, Ix 
Denhardt's solution, 1 rug/ml yea,1 !RNA, 50 mM orr and 10% 
(w/v) polyethylene glycol 6000. 
The lower body region of embryos at EI5 and EI6 wa~ separated 
from the head region and fixed in fresh Bouin's fixative ovemight at 
4'C. All in ,~itu hybridizution prO\:cdures (tis~ue embedding, slide 
preparations, pretreatments, hybridization and posthyhridization im:u-
bations) were performed as described by Z('!kr and Rogers (1991). 
The tis~ue was embedded in paraffin, and S ~(M sectiom were 
mounted on slides which were coated with poly-L-Iysine. Adjacent 
sections where mounted and stained "ilh Mayer's haematoxylin and 
cosin for tis~uc and cell identification. Thc hybridi7ations werc 
perfomled at 55'C ovcrnight in moist chambers. The slides were 
dipped in 1:1 (v;v) dilution of Kodak NTB-2 emulsion and dried at 
room temperJture for 2 hours, followed by expmure at 4'C for 2 
weeks. After developing, the sections were counterstained with 
Nuclear fast red and mounted. 
Genomic DNA isolation and peR procedures 
The head region of the emhryo, at EI5 and EI6 was snap frozen in 
liquid nitrogen and used for genomic DNA i:,olation according to 
Davis et al. (1986). This DNA wa, used in a DNA amplification 
reaction (Saiki et aI., 19!!S) using primers for mou,e Sbx and Sby 
(Mitchell et ai., 1991, Kay et aI., 1991) a, described by Mitchell et 
al. (1991). The pmduct ohtained with the 
Sbx primen. (approximately 250 bp) was 
used a, a po~iti\'e control 10 te,t the 
quality of the DNA, and the presence or 
absence of a product with the Sby primers 
(appmximately lOOO hp) wa, u~ed to 
determine the sex of the embryos (results 
not shown). 
RESULTS 
Selection of C14 
C14 was isolated from a Sertoli cell 
eDNA library as described in 
!vlaterials and methods. The 1,9 kb 
CI4 cDNA probe hybridizes on 
northem hlots to a major transcript of 
[Ipproximately 2,5 kb, which is 
expressed at high levels in cultured 
Sertoli cells (Fig, I), However, there 
was no significant stimulation of the 
expression hy testosterone. The tissue 
specificity of C14 mRNA expression 
was determined using an RNase pro-
tection assay, Fig. 2 shows that CI4 
mRNA expression in the adult rat is 
mainly restricted to the gonads, 
Based upon this marked tissue speci-
ficity of CI4 mRNA expre~sion, Cl4 
was selected for furthcr investigation. 
C14 sequence analysis 
The complete 1.9 kb CI4 cDNA was 
sequenced. It contains a single open 
reading frame that encodes a 557 
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• Fig, I. C14 mRNA 
cxpre,sion in culturcd 
Sertoli cells. C14 
eDNA probe wa, 
hybridized 10 a 
northem blot 
containing 20 pg total 
RNA isolated from 
Sertoli cells cultmed 
in the absence (-) or 
presence (+) of 
testosterone (~ec aho 
Materials and 
methotl~). Clone 14 
indicates the 25 kh 
h,md ofC14 mRNA, 
ahundantlyexpressed 
under hoth culture 
condilion~. TIle 
GAPDH hybridi7.1tion 
indicates that e{IUai 
amounts of mRNA 
wac 10Jded in each 
lane. 18S and 2RS 
indicate the locations 
of the re<;pcclive 
rRNA bands. 
amino acid protein, starting from the first methionine codon at 
residue 60 (Fig. 3A), This ATG codon and its context foml a 
potential functional initiation site (Kozak, 1987). Analysis of 
the protein sequence indicated the presence of a signal 
sequence with a predicted cleavage site before Glnt6 (yon 
Heijne, 1986), A hydrophobic region between amino acid 
residues 142-168 represents the single putative transmembrane 
domain (TMD), Thus, the mature protein consists of an extra-
cellular domain of 126 amino acid residues, a TMD of 27 
amino acid residues, and an intracellular domain of 389 amino 
acid residues. The extracellular domain is cysteine rich and 
contains 2 potential N-glycosylation sites. 
Ei\-IBL and GenBank database searches revealed that the 
intracellular domain of CI4 is most closely related to the intra-
cellular domains of the mouse activin receptor types II (ActRII; 
Mathews and Vale, 1991) and rIB (ActRIIB; Auisano et a1., 
1992), the human TGF-j3 type II receptor (TGF-pRII; Lin et 
aI., 1992), the mouse TGF-j3 type I receptor (TGF-I3RI; Ebner 
et a1., 1993), and the c. elegall.\· orphan receptor lJaf-1 (Georgi 
et al., 1990) (Fig. 3B), The ActRII, ActRIIB, TGF-j3RII, TGF-
i3RI and Daf-I together form a separate subfamily of receptors 
with intrinsic protein kinase activity (Mathews and Vale, 1991; 
Lin et a!., 1992). Recently, several rat orphan receptors have 
been cloned, that are also members of this newly defined 
receptor family (He et aI., 1993). 
The C14 intracellular kinase domain contains the 12 subdo-
mains, which arc found in all protein kinases, in the proper 
order (Hanks et aI., 1988), and also contains the two inserts 
located between subdomains VI-A and VI-B and between sub-
domains X and XI, that arc characteristic for the subfamily 
(Mathews and Vale, 1991). The percentage identical amino 
acids of the kinase domain of Cl4 compared to the ActRII, 
TGF-j3RII, TGF-pRI and Oaf-I Idna~e domains is 34%, 32%, 
33% and 29!"Jo, respectively, 
The sequences in the kinase subdomains VI-B and VIII 
indicate substrate specificity (Hanks et aI., 1988), The relevant 
sequences in CI4 within these subdolllains are more in accor-
dance with the serine/threonine kinase consensus sequence 
than with the tyrosine kinase consensus sequence, with the 
exception of serine residue 333, At this position in the kinase 
domain, a lysine residue is found in almost all known 
serine/threonine kinases including ActRII, ActRlIB, TGF-
j3RII, TGF-pRI and Oaf-I. 
The extracellular domains of C14, ActRIl and TGF-pRIl 
show a relatively low level of sequence identity (Pig. 3C), 
However, the position of most cysteine residues is conserved. 
Fig, 2, Tis~ue ~pedfidty ofCI4 mRNA expre~~ion. RNase 
pmtection :L\~ays were u'ied to ~tudy the expres\ion of CI4 mRNA in 
diffi..'rL'nt ti~"ues. From 4-week-old rat~: Te, te.'itis; Oa, omry; Ut, 
uterus. From adult rats: Oi, oviduct; Pr, pru~tate; Ep, epididymi~; Se, 
seminal ve~icle; Rr, brain; Pi, pituitary gland; Ill', heall; Lu, lung; 
Sp, "pleen; Li, liver; Ki, kidney; In, inle~tine; ~lll, nlu\cle, 10 ~tg of 
total RNA W:L\ metl for each lane. CI4 indicates the p()~itinn of thl' 
prulcL·ted RNA fr;Jgnlent. Glyceraldehyde 3-pho,phatc 
dehydrogena~e (GAPDlI) mRNA \Va.\ prc~ent in all samples (not 
~ho\\'n). 
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CCGiiCACOAGCU:rAGCTGTGCTCCTCTGTGCTGTCCiccrOr..CI\,CCtrrAGTA<;(IA==ACAcr=crrrGGACACTGCTICCTGCAGCIGCACAAGTATCCCCAAACAGG 
II L G T L G L W T L L r A A b Q V S P N II 
A(;GI\CCTGTGTGHCrHOA=e<::TGGAGTTCGCCGAAGCACMAAACACTGGCCOMGIGCTIVJATG-CAGCACCA(;(;CCCCCCGAl\GGGTAICCGCTGCCICTACAGCCAiiGCiGC 
R T C V f f EAr G v R G S T K T L G E V V 0 A (I P G P P K G I II eLY sue c 
Ti1CGGATCiG<JAATCTGACCCATGGCCGGGCl\CAAGTGGAGATCCAAGGATGCCTIVlACAGTOAHl/IJICC=TGTGAGTCCCTCCACTGTChC<:<:CGtCCCCCGAGCGCACCCC1..GC 
PC I W!:!......!.....11 G RAQVE MQO CLDSD E poe E S l,.11 COP v P Ri\1I P S 
CCCAGCICCACACiCllCACATGC1CCI=TACCGACTTCIGCAATGCCAACT/\,CACCClliClCCCiCCrTCAG<l1<MCC(lA=rCC=CCCCCAGGAG-CCTCAGGCTACCCCA 
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E PEP G S G G 0 C 5 EEL PEL II E L R P 8 Q V I Q E (l Q a II v V W II <) R L Q 
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OEM V II I K A ~ P P R A V II Q P RilE R A V T Q L L (l L Q 8 H 8 I V R P I ~ A 
GGCCAGGCAGG-CCCTG<>CCCCTTGCCCrCTGGGCC1ITGCTGGTACTGOMCTGTI'.CCCTMGGGCl'CC1:TATGCCACTACTTGAC1:CAGTACACGAGCGACTGGGGCAGrl'CCTIGAGG 
G Q G G P G P L PSG P L L V L ELY P E <) 8 L C H Y L T Q T i 8 0 W (l 8 S L R 
A1:GGC1:CTG'CCC1:G<>CCGAGGGCCTGGCGT'TCTCCACGGG<>AGC(;n:CCCACQAl'GG-CCAGTACAAACCAG<>l'A1CGC,CACCGIIGIICCTGIIGCIIGCQAGM1G1GCTCArTCGGGAA 
MAL 8 L A E <) L A ~ L H <) E R W Q D <) Q YEP G I A H R D L 5 S Q H V L IRE 
GATAGGiCATGiGCCATCG<lAGACCTGGGCCTTGCCTTGGiAC,CCC,G<>CCHGCiCAGCCCCCTGCCiTGGCC(:CiACTCAGCCCCGAGGCCCAGCTGCCATiHGGI'.GG-CTGCCACC 
DRS C II I <) D L 0 L II L V L P <) L II Q P PAL A P ~ Q P Rl G P II A I LEA 0 ~ 
CAGAGGTACATCCCTCCGO"'~CiCTTGCACMGACTCiAGIICCl'GCAG<lIlCTGGGGCACAGCrCTCCAGAGAGCCCATGTTTACTCl'CTGGCTCl'ACl'ACTGTGG'JAGATCC1<)AGCCG-C 
Q R Y HAP ELL D K T L D L Q 0 W G ~ A L Q R A D V Y 8 L ALL L WEI L S R 
lGT1CCGlliTTGAGGCCTGACCACAGACCACCACCl'l'l'iCMTTGGCTTAiGAGGCAGAACTGGGCAGCAATCCCAG,GCCTGTGAGCTCTCC<lCCCl'GGOGGTCGcGOMACQMG(:<;C 
C S P L R P D 8 R P P P F Q LAY E II E L Q S H P SAC E L W A L A V A E R K R 
CCCMCAiCCCl"tCCTCiTGOAGCTGCl'CTGCC~C'AGACCCrAGGGGGCTGIIGGGAGCTCCTCGAAGATrGCiif-A~CCCAGI'.C'CC~GMG<;M=GACAGCl'G~GTGl'GTGCAGCAG 
PHI P S 8 W S C SAT D P R (] L R ELL E D C W PAD P BAR L r ABC V Q Q 
CGCCiGGCIIGCCCl'GGCTTATCCTCAGG,GGCTiCCTCCTiCCCAG~OIlGCTGTCCACACC<lCTGCCCAGAGMCTACCCTGCAGC<lCCTGCC,C,GcGOCrT7CCC(;'!GCAGGCCTCAG 
R L II A LAY P Q v ASS r PES C P Q G C PEN Y P A II PAS II A FPC R P Q 
CAGAGiiCTiGiCiCCTCAGl'Gl'l'CAGCMGGCTCIGGCTCTAAGTCCTGMCCTGTAAGiGCCActGTTCIIGGTGT~l'Gl'M~iGI'.G<:AGCl'CATATGl\ACTCTGTIICAGGCTGACATG 
Q sse L L S V Q Q 0 S G S K S • 
CGTG.GGCCGI'.CATGCGIGTGIC<lGGTGiCI,GCCTClo.iGCC,GHGIITGICAriCTGTGT=TTl'Cl'AACCC~iCGGCTIIGCl'Al'GCiCAGGAAAGAGMTAAAGCAAGAT1CCCACTC 
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Fig. J. Anilly~i~ ufC14 eDNA. (A) The 
complete 1920 bp eDNA clone 
~equcnce en~'oding a protein of 557 
amino acid l'e'iidues is shown. The 
kina~e domain is in bold Iyp~. Th~ 
hydTllphobie ~ignal ~e{lllenCe and 
trammembrane region are underlined, 
and the potential N-glycosylation sites 
arc douhle underlined. (B) Comparison 
of the kina'ie domain ofral C14 to the 
kina~e {Inrnains of muu,c ActRlI and 
human TGf-pRlI. The Roman numerals 
under the sequencc indicate the kina..'ic 
subdomain'i. TIle in~erts between 
.'iuhdomain'i VI-A and VI-E and 
between ~ubdomains X anti XI arc 
underlined. The a,tcri,k denote~ the 
location of serine re,idue 333. 
(C) Comparison of the extracellular 
domain ofC!4 to the extracellular 
dOlllain~ of ActRII and TGF-pRII. In n 
amI C revened ~l"ript is used to 
highlight amino add residue, that are 
found in at lea~t two of the three kina'ie 
receptors. 
C14 expression during embryonic sexual 
differentiation 
growth factors. Cl4 is ('xpressed mainly in the gonads in adult 
rats (present results), whcre allti-mlillerian hormone (AMH) 
may petform specific fUllctions (Hirobe et aI., 1992; .MOnster-
berg and Lovell-Badge, 1991). This pointed to Al\·IH as an 
important candidate ligand for C14. To investigate this possi-
The fact that CI4 ent·odes a memher of the activin and TGF-
/! type 1111 reccptor family, indicates that the CI4 ligand will 
be a member of the adivin amI TGF-/!-family of pertide 
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Fig. 4, Expression of CI4 mRNA at EI5 and E16. Bright-lield photomicrographs fmrn in situ hyhridization of the llnti~en,e C14 RNA probe to 
paraffin "ection, (A,C,E,G) and from hal.'mat(}xy\inJco~in ~t<lined adjacent sections (H,n,F,H) of female embl)'o'i at E15 (A,B). El6 «(',0), \mt! 
of male embryos at El5 (E,F) and EI6 (OJ I), Emhl)'onal ~ex wa~ detennincli ;1'i de'icribetl in Maleriah and m('\hod~. g, gonad; arrowhc,ld, 
wolftlan duct; arrow, mlil1erian dud. Hyhridization of the sen~e control C14 RNA probe did Tlot result in ~ignals above background (nol 
shown). 
6B 
bility, the expre~~ion pattem of CI4 mRNA in the urogenital 
ridge of rat embryos during the induction of mUllerian duct 
regression wa~ studied. 
Using in situ hybridization, marked CI4 mRNA expression 
was detected in thc fcmale gOlwds, but not in thc male gonad~, 
of embryos at EI5 and EI6 (Fig. 4A-H). Furthermore, CI4 
mRNA is expre~sed in the female urogenital ridge~ at HI5 and 
E16, in a sickle-shaped area that includes the mesenchymal 
cclls between the mUlIerian duet and the eoclomic epithclium 
(Fig. 4A-D). In the male urogenital ridges at El5, the 
expres~ion of Cl4 mRNA is idcntical to thc H15-R16 female 
pattem (Fig. 4E,F). However, this male expression pallem has 
clearly changed at E16, when Cl4mRNA i~ present in a small 
circular area that includes the degenerating mUllerian duct (Fig. 
4G,H). No other site~ of CI4 mRNA expre~sion uboye back-
ground were detected in the lower body halves of the embryos 
at EI5 and E16. 
RNase protection as~ays were used to study the expression 
ofCI4 mRNA in isolated urogenital ridges and gonads at E15, 
RI6 and HI~ (Fig. 5). CI4mRNA was detected at much higher 
levels in ovary than in testis at all embryonic stages tested. At 
H15, CI4 mRNA expression in the urogenital ridge was 
detected at approximately equal levels in both male and female 
embryos. However, at R16, the CI4 mRNA level in the male 
urogenital ridge is lower than in the female urogenital ridge. 
Finally, at E19, CI4 mRNA was not detected in Ihe male uro-
genital ridge, whereas the C 14 mRNA level remains high in the 
female urogenital ridge. No CI4 mRNA W,L~ detected in total 
RNA isolated from RI~ intestine, skin, lung, liver, kidney, 
adrenal, stomach, hearl, thymus, muscle, ami brain (not ~hown). 
Postnatal expression of C14 mANA In testis and 
ovary 
Different testicular cell types were isolated, to study the 
cellular location of C 14 mRNA expression in the lestis using 
RNase protection assay. It was observed that CI4 Il1RNA is 
~pecilically exprcs~ed in Sertoli cells, at equal levels in cells 
isolaled from 21-day-old or mature rats (Fig. 6A). No CI4 
mRNA was detected in rollnd spem1atids and peritubular 
myoid cells. ActRII mRNA, which is expressed at a high level 
in round spenlJatids (de Winteret a\., 1992), was uscd to verify 
the integrity of the rollnd spermatid mRNA. FSHR mRNA, 
which is expressed exclusively in Seltoli cells (Heckert and 
Griswold, I~~I), was used to show the cellular colocalization 
of FSHR and C 14 mRNAs and the ahsence of Sertoli cell con-
tamination from the other isolated cell types. 
CI4 mRNA expression in lotal testis is very low at birth, 
and increases to a maximum at day 21 of postnatal develop-
ment (Fig. 6B). Since we found similar levels of cxpression in 
Seltoli cells from immature and adult rats (Fig. 6A), the 
relativc decrease in Cl4 mRNA expression ill total testis 
between days 21 and 63 can be explained by the increasing 
population of Cl4-negativc spermatids. 
In the ovar), of adult rats, marked expression of C 14 mRNA 
was detected, using in situ hyhridization, in the granulosa cell 
layers of ~mall antral follicles (not shown). 
DISCUSSION 
Bascd upon the observation that in adult rats CI4 mRNA 
expression is most abundant in the gonads, CI4 Was seleeted 
candidate AMH type /I receptor 
and characterized. C 14 encodes a novel member of the activin 
and TGF-p type IIII serine/threonine kinase receptor t:·1Il1ily. 
Including C 14, nine members of this gene family are presently 
known: Daf-I encoding an orphan receptor (Georgi et ai., 
1990), TGF-pRII (Lin et ai., 1992), TGF-pRI (Ebner et ai., 
1993), R2, R3 and R4, which arc three orphan receptors cloned 
through PCR amplification of rat fetal urogenital ridge eDNA 
with a relatively high percentage of similarity to TGF-pRI in 
the kinase domain (He et ai., 1993), and two genes encoding 
the different aetivin type II receptors, ActRII and ActRIIB 
U\'tathews and Vale, 1991; Atlisano et ai., 1992). The sequence 
identity between ActRII and ActRIIB is 51(,'t in the extracel-
lular domain and 75% in the intracellular domain, and four 
differcnt splice variants of ActRIIB have been described 
(Attisano et ai., 1992). 
There is complete structural homology between CI4 and the 
other members of the serine/threonine kinase receptor family. 
The CI4 kinase domain has the highest degree of amino acid 
identity with the kinase domain of ActRII (34%). However, the 
ActRII and TGF-pRII kinase domains are more closely related, 
showing 45% amino acid identity to one another. It has been 
shown by Nakamura et al. (1992) that AetRIIB is a dual speci-
ficity kinase, which can phosphorylate serine/threonine as well 
as tyrosine residues. It remains to be determined whether the 
changc from the conserved lysine to a serine at position 333 in 
the CI4 kinase domain has 
any significance with 
respect to substratc speci-
ficity or kinase activity. 
Our hypothesis that 
Al\·1H could be an 
important candidate ligand 
of CI4 implies that CI4 
mRNA should be 
expressed in the urogenital 
ridge during thc induction 
of mtillerian duct degener-
ation by Ai\lH, around day 
15 of emhl)'onic develop-
ment in the rat (lost, 1947; 
Tsuji et aI., 1992). It was 
observed that CI4 mRNA 
is expressed in an area that 
includes the mesenchymal 
cells between the 
mUllerian duct and the 
coelomic epithelium at 
E15, in both male and 
female emhryos. Recent 
results have shown that 
AMH can reduce DNA 
synthesis of cuitured uro-
genital ridge mesenchymal 
cells but nol of cultured 
mUllerian duct epithelial 
cells (Tsuji et ai., 1992). 
This wggests that Al\UI 
most likely elicits its effect 
upon the mHlIerian duct 
epithelium via the sur-
rounding mesenchyme 
A 2 3 4 
C14 
----
GAPOli •••• 
a 
C14 
-
GAPDH ...... 
C 
C14 
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Fig. 5. Expr~ssion ofC14 mRNA in 
different embryonal tissues at E15, 
EI6 and E19. Embryu~ were 
collected at EI5 (A): El6 (U) and 
EI9 (C), anti CI4 mRNA 
expres~iun was ~tudied using RNase 
protection as~ays in: Lane I, ovary; 
2, female urogenital ridge; 3, testis; 
4, male urogenital ridge. CI4 and 
GAPDH indicate the positions of 
the respective protected fragments. 
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(Tsuji et aI., 1992). Light and electron microscopic studies 
have demonstrated that the regression of the miillcrian duct 
epithelium is closely associated with changes in the surround-
ing mesenchymal cells and changes in the epithelial-mes-
enchymal interface. One of the observed changes during 
miillenan duct regression is the formation of a dense circular 
whorl of mesenchymal cells around the epithelial duct 
(Trelstad ct al., 1982), These observations all the ccllulnr sill'S 
of AMH action and histological changes associated with 
mUlierian duct regression, correlate with C14 mRNA 
expression. 
The level ofC14 mRNA in the urogenital ridges at EI6 is 
relatively low in male compared to female embryus. AI E19, 
C14 mRNA is expressed at a high level in the female urogen-
ital ridge whereas at this stage it is no longer detected in the 
male urogenital ridge. This correlates with the gradual degen-
eration of the millJerian ducts in male embryos between El6 
ami E19 (Trelstad et al., 1982). Furthermore, in the female, the 
Ai'vlH receplor indeed persists after the critical period of 
induction of mtillerian duct regression as can be concluded 
from the observation that A~'fH induces the formation of 
bulges in the cranial portion of the mUllerian duct, in cultllfed 
urogenital ridges that were isolated from female emhryos at 
E18.5 (Tsuji et al., 1992). 
Using in situ hybridization at EI5 and E16, marked CI4 
Il1Rt~A expression was detectcd in devcloping ovarics but not 
in testes. However, llsing RNase protection assay'" at E15, EI6 
and E19, C14 mRNA was detccted at low levels in the testis 
(and at a high level in the ovary); the RNase protection assay 
appears to be more sensitivc than ill situ hyhridization. In view 
of this CI4 mRNA expression in fetal te~tis, A~lH and its 
receptor might be involved in normal testis differentiation in 
the male. Overexpression of A;vlH in transgenic mice can 
induce formation of testis cord-like structures in fetal ovaries 
(Behringer et aI., 1990). Furthermore, AMH exerts an 
inhibitory effect on aromatase activity in cultured fetal O\'arie~ 
(Vigier et a\., 1989). Arornatasc catalyzes the conversion of 
testosterone to estradiol during female gonadal development, 
and inhibition of ovarian aromatase activity by AMH leads to 
production of testosteronc rather than estradiol. These biolog-
ical responses to AMH suggest that the AMH receptor indeed 
is present in fetal O\'aries, where it is probably inactive due to 
the absence of MvIH. Following day 3 of postnatal develop-
ment, Ai'vIH is expressed in the ovary where it might playa 
role in oocyte maturation (Hirobe ct aI., 1992; l\-liinsterbcrg and 
Lovell-Badge, 19(1). In agreement with this, we observed 
postnatal ovarian expression of CI4 mRNA in the granulosa 
cells of small antral follides. Future studies will have to 
provide more infonnation about the pattern and regulation of 
CI4 mRNA expression in the ovary. 
It is not known whether AMH plays a physiological role in 
the testis after birth. We have shown that CI4 mRNA 
expression increases in Sertoli cells to a maximum during 
postnatal testis development, and remains high in the adult rat 
testis. With respect to testicular production of the ligand, it is 
known that testicular Ai'vlH rnRNA expression decreases after 
birth, but persists at a low level throughollt adulthoml (Lee et 
aI., 1992). Low levels of AMH may exert autocrine actions 
upon Sertoli cells in immature and mature te~tis. It is also 
possible that testicular AMH production varies at different 
stages of thc spermatogenic cycle and hence involves local 
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concentration gradients. Inherited defeds in the biosynthesis 
of MvlH do not seem to have a major effect on male fertility 
(Josso, 1992), but this does not exclude a quantitative defect 
in spermatogenesis. Moreover, other testicular factors 
(possibly members of the activin and TGF-p family of peptide 
growth factors) Illay partly compensatc for a lack of A"l\·IH by 
binding to their specific receptors and activation of similar 
intracellular pathways. 
The present results are in accordancc with but do not 
provide conclusive evidencc for - the hypothesis that Cl4 
encodes an A~'lH receptor. Evidence might be provided by 
showing AMH binding to cells that are transfected with a C14 
expression vector. Howevcr, allcmpts that have heen made in 
the past to show hinding of AMH to its receptur on AMH-
responsive cells have been hampered by the fact that radiola-
belling of A"l\·1H seems to abolish its ability tll bind to the 
receptor (Donahoe et al., 1977). furthermore, conclusive 
results that identify a receptor ligand throH~h a binding assay 
using a cell line that stably expresses the relevant receptor, 
might be dif11cult to obtain if this receptor hehaves as a type I 
receptor; such a receptor would require cooperation with a 
sped lie type II receptor which may not be endogenously 
expressed in the cell line used. To resolve these problems, it 
will be necessary to develop a binding assay for A~IH. Then 
the possible existence of different types of A"l\·IH receptors ean 
be studied, and suitable model cell lines can be developed to 
te~t c;mdidate receptors for ligand binding. 
The persistent mtilledan duct syndrome (p;\'mS) is a rare 
forlll of male p.\cudohcnnaphroditism that is characterized by 
Fig, 6, Cl4 mRNA e.\pn.~,~ion in te~ti~. (A) The l'.\pre,\ion ofCl4, 
:telivin type II H::eeptur (ActRIl) and follide-stimulating hOffilOne 
receptor (FSHR) mRNAs in different te,tkular cell types, 
detemlined using RNase protection a,~ay~: LlIle t, 2 t-day-old rat 
AclRI! 
FSHH 
C14 
GAPDH 
C14 
GAPDH 
2 3 4 
-. 
•• 
--
, 
• 
Sertoli cells; 2, adult rat Serto]j 
cdb; 3, rollnd ~renl1~tid, 
isolated from J5-day-old rat 
{e'iti,; 4, pl'ritubulnr myoid cdls 
(P~IC) i,o[a!ed from 21-day-
old ml te\lis. CJ4. ActRII and 
ESliR indit;lle the pmitinl1' of 
the [;"pective prok'ek'd 
fragments. (B) Cl4 mRNA 
levels in total testis from rats of 
diffaent age\ u,ing RNa'ie 
proll'ctilln a~'liys. TIle nUlllhe[~ 
above each lane t'orr6pond to 
the postnatal agl' in days of the 
rat~. CJ4 and GAPDH indicate 
the pmitiOJi\ t1fthe re\pe~'li\'e 
protected fr'lgmenh. GAPDH 
mRNA lc\'ds an~ included in 
this tigur~' 10 ,how that the 
mRNA was intact. 
o 4 'r 10 14 21 28 42 49 57 63 
--_. 
----
the presence of uterus and fallopian tubes in othenvise 
nonnally Yirilized males (Jasso et at, 1991). In some of these 
patients it has been shown that the phenotype is caused by a 
mutation in the AMH gene (Knebel mann et ai., 1991), but 
other patients express a nOffilal amount of bioactive testicular 
AMH (Gucrrier ct aI., 1989). The existence of this type of 
PMDS indicates that lllutation of the AMH receptor gene(s) 
can result in a complete loss of responsiveness to AMH. In the 
future, ultimate proof that CI4 encodes an AMH receptor can 
be obtained through genetic analysis of PMDS, or when knock-
out transgenic mice are generated that show the characteristics 
of Pl\·IDS. 
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Summary 
Anti-mOlierian hormone (AMH) induces degeneration of the mOlierian ducts during 
male sex differentiation, and may have additional functions concerning gonadal 
development. In the immature rat testis, there is a marked developmental increase 
in AMH type II receptor (AMHRII) mRNA expression in Sertoli cells, concomitant with 
the initiation of spermatogenesis. AMHRII mRNA is also expressed at a high level in 
Sertoli cells in adult rats. To obtain information about the possible functions of AMH 
in the testis, we have investigated the postnatal expression patterns of the genes 
encoding AMH and AMHRII in the rat testis in more detail. 
Using RNase protection assays, AMH and AMHRII mRNA expression was 
measured in total RNA preparations from testes or testicular tubule segments, isolated 
from control rats and from rats that had received various treatments. The testicular 
level of AMHRII mRNA was found to be much higher than that of AMH mRNA in adult 
rats. AMH mRNA was detected at a maximal level at stage VII of the spermatogenic 
cycle, and at a low level at the other stages. AMHRII mRNA increases from stage 
XIII, is highest at stages VI and VII, and then rapidly declines at stage VIII to almost 
undetectable levels at stages IX-XII. It was found that the increase in testicular 
AMHRII mRNA expression during the first three weeks of postnatal development also 
occurs in sterile rats (prenatally irradiated), and hence, is independent of the presence 
or absence of germ cells. Yet, the total testicular level of AMHRII mRNA was 
decreased in sterile adult rats (prenatally irradiated, and experimental cryptorchidism), 
as compared to intact control rats. However, treatment of adult rats with 
methoxyacetic acid or hydroxyurea, which resulted in partial germ cell depletion, had 
no effect on total testicular AMHRII mRNA expression. It is concluded that a 
combination of multiple spermatogenic cycle events, possibly involving changes of 
Sertoli cell structure and/or Sertoli cell-basal membrane interactions, regulate autocrine 
AMH action on Sertoli cells, in particular at stage VII of the spermatogenic cycle. 
Introduction 
Anti-mOlierian hormone (AMH), also called mOlierian-inhibiting substance 
(MIS), is a member of the activin and TGFp family of peptide growth/differentiation 
factors (Cate et al. 1986). During male embryonic sex differentiation, AMH induces 
the degeneration of the mOlierian ducts, which form the anlagen of the uterus, the 
oviducts and the upper part of the vagina. AMH is the earliest product known to be 
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secreted by fetal Sertoli cells, starting at day 13 of embryonic development in the rat 
(Tran and Josso, 1982; MOnsterberg and Lovell-Badge, 1991; Hirobe et al. 1992). 
Sertoli cells are the exclusive source of AMH in the male. Granulosa cells also can 
produce AMH, but there is no ovarian AMH production during fetal development 
(MOnsterberg and Lovell-Badge, 1991; Hirobe et al. 1992). 
Recently, we have isolated a cDNA clone named C14, that encodes the 
candidate rat AMH type II receptor (Baarends et al. 1994). During embryonic 
development, C14 mRNA is specifically expressed in mesenchymal cells located 
adjacent to the mOlierian duct epithelium (Baarends et al. 1994), which is in agreement 
with the expected site of AMH action during mOlierian duct regression (Tsuji et al. 
1992). Furthermore, this gene is expressed in fetal ovaries and testes, and in 
granulosa cells and Sertoli cells in postnatal developing and adult gonads (Baarends 
et al. 1994). C14 is a member of the family of transmembrane serine/threonine kinase 
receptors, which also includes the TGF~ and activin receptors (reviewed by Lin and 
Moustakas, 1994). Members of the activin and TGF~ family signal through 
heteromeric complexes composed of type I and type II receptors (Wrana et al. 1994). 
The structural characteristics of C14 indicate that it is a type II receptor. di Clemente 
et al. (1994) have shown that the rabbit homologue (H1) of C14 specifically binds 
AMH. This provides further evidence that C14 and H1 encode, respectively, the rat 
and rabbit AMH type II receptor. Herein, this receptor will be referred to as the AMH 
type II receptor (AMHRII), in analogy to the nomenclature that is used for the TGF~ 
receptors. An AMH type I receptor may also exist. Moreover, the existence of 
additional AMH type II receptors is not excluded. 
In addition to its function during mOlierian duct regression, AMH may play an 
intratesticular role during gonad differentiation. This hypothesis is based on several 
observations. First, overexpression of the cDNA encoding AMH in transgenic mice, 
not only leads to mOlierian duct regression in female embryos, but also induces the 
formation of testis cord-like structures in fetal ovaries (Behringer et al. 1990). In 
transgenic males, high levels of AMH can perturb normal testicular development and 
testosterone secretion, resulting in partial feminization of genitalia (Behringer et al. 
1990). Second, the phenotypic sex reversal of fetal ovaries induced by AMH in vivo, 
is confirmed by the hormonal sex reversal that has been observed in cultured fetal 
ovaries, where exogenous AMH inhibits aromatase activity (Vigier et al. 1989). 
Aromatase catalyses the conversion of testosterone to estradiol during female gonadal 
development, and inhibition of ovarian aromatase activity by AMH leads to production 
of testosterone rather than estradiol. Third, the prenatal and neonatal expression of 
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AMH is high around the time of mitotic arrest, and decreases during the first 2-3 
weeks after birth in rat and mouse, concomitant with the initiation of spermatogenesis 
(Kuroda et al. 1990; MOnsterberg and Lovell-Badge, 1991). Also, there is a strong 
correlation between mitotic arrest at the prespermatogonia stage and expression of 
AMH in adjacent somatic cells, in ovotestis which occur in B6y'om mice (Taketo et al. 
1991). Based on these data, it has been suggested that AMH plays a role in the 
mitotic arrest of gonocytes (Cate and Wilson, 1993). Results from tissue culture 
experiments of neonatal mouse testes in the presence or absence of exogenous AMH 
indicate a related but different function, namely that the maturation from gonocytes to 
type A spermatogonia requires AMH (Zhou et al. 1993). 
Thus, although there are many indications for a role of AMH in the testis, further 
investigation is needed to clarify the exact nature of testicular AMH actions. The 
cloning of the AMHRII has provided a new tool to study the targets of AMH action. 
There is a marked increase in rat testicular AMHRII mRNA expression, derived mainly 
or exclusively from Sertoli cells, concomitant with the initiation of spermatogenesis 
between birth and postnatal day 21 (Baarends et al. 1994). Furthermore, the level of 
AMHRII mRNA in Sertoli cells remains high during adult life (Baarends et al. 1994). 
This postnatal upregulation of AMHRII is in contrast to the reported decrease in AMH 
expression during postnatal testis development (MOnsterberg and Lovell-Badge, 1991; 
Hirobe et al. 1992; Kuroda et al. 1990). No effects of AMH on adult testis function 
have been reported. 
To gain more insight in the possible roles of AMH and its type II receptor in 
postnatal testis development, we have studied the testicular mRNA expression 
patterns of AMH and AMHRII during testis development in immature rats and during 
the spermatogenic cycle in adult rats. 
Materials and Methods, 
Animals and treatments 
Wistar rats were maintained under standard animal house conditions. Four different 
experiments were performed to lest the effects of germ cell depletion on AMH and AMHRII (C14) 
expression in the testis. In Experiment 1, pregnant rats were y-irradiated (1.5 Gy) at day 19.5 posl 
coilum, as described by Beaumont (1960). This treatment results in a total or near total toss of 
gonocytes. Testes from control and irradiated rats were isolated at postnatal days 9,14,21, and 70. 
One testes of each animal was used for RNA analysis and the other was used for histological 
observation. 
In Experiment 2, ten adult rats (9-11 weeks of age) were made experimentally cryptorchid by 
suturing both testes to the abdominal wall. At 2, 4, 8, 12, and 14 days after the operation, two 
cryptorchid anImals were anesthesized (the experiment included also two control rats). One testis of 
each rat was removed and snap frozen for RNA isolation, prior to perfusion of the rat with physiological 
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saline followed by Bouln's fixative via the aorta. The tesUs was postfixed overnight in Bouin's fixative 
and used for histological examination. 
In Experiment 3, twelve adult rats were used, ten of whIch were treated with a single oral dose 
of methoxyacelic acid (MAA) (Janssen Chimica, Beerse, Belgium) (650 mg in 2.9 ml physiological 
saline/kg body weight) according to Bartlett et al. (1988). MAA is a germ cell toxicant that leads to 
selective loss of pachytene and later spermatocytes at aU stages of the spermatogenic cycle other than 
early-la-mid stage VII. In MAA-treated rats, spermatogenesis proceeds with normal kinetics, which 
results in the absence of specific germ cell types at different time points after MAA treatment, due to 
maturation deplellon. Two control rats received physiological saline alone. At 3, 7, 14,21, and 28 days 
after treatment, two MAA-treated rats (control rats at 3 and 28 days after saline injection) were 
sacrificed and the testes were processed as described for Experiment 2. 
In Experiment 4, four adult rats were given three I.p. injections with 500 mg/kg body weight 
hydroxyurea (Aldrich, Sigma, Bornem, Belgium) In physiological saline (HU) or physiological saline 
alone (controls) every 16 hours. HU affects cells in the S·phase except for a 4h delay in the G1-S 
transition (Cud et al. 1979). This HU injection protocol depletes the testis of some undifferentiated 
spermatogonia and all differentiating spermatogonIa types A, Intermediate and B (Oud et al. 1979). 
Five days (115h) after the last injection the animals were sacrificed, and Ihe testes were processed as 
described for Experiment 2. 
Histology 
After perfusion fixation and overnight post-fixation in Bouln's fixative, testes were dehydrated 
and embedded in paraffin. Eighl-f.lm sections were made and stained with periodic acid-Schiff and Gill's 
haematoxylin No.3 (Polysclences Inc., Warrington, USA). From each animal, numerous tubular cross-
sections were examined using light microscopy, to determine which spermatogenic cell types were 
present or depleted. 
Tissue and RNA isolation 
Seminiferous tubule segments al defined stages of the spermatogenic cycle were collected 
according to Parvinen and Ruokonen (1982). 
Total tissues or pooled tubule segments were snap frozen in liquid nitrogen and stored at -80 
C until used for RNA isolation. Total RNA was isolated using the LlCllurea method (Auffray and 
Rougeon, 1980). 
RNase protection assay 
A Ps~ fragment containing bp 1243-1640 from C14 was subcloned in pSluescript KS (Stratagene, 
Westburg, Leusden, The Netherlands) and used to generate C2P]-UTP-labelled anti-sense transcripts 
In vitro. All radiolabelled agents were from Amersham ('S Hertogenbosch, The Netherlands). A rat 
AMH DNA template for in vitro transcription was generated using a DNA amplification reaction (Saiki 
et al. 1988). Railiver was used for genomic DNA isolation according to Davis et al. (1986). The 
primers 5'GCTGCTGCTAGCGACTATG3' (forward primer) and 5'AGATGTAGGCTAGCAACTG3' 
(reversed primer) were used to amplify bp 38-400 of the lirst exon of the rat AMH gene (Haqq et al. 
1992). An amount of 200 ng of each of the primers was added to the DNA amplification reaction using 
700 ng genomic DNA as a template in a standard reaction mixture containing 1.5 mM MgCI2• The 
reaction conditions were as follows: a hot start (5 min 95 C), followed by 35 cycles of 1 min 94 C, 2 
min 58 C, 2 min 72 C. The DNA amplification reaction generated a fragment of 362 bp, which was cui 
with Nhel and subcloned in the Smal Site of Sluescript KS. The control glyceraldehyde 3-phosphate 
dehydrogenase (GAPD) RNA probe was synthesized using a construct containing a 291 bp 
Xbal/Sau3AI fragment from rat GAPD eDNA (Fort et al. 1985). Approximately 5x10' cpm of either C14 
or AMH probe, together wlth 5x104 cpm of GAPD probe, was mixed with 5 ~g of tolal RNA in a total 
volume of 30 f.ll hybridization mixture containIng 40 mM Pipes pH 6.4, 1 mM EDTA, 0.4 M NaCI and 
80% (v/v) formamide. Care was taken to use equal amounts of mRNA in each sample through 00 
measurement at 260/280 nm of the ANA preparations immediately prior 10 the RNAse protection 
experiment. The hybridizations were performed overnight at 55 C. The RNase protection assay was 
performed as described by Baarends et al. (Saarends et al. 1994). The relative amount of protected 
mANA fragments was quantified through exposure of the gels to a phosphor screen (Molecular 
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Dynamics, B&L Systems, Zoetermeer, The Netherlands), followed by a calculation of the relative density 
of the obtained bands using a phospho-Imager (Molecular DynamIcs) and Image Quant computer 
analysis software. The ratio between the arbitrary units obtained for the AMHRII mRNA level and for 
the GAPD mRNA level (AMHRIl/GAPD) was determined. Control samples 01 each experiment were 
set at a ratio of 1.0. 
Results 
AMH and AMHRII mRNA expression during postnatal development in control and 
prenatally irradiated rat testes 
Histological obselVation confirmed (van Haaster and de Rooij, 1993) that 
spermatogenesis advanced from the differentiating spermatogonia type A present at 
day 9, to zygotene and early pachytene at day 14 and mid-to-Iate pachytene 
spermatocytes at day 21 in normal testes of immature control rats. In the prenatally 
irradiated testes from the immature rats, no germ cells were obselVed, with the 
exception of a few degenerating gonocytes on day 9. In the prenatally irradiated adult 
rats, normal spermatogenesis took place in approximately 6% of the tubular cross-
sections in one rat, and no germ cells were obselVed in tissue sections of another rat 
Using RNase protection assay, AMH mRNA was detected at low levels at days 
9, 14, and 21 in control and in prenatally irradiated testes (Fig 4.1). The pattern of 
induction of AMHRII mRNA expression between days 9 and 21 was similar in total 
testis RNA extracted from control and prenatally irradiated rats (Fig. 4.1). The major 
increase in testicular AMHRII mRNA expression was detected between days 9 and 14, 
the AMHRII mRNA level on day 9 seemed somewhat higher in prenatally irradiated 
rats compared to control rats. There was no difference in the AMHRIl/GAPD mRNA 
ratio between control and irradiated rats at day 21 (Fig. 4.2), but the AMHRIl/GAPD 
mRNA ratio in adult prenatally irradiated testes was decreased compared to the ratio 
in control adult rat testes (Fig. 4.2). The level of GAPD mRNA is used as an 
approximate measure for the relative amount of somatic cell-derived mRNA in the total 
testis RNA preparations (see Discussion). 
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Fig. 4.1: AMHRII and AMH mRNA expression In testes (rom control and prenatafly irradIated Immature 
rats of different ages. 
AMHRJI, AMH and GAPD mRNA expression was studied using RNase protection assays on total 
testicular RNA from: control and prenatally Irradiated g-day-old, 14·day-old, and 21-day-o/d rats. The 
numbers above the fanes Indicate the age (in days) of the rats. Each lane represents at least one rat, 
AMHRII, AMH and GAPD indicate the positions of the respective protected fragments. 
Effect of experimental cryptorchidism on AMHRII mRNA expression in adult rat testes 
Histological observation of the Bouin's fixed testes showed that cryptorchid testes 
at 2 days post-operation had normal spermatogenesis, but 5 days post-operation a 
depletion of many round and elongating sperrnatids was observed. This depletion had 
become more complete after 8 days of cryptorchidism, when most tubules contained 
only spermatogonia and spermatocytes. At 12 and 14 days after the operation, no 
further depletion of germ cell types was observed. No difference in the AMHRII and 
GAPD mRNA levels in the cryptorchid testes were observed at 2 days post-operation, 
compared to control testes. Concomitant with the depletion of germ cells at later time 
points, the GAPD mRNA level increased (per constant amount of total RNA). This 
resulted in a decrease of the AMHRIl/GAPD mRNA ratio (Fig. 4.3). 
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Fig. 4.2: AMHRII expressIon in 
testes from control and 
prenatafly irradiated immature 
and mature rats. 
AMHRII and GAPD mRNA 
expression was studied using 
RNase protection assays on 
total testicular RNA from: 21· 
day-old control and prenatally 
irradiated rats (left four lanes), 
and 70-day-old control and 
prenatally Irradiated rats (right 
four fanes). C, control rat 
testes; /, prenatally irradiated 
rat testes, Each lane 
represents on rat, Top: results 
of the RNAse protection assay. 
AMHRII and GAPD indicate the 
positions of the respective 
protected fragments. Bottom: 
quantitative analysis of the 
AMHRIl/GAPD mRNA rallos. 
The AMHRIl/GAPD mRNA ratio 
in the 21-day-old control rat 
testis in the first Jeft lane was 
set at 1.0, 
Fig. 4.3: AMHRII mRNA 
expression in total testes RNA 
isolated {rom control rats and 
experimentafly cryptorchfd rats. 
AMHRII and GAPD mRNA 
expression was studied using 
RNase protection assays on 
total testicular RNA from: 
control adult rats (C), and 
experimentally cryptorchid aduft 
rats at 2, 5, 8, t2, and 14 days 
post-operation. The numbers 
above the lanes and below the 
histogram indicate the number 
of days post-operation. C, 
control rat testis. Each lane 
represents one rat. Top: results 
of the RNAse protection assay. 
AMHRII and GAPD IndIcate the 
positions of the respective 
protected fragments. Bottom: 
quantitative analysis of the 
AMHRIl/GAPD mRNA ratios. 
The AMHRIl/GAPD mRNA ratio 
In the control adult rat testis in 
the firsl/eft lane was set aI1.0. 
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AMH and AMHRII mRNA expression during the spermatogenic cycle 
The expression of AMH and AMHRII mRNAs showed a marked regulation during the 
different stages of the spermatogenic cycle (Fig. 4.4). The expression of AMHRII 
mRNA increased from stage XIII to a maximum at stages VI and Vllab, followed by 
a sudden drop in the expression level at stage VIII to a very low level at stages IX-XII. 
The AMH mRNA level was very low compared to AMHRII mRNA expression. 
However, at stages Vllab and VII cd, AMH mRNA expression was relatively high, 
compared to a low expression level at the other stages of the cycle. 
Expression of AMHRII mRNA in adult testes depleted of specific germ cell types 
Three days after MAA treatment, histological examination showed that all pachytene, 
diplotene and meiotically dividing spermatocytes (with the exception of pachytene 
spermatocytes that were associated during stage VI), and all round spermatids at 
steps 1 and 2 of spermiogenesis, were lost. Seven days after MAA administration, 
pachytene spermatocytes associated with stages VI-VII, and XI-XII were lost, and also 
the round spermatids at Steps 1-7 of spermiogenesis were depleted. Fourteen days 
after MAA administration, Step 1 spermatids, and Steps 5-15 spermatids were lost 
from the seminiferous epithelium. Steps 7,8, 13 and 16-19 spermatids were lost at 
21 days after MAA administration, but one week later only Steps 17-19 spermatids 
were absent. In contrast to the clear effects of MAA on the composition of the 
spermatogenic cell population, there was no major change in the AMHRIl/GAPD 
mRNA ratio at any of the time points studied (Fig. 4.5). 
Hydroxyurea treatment resulted in the loss of all Intermediate and type B 
spermatogonia, and preleptotene, leptotene and almost all zygotene spermatocytes, 
4.8 days after the last injection of HU. However, at that time point, we found no 
change in the expression of AMHRII and GAPD mRNAs in total testes from HU-
treated rats compared to control rats (Fig. 4.6). 
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Fig. 4.4: AMHRII, AMH and GAPD mRNA expression at different stages of the spermatogenic cycle. 
AMHRII, AMH and GAPD mRNA expression was studied using RNase protection assays on tubule 
segments that were sectioned and separated according to the stages of the spermatogenic cycle. The 
Roman numerals above the lanes indicate the stage numbers that were collected together in each 
sample. As a reference to the cell types that are associated at the different stages of the 
spermatogenIc cycfe, and the relative duration of the stages (represented by the width of boxes 1-14), 
a schematic drawing /s presented (adapted from van Pelt, 1992). As. Ap. As/' single, paired, and 
aligned undifferentiated type A spermatogonia,' A,..,. In, B, different types of differentiating 
spermatogonia; PL, L, Z, P, D, spermatocytes at the prefeptotene, leptotene, zygotene, pachytene, and 
diplotene stages of the meioNc prophase; M, spermatocytes undergoing meiotic divisions; 1H 19, 
spermatids at subsequent steps of spermiogenesis. Note: the obseNed AMH mRNA level results from 
exposure of the gel to radiographic film for 14 days, whereas the signal tllat represents AMHRII mRNA 
expression was obtained after exposure for 24 h. 
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Discussion 
In the testis, AMH is known to be secreted specifically by Sertoli cells (Tran 
and Josso, 1982), and also AMHRII expression mainly or exclusively occurs in Sertoli 
cells. Using RNase protection, we have shown in previous studies (Baa rends et al. 
1994) that AMHRII mRNA is absent from total RNA prepared from isolated cell 
preparations highly enriched in pachytene spermatocytes and spermatids, or in 
interstitial and peritubular myoid cells. Furthermore, preliminary in situ hybridization 
results of 21-day-old rat testes demonstrated that the AMHRII mRNA expression 
patterns were similar in testes from control as compared to sterile (prenatally 
irradiated) immature rats (not shown), indicating that AMHRII mRNA expression in 
spermatogonia is low or absent. Thus, it can be suggested that primary effects of 
AMH/AMHRII on testis function are autocrine effects on Sertoli cells. 
The expression of the mRNA encoding the ligand AMH did not show a major 
quantitative change between postnatal days 9 and 21 in control rat testes, and the 
absence of germ cells in prenatally irradiated rats did not result in a different 
developmental expression pattern. These results are in accordance with the fact that 
the most dramatic decrease in AMH mRNA level occurs during the first week of 
postnatal testis development in the rat (MOnsterberg and Lovell-Badge, 1991; Hirobe 
et al. 1992; Kuroda et al. 1990). 
AMHRII mRNA expression occurs in fetal and neonatal testes, but the 
expression markedly increases during the first three weeks of postnatal development 
in the rat (Baa rends et aI., 1994; and present results). It was found that the 
developmental AMHRII mRNA expression pattern in the testis, was not distinctly 
influenced by induction of sterility by prenatal irradiation, and hence, is independent 
of the presence or absence of germ cells. 
Concerning the development of Sertoli cell characteristics in testes from 
prenatally irradiated rats, it is known that some events are delayed, such as formation 
of the blood-testis barrier and lumen formation (Means et al. 1976). The present 
results indicate that the timing of the postnatal increase in AMHRII mRNA expression 
in prenatally irradiated rats seems to be slightly advanced rather than delayed. 
In adult prenatally irradiated rats, the absence of germ cells results in in a testis 
that is relatively enriched in somatic cell types, including Sertoli cells. We have 
previously reported that the GAPD mRNA that is detected with the probe used in our 
studies is not expressed in rat spermatocytes and spermatids (Baarends et al. 1994). 
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Fig. 4.5: AMHRII mRNA 
expressIon in total testes 
from control and 
C C 3 3 7 7 14 14 21 21 28 28 
melhoxyacetic acld·lrealed AMHRII 
rats. 
AMHRII and GAPD mRNA 
expression was studied 
using RNase protection 
assays on fotal testicular 
RNA from: control adult rats 
(C), and adull rals Ihal had 
received a single oral dose GAPD 
of melhoxyacetic acid (MAA) 
at 3, 7, 14, 21, or 28 days 
after MAA administration. 
The numbers above the 
fanes and below the 
histogram indicate the 1.0 
number of days after MAA 
treatment (e, control rat 
testis), Each lane 
represents one rat. 0.5 
Top: results of the RNAse 
protection assay. AMHRII 
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positions of the respective C C 3 3 7 
protected fragments. 
Bottom: quantitative analysis of the AMHRIIIGAPD mRNA ratios, 
The AMHRIIIGAPD mRNA ratio in Ihe conlrol adull ral lestis In Ihe 
first left lane was set at 1.0. 
FIg. 4.6: AMHRII mRNA expression in total testes from control and 
hydroxyurea-treated rats 
AMHRII and GAPD mRNA expression was studied using RNase 
protection assays on total testicular RNA isolated from a control 
adult rat (lane 1), and adult rats that were injected with hydroxyurea 
(HU) and killed 4.8 days afler Ihe lasl HU injection (lanes 2 and 3). 
Top: results of the RNAse protection assay. AMHRII and GAPD 
indicate the positions of the respective protected fragments. 
Bottom: quantilative analysis of Ihe AMHRttlGAPD mRNA ratios. 
The AMHRIIIGAPD mRNA ratio in Ihe conlrol adult ral lestis in Ihe 
first left lane was set at 1.0. 
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This is in accordance with results from other investigators (Mori et al. 1992; Welch et 
al. 1992) who reported that the germ cells express a testis specific GAPD-s gene. 
Only the early germ cells express GAPD, whereas this gene is silenced in the more 
advanced germ cell types that make up the bulk of the germ cells in the adult testis. 
Therefore, the GAPD mRNA level can be viewed as an approximate measure for the 
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relative amount of somatic cell-derived mRNA. Following this argument, we have used 
the ratio between AMHRII mRNA and GAPD mRNA levels, to study the level of 
AMHRII mRNA corrected for the amount of somatic cell-derived mRNA. Expressed 
in this manner, the present results show that the level of AMHRII mRNA expression 
in adult Sertoli cells is quantitatively reduced in sterile testes from prenatally irradiated 
rats. 
Similar to the difference in AMHRII mRNA expression in adull control and 
prenatally irradiated rats, pronounced derangement of spermatogenesis upon 
experimental cryptorchidism also resulted in a relative decrease of AMHRII mRNA 
expression. The decreased AMHRII mRNA expression in cryptorchid rat testes may 
reflect a direct effect of the abdominal temperature on Sertoli cells (Kerr et al. 1979) 
or, may be caused by structural changes that occur in Sertoli cells as a result of the 
disorganization of the spermatogenic epithelium. 
To study the possible regulation of AMH and AMHRII expression in Sertoli cells 
by spermatogenic cells in more detail, the mRNA levels were determined in isolated 
tubule segments that were separated according to the stages of the spermatogenic 
cycle. It was found that both AMH mRNA and AMHRII mRNA show a marked 
regulation during the spermatogenic cycle. Maximal AMH and AMHRII mRNA levels 
were found at stage VII. AMHRII mRNA levels are at a minimum during stages IX-XII. 
It has been shown that FSH receptor mRNA (Heckert and Griswold, 1991) and binding 
(Kangasniemi et al. 1990) are at a minimum at stage VII. Since FSH has been shown 
to down-regulate AMH expression during early postnatal development (Kuroda et al. 
1990), the nadir in FSH action at stage VII might be involved in the observed up-
regulation of AMH mRNA expression. Another candidate factor that may modulate the 
pattern of AMH mRNA expression during the spermatogenic cycle is steroidogenic 
factor-1 (SF-1) (Honda et al. 1993; Lala et al. 1992), which is an orphan nuclear 
receptor that is crucial for adrenal and gonad formation, and regulates the expression 
of a number of steroidogenic enzymes (Morohashi et al. 1992; Lynch et al. 1993). 
This factor is capable of binding to an upstream conserved element in the AMH 
promoter in vitro (Shen et al. 1994; Hatano et al. 1994). The expression pattern of 
SF-1 in rat embryos suggests that it is involved in a positive regulation of the prenatal 
expression of AMH (Shen et al. 1994), although conflicting data are reported indicating 
a stimulatory effect of SF-1 on AMH gene transcription in one study (Shen et al. 1994) 
and an inhibitory effect in another study (Haqq et al. 1994), using different 
experimental approaches in vitro. It will be of interest to study whether postnatal 
expression of SF-1 in Sertoli cells correlates with AMH expression. 
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Sertoli cells support spermatogenesis, and at each stage of the spermatogenic 
cycle different combinations of spermatogenic cell types are present that require 
distinct Sertoli cell actions. The cyclic expression of many Sertoli cell proteins has 
been established (reviewed by Parvinen, 1993), providing evidence that spermatogenic 
cells influence Sertoli cell function. Therefore, we have studied the effect of depleting 
the adull testes of various germ cell types on AMHRII mRNA expression. Treatment 
with methoxyacetic acid (MAA) or hydroxyurea (HU) resulted in selective loss of 
several types of spermatogenic cells. However, in both experimental models, there 
was no major change in the testicular AMHRIl/GAPD mRNA ratio after treatment. 
These results do not identify a single defined group of germ cell types that is involved 
in the up- or down-regulation of AMHRII mRNA expression in Sertoli cells. It is of 
interest to note that immunohistochemical studies of androgen receptor expression in 
Sertoli cells of adult rats showed a marked pattern of androgen receptor protein 
expression during the spermatogenic cycle, which was very similar to the pattern of 
AMHRII mRNA expression described herein, and which also was not influenced by 
treatment of the rats with MAA (Bremner et al. 1994). 
Since both AMH and AMHRII mRNA levels are high at stage VII, actions of 
AMH on Sertoli cell function might occur mainly at that stage. There are various 
events that take place at stages VII-VIII of the spermatogenic cycle in which AMH 
could have a function. Leptotene spermatocytes leaving the basal membrane starting 
to migrate through the blood-testis barrier, the onset of spermatid elongation, and 
spermiation of Step 19 spermatids, all occur at stages VII and VIII (reviewed by de 
Kretser and Kerr, 1994). 
The mechanism of AMH-induced regression of the mullerian ducts may involve 
a secondary effect on the extracellular matrix (Trelstad et al. 1982; Tsuji et al. 1992), 
induced by the surrounding mesenchymal cells. Since the spermatogenic events that 
take place at stage VII involve major changes in the structure of Sertoli cells and their 
interaction with the basal membrane, it is tempting to suggest that testicular AMH 
action may involve some effect on the extracellular matrix components in the basal 
membrane. As part of a feedback mechanism, major structural changes in the 
tubules, rather than specific germ cell products, may regulate the cyclic AMH and 
AMHRII mRNA expression patterns. 
A possible function of AMH can be inferred from the inverse relationship 
between AMHRII mRNA expression and ['H)-thymidine incorporation during the 
spermatogenic cycle, showing minimal ['H)-thymidine incorporation at stage VII (Soder 
et al. 1991). In concordance with this, mitotic divisions of differentiating spermatogonia 
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take place at stages IX-VI, but not at stages VII and VIII (Huckins, 1970; Huckins, 
1971). Factors that have been postulated to stimulate spermatogonial cell proliferation 
(interleukin-1, EGF, Kit ligand, activin), show their lowest expression at stage VII 
(Soder et al. 1991; Manova et al. 1993; Bartlett et al. 1990; Klaij et al. 1994). Since 
AMH and its receptor are at a maximum at this stage, the inhibition of mitotic divisions 
of undifferentiated and/or differentiated type A spermatogonia could be one of the 
possible effects of AMH on spermatogenesis. 
If AMH plays a role in determining the amount of spermatogonia that enter 
spermatogenesis, lack of AMH action may result in a subtle change in the balance 
between stimulatory and inhibitory effects on spermatogonial proliferation and 
degeneration. Activin and inhibin, two members of the activin and TGFp family of 
growth factors, have also been reported to regulate spermatogonial proliferation 
(Mather et al. 1990; van Oissel-Emiliani et al. 1989). Several members of the activin 
and TGFp family of growth factors show overlapping or counteracting actions. A 
redundancy phenomenon may prevent clear loss of function effects when a single 
factor is missing. 
Natural mutations that block AMH action lead to the persistent mOlierian duct 
syndrome (PMOS), that is characterized by the presence of a uterus and fallopian 
tubes in otherwise normal males (Josso et al. 1991). The testes develop normally in 
these patients, but do not descent, which results in infertility. Behringer et al. (1994) 
have recently generated AMH gene knock-out mice. Analogous to the PMOS human 
males, male AMH-deficient mice were born with both mOlierian duct- and wolffian duct-
derived reproductive organs. The testes in these animals produced functional sperm, 
and Leydig cell hyperplasia was the only testicular abnormality that was observed 
(Behringer et al. 1994). These results indicate that, through an autocrine action on 
Sertoli cells, AMH may negatively regulate Leydig cell proliferation and/or maturation. 
The existence of other type II receptors for AMH on Leydig cells, however, cannot be 
excluded. With respect to the cyclic regulation of AMH and AMHRII mRNA 
expression, it is of interest to note that the morphology of Leydig cells surrounded by 
stage VII seminiferous tubules differs from the morphology of those located near other 
stages (Bergh, 1983; Bergh, 1985), and also the expression of certain genes in Leydig 
cells depends on the stages present in the neighbouring tubules (Gizang-Ginsberg and 
Wolgemuth, 1985). 
The results presented herein indicate that there may be a function of AMH in 
the adult rat testis. In order to identify the nature of this function, future studies will 
be directed towards the development of strategies that allow modulation of AMH and 
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AMHRII action at certain time points during postnatal testis development. 
In conclusion, a high level of AMHRII mRNA is an intrinsic feature of mature rat 
Sertoli cells, which is down-regulated at stages IX-XII of the spermatogenic cycle. 
AMH mRNA is expressed at a low level in adult Sertoli cells, but specific up-regulation 
of this mRNA at stage VII of the cycle would permit a local autocrine action of AMH. 
The postulated functions of AMH with respect to proliferation of spermatogonia and/or 
Leydig cells might be explained by effects of AMH on the extracellular matrix, thereby 
influencing the communication between the different testicular cell types. 
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Summary 
During fetal development, anti-mOlierian hormone (AMH) is produced only by Sertoli 
cells, but postnatally granulosa cells also produce this peptide growth/differentiation 
factor. We have recently identified a candidate AMH type II receptor (AMHRII) 
(Baarends et al. 1994). In the present study, postnatal ovarian AMH and AMHRII 
mRNA expression was studied by in situ hybridization and RNase protection. In 
ovaries from adull rats, AMH and AMHRII mRNAs were found to be mainly expressed 
in granulosa cells from preantral and small antral follicles. Corpora lutea and large 
antral follicles express little or no AMH and AMHRII mRNA, and primordial follicles and 
oocytes appeared to be AMH and AMHRII mRNA negative. Theca and interstitial 
cells express no detectable amount of AMH mRNA, and little or no AMHRII mRNA. 
The co localization of AMH and AMHRII mRNAs in granulosa cells of specific follicle 
types, suggests that actions of AMH via AMHRII are autocrine in nature. There is a 
decreased level of AMH and AMHRII mRNA expression when follicles have become 
atretic. Both mRNA species are eventually lost from atretic follicles, although AMHRII 
mRNA expression seems to persist somewhat longer than AMH mRNA. During the 
estrous cycle, no marked changes in the patterns of AMH and AMHRII mRNA 
expression were detected, except at estrus, when expression of both mRNA species 
in preantral follicles was decreased compared to the other days of the cycle. 
At postnatal day 5, total ovarian AMH mRNA expression is low, and is located 
in small preantral follicles. During the first weeks of postnatal development, AMH 
mRNA expression in preantral follicles increases, and the later formed small antral 
follicles also express AMH mRNA. In contrast, AMHRII mRNA is expressed at 
postnatal day 5 at a higher level than AMH mRNA, but cannot be localized to specific 
cell types. From postnatal day 15 onwards, AMHRII mRNA expression becomes more 
restricted to the preantral and small antral follicles. 
Treatment of prepubertal rats with GnRH antagonist (Org 30276) and human 
recombinant FSH (Org 32489), or with GnRH antagonist and estradiol benzoate, 
resulted in follicle growth, and in an inhibition of AMH and AMHRII mRNA expression 
in some, but not all preantral and small antral follicles. These results indicate that 
FSH and estrogens may playa role in the downregulation of AMH and AMHRII mRNA 
expression in vivo, when small antral follicles differentiate into large antral follicles. 
Furthermore, the FSH surge on the morning of estrus may inhibit AMH and AMHRII 
mRNA expression in preantral follicles. It is discussed that autocrine action of AMH 
on granulosa cells of preantral and small antral follicles might result in an inhibition of 
follicle maturation and/or playa role in follicle selection. 
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Introduction 
Anti-mOlierian hormone (AM H), also called mOlierian inhibiting substance, is a 
member of the activinrTGFp family of peptide growth and differentiation factors (Cate 
et al. 1986). During male embryonic/fetal sex differentiation, AMH is synthesized by 
the fetal Sertoli cells, and induces the degeneration of the mOlierian ducts, which are 
the anlagen of the uterus, the oviducts and the upper part of the vagina. There is no 
ovarian AMH production during normal female fetal development (MOnsterberg and 
Lovell-Badge, 1991; Hirobe et al. 1992). However, overexpression of the gene 
encoding AMH in transgenic mice, leads to mOlierian duct regression also in female 
embryos, and in addition induces the formation of testis cord-like structures in fetal 
ovaries (Behringer et al. 1990), indicating that the fetal ovary is sensitive to AMH. In 
cultured fetal ovaries, AMH inhibits oogonial replication (Vigier et al. 1987) and 
granulosa cell aromatase activity (Vigier et al. 1989; di Clemente et a/. 1992). 
Aromatase catalyses the conversion of testosterone to estradiol, and inhibition of 
ovarian aromatase activity by AMH leads to production of testosterone rather than 
estradiol. The effects of AMH on the fetal ovary may reflect some function of AMH 
during prenatal testis development, rather than a function during prenatal ovary 
development, since the ovary is normally not exposed to AMH prior to birth. 
In the female rat, AMH mRNA expression is detected in ovarian granulosa cells 
from postnatal day 3 onwards (Hirobe et al. 1992). Immunohistochemical (Ueno et al. 
1989b; Ueno et al. 1989a) and mRNA in situ hybridization (Hirobe et a/. 1992; Hirobe 
et a/. 1994) data have shown specific expression of AMH in granulosa cells during 
defined stages of follicle development in the rat. It has been shown that exogenous 
AMH inhibits biosynthesis of aromatase (di Clemente et al. 1994a), and decreases the 
number of LH receptors (di Clemente et al. 1994a) in cultured rat granulosa cells. 
Furthermore, AMH opposes EGF-induced progesterone biosynthesis and proliferation 
of cultured human granulosa-luteal cells (Kim et al. 1992; Seifer et a/. 1993). 
Conflicting data have been reported concerning possible effects of AMH on oocyte 
maturation; inhibition of meiosis by AMH was observed in one case (Takahashi et a/. 
1986), but no effect of AMH could be found in another study (Tsafriri et al. 1988). 
The marked regulation of AMH expression and the reported effects of AMH in 
in vitro culture systems, indicate that AMH may perform certain functions during follicle 
development in the postnatal ovary. More insight in these functions could come from 
studies on ovarian expression of the receptor for AMH. Recently, we have cloned a 
eDNA, named C 14, that encodes the candidate rat AMH type II receptor (Baa rends 
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et al. 1994). C14 is a member of the family of transmembrane serine/threonine kinase 
receptors to which also the TGFp and activin receptors belong (reviewed by Lin and 
Moustakas, 1994). Members of the activinlTGFp family of growth and differentiation 
factors signal through heteromeric complexes composed of type I and type II 
transmembrane serine/threonine kinase receptors (Wrana et al. 1994). The structural 
characteristics of C14 indicate that it is a type II receptor. di Clemente et al. (1994b) 
have cloned the rabbit homologue (H1) of C14, and have shown that H1 binds AMH. 
Together with the observed expression of C14 mRNA in AMH target cells during 
embryonic sex differentiation, these data provide evidence that C14 and H1 encode, 
respectively, the rat and rabbit AMH type II receptor (AMHRII). The existence of an 
AMH type I receptor can be anticipated, but this receptor has not been identified yet. 
Herein, C14 will be referred to as the AMH type II receptor, in analogy to the 
nomenclature that is used for the TGFp receptors. 
In the present study, mRNA in situ hybridization and RNase protection were 
used to study in detail the expression of both AMH and AMHRII mRNA in rat ovaries. 
The cellular localization, temporal expression pattern, and response to hormonal 
treatment of AMH and AMHRII mRNA expression were determined, to identify ovarian 
AMH target cells, and to study the regulation of AMH and AMHRII mRNA expression 
during postnatal development, the estrous cycle, and gonadotropin-induced follicular 
growth. 
Materials and Methods 
Animals and treatments 
Wistar rats, locally bred, were maintained under controlled conditions (20·23 C, lights on from 
05.00 h to 19.00 h). AMH and AMHRII mANA expression was studied in ovaries collected from rats at 
various reproductive stages. Animals were killed by an overdose of ether between 09.00 -10.00 h. Four 
different experiments were performed. In Experiment 1, female rats were killed at 5 (8 animals), 10 (4 
animals), 15 (4 animals), 20 (2 animals), 25 (2 animals), 30 (2 animals), and 35 days (2 animals) aHer 
birth, From each animal, one ovary was snap·frozen in liquid nitrogen and used for RNA isolation, and 
the other ovary was lixed overnight at 4 C In Bouins' fixative and used for histological examination and 
in situ hybridization purposes. Frozen ovaries isolated at postnatal days 5,10, and 15 were pooled. 
In Experiment 2, fo!liculogenesis and ovulation was induced by injecting (s.c.) 26-day·old female 
rats with 10 IU PMSG followed 56 h later by injection of 10 IU hCG. Ovaries were isolated 0, 1, 2, 3 
and 6 days after PMSG injecllon. Two animals were used at each time point, and the ovaries were 
isolated; one ovary was used for RNA isolation, the other ovary was fixed overnight at 4 C in Boulns' 
fixative and used for histologIcal examination. 
In Experiment 3, ovaries were collected from adult rats at different stages of the 5·day estrous 
cycle. The stage of the cycle was determined through analysis of dally vaginal smears. Only animals 
with a regular 5-day cycle were used. Two animals were studied for each day of the cycle. The 
ovaries were fixed overnight at 4 C in Bouins' fixative and used for histological examination and in situ 
hybridization, 
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In Experimenls 4 and 5, ellecls of FSH, hCG and eslradlol benzoale (EB) on AMH and AMHRII 
mRNA expression were studied in immature rats. GnRH antagonist (GnRHant) (Org 30276), human 
recombinanl FSH (FSH) (Org 32489), and hCG (Pregnyl) were oblained from Organon Inlernalional 
(Oss, The Netherlands). Endogenous levels of gonadotropins were reduced by administration of 
GnRHanl (500 ~g/l 00 g body weighl) al days 22, 24, 26 and 28 (Meils-Roelofs el al. 1990)_ FSH, hCG 
and EB were given al days 26, 27, 28 and 29. FSH and hCG were given lWice daily al 09.00 hand 
17.00 h; FSH in a total daily dose of 10 IU, and hCG in a total daily dose of 1 lU. EB was given once 
daily in a dose of 100 ~gllnjection. The animals were killed at day 30, In Experiment 4, rats were trea-
ted with GnRHant alone, with GnRHant plus FSH, or with GnRHant plus FSH plus hCG. In Experiment 
5, rats were treated with GnRHant alone, with GnRHant plus FSH, with GnRHant plus EB, or with 
GnRHant plus FSH plus EB. Two animals were used for each treatment group, and two untreated 30-
day-old female rats were included in both experiments. The ovaries were Isolated as described in 
Experiment 1. 
Isolation of follicles and corpora lutea 
From adult rals, the 10 largest follicles at estrus, and the 10 largest follicles and corpora lutea 
at proestrus were isolated under a dissection microscope in phosphate buffered saline. The follicles 
isolated at estrus are small antral follicles, and those isolated at proestrus are large preovulatory foHi-
cles. Twenty corpora lutea, twenty large antral follicles, and forty small antral follicles were pooled in 
two fractions each, and snap-frozen in liquid nitrogen for RNA isolation. Half of the total amount of total 
RNA Ihat was isolated for each sample was used in a single RNase protection assay. 
RNA isolation and RNase protection assay 
Tolal RNA was isolated using Ihe LiCl/urea method (Auffray and Rougeon, 1980). A Pstl fragment 
conlaining bp 1243-1640 from C14 (AMHRII) was subcloned in pBluescripl KS (Slralagene; Weslburg, 
Leusden, The Netherlands) and used to generate [32p]-UTP-labelled anti-sense transcripts in vitro. All 
radiolabelled agents were from Amersham ('s Hertogenbosch, The Netherlands). A rat AMH DNA 
template for in vitro transcription was generated using a DNA amplification reaction (Saiki et al. 198B). 
Rat liver was used for genomic DNA isolation according to Davis et al. (1986). The primers 
5'GCTGCTGCTAGCGACTATG3' (forward primer) and 5'AGATGTAGGCTAGCAACTG3' (reverse 
primer) were used to amplify bp 38-400 of the first exon of the rat AMH gene (Haqq et at. 1992). An 
amount of 200 ng of each of the primers was added to the DNA amplification reaction using 700 ng 
genomic DNA as a template in a standard reaction mixture containing 1.5 mM MgCI2• The reaction 
conditions were as follows: a hot start (5 min 95 C), followed by 35 cycles of 1 min 94 C, 2 min 58 C, 
2 min 72 C. The DNA amplification reaction generated a fragment of 362 bp, which was cut with Nhel 
and subcloned in the Smal site of Bluescript KS. The control glyceraldehyde 3-phosphate 
dehydrogenase (GAPD) RNA probe was synthesized using a construct containing a 291 bp 
Xbai/Sau3AI fragment from rat GAPD cDNA (Fort et al. 1985). Approximately 5x104 cpm of either C14 
or AMH probe, together with 5x104 cpm of GAPD probe, was mixed with 5 ).Ig of tolal RNA (unless 
otherwise indicated) in a total volume of 30 ).II hybridization mixture containing 40 mM Pipes pH 604, 
1 mM EDTA, 004 M NaCI and 80% (v/v) formamide. Care was taken to use equal amounts of mRNA 
in each sample through 00 measurement at 260/280 nm of the RNA preparations immediately prior 
to the RNAse protection experiment. The hybridizal10ns were performed overnight at 55 C, The RNase 
protection assay was periormed as described (Baarends et al. 1994). The relative amount of protected 
mRNA fragments was quantified through exposure of the gels to a phosphor screen (Molecular 
Dynamics; B&L Systems, Zoetermeer, The Netherlands), followed by a calculation 01 the relative density 
of the obtained bands using a phospho-imager and Image Quant (Molecular Dynamics) as computer 
analysis software. The ratio between the arbitrary units obtained for the AMHRII mRNA level and for 
the GAPD mRNA level was determined. The ratios of control samples of each experiment were set 
aI1.0. 
In situ hybridization 
The AMH and AMHRII subclones that were used for RNAse protection assays were also used 
to generate sense and antisense eSS]-UTP-labeUed transcripts in vitro. In situ hybridization procedure 
was periormed as described by Zeller and Rogers (ZeUer and Rogers, 1991) with some modifications 
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(Baarends et al. 1994). Ovaries were embedded in paraffin, and 8)lm sections were mounted on slides 
which were coated with 3-amlnopropyl-elhoxysl1ane. After deparaflination sections were treated with 
0.2 N HGI (20 min), digested with proteinase·K (1 ~g/ml in 0.2 M Tris, 2 mM GaGI,; incubation 15 min 
at 37 G) and postfixed In 4% paraformaldehyde In 0.1 M PBS. After treatment with dithlothreitol and 
blocking non-specific binding with 0,1 M triethanolamine, followed by 0.1 M triethanolamine and acetic 
anhydride, secUons were incubated with 35S-labeUed antisense and sense AMH and AMHRII cRNA 
probes in a final concentration of 5 x 105 cpm/J-lt. Hybridization was carried out overnight at 55 C in 
moist chambers. The hybridization mixture contaIned: 50% (vlv) delonised formamide, 0.3 M NaCI, 10 
mM Tris pH 8.0,1 mM EDTA, 1x Denhardt's solution, 1 mg/ml yeast tRNA, 50 mM DTT and 10% (w/v) 
polyethylene glycol 6000. Slides were washed four times in 2x sse, 55% (v/v) formamide, at 55 C for 
15 min, then treated with RNAse solution (40 ~g RNAse Nml, 700 U RNAse T/ml, in 0.3 M NaGI, 5 mM 
EDTA, 10 mM Tris) for 15 min at room temperature, and washed again two times in 2x sse (55 C, 30 
min), and two Umes in 1x sse, 55% (v/v) formamide (55 e, 30 min). After dehydration, slides were 
dipped in Kodak NTB-2 emulsion and dried at room temperature for 3 hours, followed by exposure at 
4 e for 1 week. After developing, the sectlons were counterstained with haematoxylin and mounted. 
Hislology 
Histological examination of the follicles was based on sections, stained with haematoxylln and 
eosin, adjacent to sections used for in situ hybridization. Healthy and atretic follicles were grouped in 
primordial follicles « 50 ~m), small preantral follicles (50·200 ~m), large preantral follicles (201·274 
~m), small antral follicles (275·450 ~m) and large antral follicles (>450 ~m). Follicular size was calcula· 
ted from two perpendicular diameters of the follicle. Atretic and healthy follicles were distinguished 
according to criteria described by Osman (Osman, 1985). 
Results 
AMH and AMHRII mRNA expression in prepubertal rat ovaries 
At day 5 of postnatal development, the ovaries contained only primordial follicles and 
follicles with a single layer of granulosa cells (primary follicles) (Fig. 5.1A). The 
granulosa cells of some primary follicles that were present at day 5 expressed AMH 
mRNA (Fig. 5.1B). At days 10 and 15, AMH mRNA expression became more 
pronounced in granulosa cells of small preantral follicles. Oocytes and interstitial 
tissue were AMH mRNA negative (below the level of detection). AMHRII mRNA 
expression was detected in an evenly distributed pattern at days 5 and 10 (Fig. 5.1 C). 
From day 15 onwards, AMHRII mRNA expression became mainly restricted to the 
granulosa cells of primary and preantral follicles (not shown). 
At day 20, AMH mRNA positive follicles were mainly found in the peripheral 
region, whereas AMHRII mRNA positive follicles were also present in the center of the 
ovary (Fig. 5.2B,C). At days 25-35, AMH and AMHRII mRNA expression was high, 
and most of this expression colocalized to the same follicles. The expression of both 
mRNAs was highest in preantral follicles. Small antral follicles also expressed some 
AMH and AMHRII mRNA from day 25 onwards (Table 5.1). The signal was lost in 
larger antral follicles (Fig. 5.2E,F). 
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A 
Fig. 5.1: Localization of AMH and AMHRII mRNA expression in ovaries of 5-day-o/d rats, using in situ 
hybridization. 
A: ovarian section stained with haemafoxylin and eosin; B: AMH mRNA expression pattern; C: AMHRII 
mRNA expression; 0: negative control, hybridized with AMHRII sense RNA (B,e, and 0 are darkfield 
views). Note the presence of AMH mRNA in primary follicles and the even distribution of AMHRII 
mRNA over the whole ovary. Bar represents 200 pm. 
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Preantral atretic follicles expressed less AMH and AMHRII mRNA than healthy follicles 
of the same size class, but the expression seemed to increase somewhat with 
increasing age (Table 5.1). 
In general, AMH mRNA produced stronger signals than AMHRII mRNA. The 
AMH and AMHRII cRNA antisense probes are comparable with respect to probe 
length and percentage of GIC residues. However, it is difficult to compare the 
absolute levels of AMH and AMHRII mRNA due to two major differences between the 
expression patterns of these mRNAs First, in small preantral follicles, AMHRII mRNA 
is evenly expressed in the granulosa cells of single positive follicles, whereas AMH 
mRNA expression is not always evenly distributed, but sometimes highest in the 
granulosa cells immediately surrounding the antrum andlor the oocyte (compare Fig. 
5.2E with Fig. 5.2F). Second, a low level of AMHRII mRNA expression in interstitial 
cells at some stages of ovarian development is not excluded, whereas there was a 
clear contrast between AMH mRNA positive follicles and AMH negative interstitium in 
all studied ovarian sections. 
RNase protection results showed, that there was a small increase in total 
ovarian AMHRII mRNA expression between days 10 and 15 (Fig. 5.3). From day 15 
onwards, the total ovarian AMHRII mRNA expression was maintained within the same 
range. Compared to AMHRII mRNA expression, there was a more pronounced 
increase in the level of total ovarian AMH mRNA expression between days 5 and 15, 
and subsequently between days 25 and 30 (Fig. 5.3). 
Fig, 5,2: (Next page) Locafization of AMH and AMHRII mRNA expression during postnatal ovary 
development, and in adult cycling rats, using in situ hybridization. 
The (eft figures (A,D,G) are ovarian sections stained with haemaloxylin and eosin. The middle and right 
figures show darkfie/d views of AMH (B,E,H) and AMHRII (C,F,I) mRNA expression in adjacent 
sections. A,a,G: 20-day-old rat ovary, showing AMH mRNA expression in preantral follicles, mainly 
located in the peripheral area, and AMHRII mANA expression in preantral follicles, both in the 
peripheral as wef{ as in the central ovarian region; 0, E, F: 30-day-old rat ovary, showing colocalizafion 
of follicular AMH and AMHRff mRNA expression. Note the presence of AMH and AMHRff mRNA 
expression in preantral follicles, and the absence In large antral follicles. Also, small antral follicles are 
Indicated that show expression of AMH mRNA mainly In granufosa cells surrounding the oocyte,' G,H,I: 
adult rat ovary (at proestrus), showing absence of AMH and AMHRII mRNA expression in preovulatory 
follicle and corpus luteum, HF, healthy fofficle; AF, atretic follicle; SPF, smafl preantral follicle; LPF, 
large preantral follicle; eL, corpus luteum. Bar represents 200 {Jm. 
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0 Table 5.1: Expression of AMH and AMHRII mRNAs in ovaries of prepubertal rats, as measured by in situ hybridization 
'" 
Day 20 Day 25 Day 30 Day 35 
0 AMH AMHRlI 0 AMH AMHRII 0 AMH AMHRII 0 AMH AMHRII 
Healthy preantral (30) 01+ + (31) + +1++ (17) +1++ +1++ (24) ++ +1++ 
small antral (2) 0 0 (10) O/± Ol± (4) O/± + (4) +1++ 
large antral (2) 0 0 (3) 0 0 
Atretic preantraJ (1) 0 0 (11) 0 O/± (8) ± + (8) ±1+ ±I+ 
small antral (5) 0 0 (6) O/± O/± (4) 0 0 
large antral 
- = follicle not present 
a = no silver grains above baCkground, ± = moderate expression, + = clear expression, ++ = highest expression 
Number of follicles (n) is given in parentheses 
AMH and AMHRII mRNA expression in rat oval}' 
Expression of AMH and AMHRII mRNAs during the estrous cycle 
In situ hybridization results showed, that in adult rats, AMH and AMHRII mRNAs 
colocalized mainly in granulosa cells of healthy preantral and small antral follicles 
(Table 5.2, Fig. 5.2H,I). In large antral follicles the AMH and AMHRII mRNA signal 
was not above background, and corpora lutea and primordial follicles also were 
negative (Fig. 5.2H,I). Both AMH and AMHRII mRNA expression was gradually lost 
from atretic follicles, with AMHRII mRNA persisting somewhat longer than AMH mRNA 
(Table 5.2). There were no marked changes in the follicle types that express AMH 
and AMHRII mRNA during the estrous cycle (Table 5.2), except at estrus, when the 
granulosa cells of some of the preantral follicles expressed little, or no, AMH and/or 
AMHRII mRNA. 
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Fig. 5.3: Expression of AMH and AMHRII mRNAs in total ovaries during postnatal development. 
AMH, AMHRII, and GAPD mRNA expression was studied using RNase protection assays on total RNA 
from whole ovaries, from rats of different age. The numbers above each lane in (A) and below the 
histogram in (8) correspond to the age of the rats in days. 
A: results of the RNAse protection assay. AMH, AMHRIt, and GAPD indicate the positions of tile 
respective protected fragments. Each lane represents at least one rat, B: quantitative analysis of the 
AMHIGAPD (open bars) and AMHRItIGAPD (closed bars) mRNA ratios. Values at days 5, 10, 15, and 
25 are derived from one rat, or from a number of rats whose ovaries were pooled before RNA isolation; 
values at days 20,30, and 35 are the mean and individual values from 2 rais. The AMHIGAPD and 
AMHRIIIGAPD mRNA ratios in the 5-day-otd rats were set at t.o. 
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RNase protection assays, performed with total RNA from isolated antral follicles 
and corpora lutea, showed that AMH and AMHRII mRNA is clearly expressed in small 
antral follicles. Using this method, AMH and AMHRII mRNA expression was also 
detected in large antral follicles as well as in corpora lutea, albeit at a very low level, 
not detectable by in situ hybridization (Fig. 5.4). 
Expression of AMH and AMHRII mRNAs during PMSG-induced follicle growth and 
after subsequent hCG-induced ovulation, in ovaries of immature rats 
Treatment of 30-day-old rats with PMSG followed 56 h later by hCG injection, resulted 
in the presence of a large number of antral follicles at 24 and 48h, recently ovulated 
follicles at 72h, and fully developed corpora lutea 7 days after start of PMSG treat-
ment. AMH and AMHRII mRNA levels in total ovaries were decreased four to five-fold 
at 24h and at 48h, compared to untreated rats. A further decrease (two to three-fold) 
was seen at 72 h, followed by a small increase in the levels of AMH and AMHRII 
mRNAs at 7 days (Fig. 5.5). 
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Fig. 5.4: Expression of AMH and AMHRII mRNAs in isolated 
anlral follicles and corpora lulea. 
AMH, AMHRII, and GAPD mRNA expression was studies 
using RNase protection assays on total RNA from isofated 
corpora lufea (eL), small antral follicles (SA) and large antral 
follicles (LA). The source of the RNA is indicated above the 
tanes in (A) and be/ow the histogram in (B). 
A: results of the RNase protection assay. Each lane 
represents a number of poofed follicles or corpora lulea. 
AMH, AMHRII, and GAPD indicate the positions of the 
respective protected fragments. B: quantitative analysis of 
the AMHIGAPD (open bars) and AMHRII/GAPD (c/osed bars) 
mRNA ralios, The bar/dots represent the mean and 
indivIdual values of two different isolated fOllicle fracUons. 
The AMHIGAPD and AMHRIIIGAPD mRNA ratios in the 
small antral fofl/cles were set at 1.0. 
A) 
AMH 
GAPD 
AMHRII 
GAPD 
B) 
1.20 
1.00 
0.80 
a 
~ 
« 0.60 
z 
a: 
E 
0.40 
0.20 
0.00 
AMH and AMHRII mRNA expression in rat ovary 
PMSG 
t 
00242448 
C 24h 48h 
hCG 
t 
48 72 
72h 7d 
72 7d 7d 
Fig. 5.5: Expression of AMH and AMHRII mRNAs in total ovaries from immature rats treated with 
PMSG and hCG. 
AMH, AMHRII, and GAPD mRNA expression was studied using RNase protection assays on totaf RNA 
from whole ovaries, from rats at different lime points after PMSG treatment (at I=Ohj followed by hCG 
treatment (at f==56h). The numbers above each lane in (A) and be/ow the histogram in (B) correspond 
to number of hours after start of the treatment. 
A, results of the RNAse protection assay. Each lane represents one rat. AMH, AMHRIJ, and GAPD 
indicate the positions of the respective protected fragments. B: quantitative analysis of tI)e AMHIGAPD 
(open bars) and AMHRIIIGAPD (closed bars) mRNA ratios, The bar/dots represent the mean and 
Individual values of two rats, The AMHIGAPD and AMHRIIIGAPD mRNA ratios at (=0 were set at 1,0, 
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Hormonal regulation of AMH and AMHRII mRNA expression 
GnRHant treatment (see Materials and Methods) resulted in an inhibition of follicular 
development. The ovaries of GnRHant-treated rats contained mainly preantral follicles 
and a few small antral follicles (Fig. 5.6A). Combined treatment with GnRHant and 
10 IU FSH resulted in the presence of small antral follicles (not shown), while 
combined treatment with GnRHant and 100 Ilg EB resulted in follicle growth with little 
antrum formation (Fig. 5.6D). Treatment with GnRHant plus FSH plus hCG, or 
GnRHant plus FSH plus EB, resulted in ovaries containing many large antral follicles 
(Fig. 5.6G). 
The patterns of AMH mRNA localization in healthy follicles were similar in 
ovaries isolated from GnRHant-treated rats and control 30-day-old rats, whereas the 
AMHRII mRNA signal in the healthy preantral follicles was slightly decreased in the 
GnRHant-treated rat ovaries (Table 5.2 and Table 5.3). AMH and AMHRII mRNA 
expression in preantral atretic follicles was lower in GnRHant-treated rats compared 
to control 30-day-old rats. Moreover, no, or very little, AMH and AMHRII mRNA 
expression was detected in atretic follicles in ovaries of rats from all other treatment 
groups. In some ovaries, AMH mRNA expression was restricted to follicles located 
in the periphery of the ovary, similar to the expression pattern found in 20-day-old rats. 
This pattern was found in several ovaries from different treatment groups, but no 
correlation between this expression pattern and hormonal treatment was found (see 
for example Fig. 5.6E,F). 
In ovaries from rats treated with GnRHant plus FSH, small preantral follicles 
clearly expressed AMH mRNA, whereas the expression was inhibited in large preantral 
follicles, and/or located in the granulosa cells closest to the oocyte. AMHRII mRNA 
expression in both small and large preantral follicles was highly variable; some follicles 
still expressed a high level of AMHRII mRNA whereas other follicles were AMHRII 
mRNA negative. In healthy small antral follicles no AMH mRNA was observed. 
AMHRII mRNA expression in small antral follicles was lower, and showed more 
variation, than in similar follicles present in ovaries from GnRHant-treated rats. 
Fig. 5.6: (Next page) Localization of AMH and AMHRIJ mRNAs in Immature ra.t ovaries after hormonal 
treatment using In situ hybridization, 
The left figures (A,D,E) are ovarian sections stained with haemafoxylin and eosin. The middle and right 
figures show darkfield views of AMH (B,E,H) and AMHRfI (G,F,I) mRNA expression in adjacent 
sections. A,B,C: ovary from GnRHant-treated rat (AMH and AMHRII mRNA expression is colocafized 
in preantral and small antral follicles): D,E,F: ovary from GnRHant plus EB·treafed rat (AMH and 
AMHRII mRNA expression is lost from a number of healthy preantra.f (ollieles; note the pedpheraf 
focalization of AMH positive follicles and even distdbution of AMHRII mRNA expressing follicles); G,H,I: 
oval}' from GnRHant plus FSH plus hCG-treated rat (numerous large antral follicles are present, 
showing no AMH and AMHRII mRNA expression). AF, atretic follicle. Bar represents 200 pm, 
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Combined treatment with GnRHant plus EB resulted in an inhibition of AMH and 
AMHRII mRNA expression in a number of preantral and small antral follicles. Both 
AMH and AMHRII mRNA expression were highly variable, and no consistent 
morphologic difference between AMH and/or AMHRII mRNA positive and negative 
follicles was observed. 
Ovaries isolated from rats treated with GnRHant plus FSH plus hCG, or 
GnRHant plus FSH plus EB contained many large follicles which did not show any 
AMH and AMHRII mRNA expression. The few preantral follicles that were present 
had no or variable AMH and AMHRII mRNA expression, similar to the mRNA 
expression detected in GnRHant plus FSH-treated rat ovaries (Fig. 5.6G-I). 
RNase protection assays of total RNA isolated from ovaries from the different 
treatment groups showed that the total ovarian levels of AMH and AMHRII mRNAs 
were increased in ovaries from GnRHant-treated rats compared to control 30-day-old 
rats. All combined hormonal treatments resulted in decreased levels of total ovarian 
AMH and AMHRII mRNA expression, compared to GnRHant treatment alone (Fig. 
5.7); the relative decrease of AMH mRNA was more pronounced than the decrease 
of AMHRII mRNA expression. 
Discussion 
The specific patterns of AMH mRNA and protein expression during postnatal ovary 
development in mouse and rat (MOnsterberg and Lovell-Badge, 1991; Hirobe et al. 
1992; Ueno et al. 1989a; Ueno et al. 1989b; Hirobe et al. 1994) and the expression 
of AMHRII mRNA in adult rat ovary (8aarends et al. 1994; di Clemente et al. 1994b), 
have provided indications that AMH rnay playa role in the hormonal network that 
regulates ovarian functions. 
In the experiments reported herein, we have made use of mRNA in situ 
hybridization and RNase protection assay, to determine the ovarian AMH and AMHRII 
mRNA expression patterns in detail. The in situ hybridization results provide 
information about the cellular location of AMH and AMHRII mRNA expression. RNase 
protection assay is more sensitive and quantitative than in situ hybridization, and was 
used to determine the relative levels of AMH and AMHRII mRNAs in isolated follicles 
and corpora lutea, and to study quantitative changes in total ovarian levels of AMH 
and AMHRII mRNAs during ovarian development and in immature rat ovaries following 
hormonal treatment. Comparison of in situ hybridization results and RNase protection 
results, combined with the morphologic characterization of the ovaries, are essential 
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to obtain complete information about the AMH and AMHRII mRNA expression patterns 
and their regulation. 
In situ hybridization revealed that AMH and AMHRII mRNAs in the rat ovary are 
specifically expressed in granulosa cells. Oocytes, theca and interstitial cells, express 
no, or a very low amount of AMH and AMHRII mRNAs. In analogy to the proposed 
autocrine action of AMH on Sertoli cells in postnatal rat testes (Baarends et al. 1994), 
these results indicate that most actions of AMH via AMHRII in the ovary will be 
autocrine in nature. 
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Fig. 5.7: Expression of AMH and AMHRII mRNA In total ovaries from immature rats after hormonal 
treatment. 
AMH, AMHRII, and GAPD mRNA expression was studied using RNase protection assays on total RNA 
from whole ovaries, from immature rats after different treatments. Ovaries were isolated from: 1, 
control 30-day-old rats; 2, GnRHant-treafed rats; 3, GnRHant plus FSH-trealed rats; 4, GnRHant plus 
FSH plus hCG-treated rats (not shown; results of this group were very similar to the mRNA expression 
data obtained for group 6); 5, GnRHant plus EB·treated rats; 6, GnRH plus FSH plus EB-treated rats. 
A: results from the RNase protection assays, Each lane represents one rat, AMH, AMHRII, and 
GAPD indicate the positions of the respective protected fragments, B: quantitative analysis of the 
AMH/GAPD (open bars) and AMHRII/GAPD (closed bars) mRNA ratios. The bar/dots represent the 
mean and individual values of two rats, The AMHIGAPD and AMHRIIIGAPD mRNA ratios from control 
30-day-old rats were set at 1,0, 
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Table 5.2: Expression of AMH and AMHRII mRNAs in follicles during the estrous cycle in ovaries of adult rats, as measured by 
in situ hybridization 
Proestrus Estrus Metestrus Diestrus·1 Diestn.Js..2 
0 AMH AMHRII 0 AMH AMHRII 0 AMH AMHRI 0 AMH AMHRII 0 AMH AMHRIl 
Healthy preantral (18) +1- +1- (21) 0/+ 0/_ (41) +1- +1++ (16) +1++ + (28) +1++ + 
small antral (5) + + (8) ± ±I+ (13) O/± ±I+ (6) ±I+ ±I+ (4) O/± O/± 
large antral (10) 0 0 (2) 0 0 (2) 0 0 
Atretic preantra! (3) 0 0 (3) 0 ± (1) 0 + (2) ± ± 
small antral (4) 0 0 (7) 0 O/± (4) 0 ± (5) 0 O/± 
large antral (1) 0 0 
- == follicle not present 
a = no silver grains above background, ± :::: moderate expression, + :::: clear expression, ++ :::: high expression 
Number of follicles (n) Is given in parentheses 
AMH and AMHRII mRNA expression in rat ovary 
During follicle development, AMH and AMHRII mRNAs are expressed mainly 
in preantral and small antral follicles, resulting in a marked colocalization of the two 
mRNAs. Primordial and large antral follicles, as well as corpora lutea, are AMH and 
AMHRII mRNA negative (below the limit of detection). AMH mRNA is expressed in 
some preantral atretic follicles, but rarely in antral atretic follicles. Also AMHRII mRNA 
expression gradually disappears in atretic follicles, although this mRNA persists 
somewhat longer than AMH mRNA. It is of interest to note, that AMHRII mRNA is 
always evenly distributed in the granulosa cell layer, whereas AMH expression is often 
restricted to granulosa cells surrounding the oocyte and/or the antrum in some follicle 
types. This pattern of AMH mRNA expression is found mainly in follicles that start 
expressing AMH mRNA (small preantral follicles) and in follicles that loose AMH 
mRNA (large preantral follicles, atretic follicles), in prepubertal as well as in adult rat 
ovaries. This AMH mRNA distribution pattern may reflect functional differences 
between the granulosa cells surrounding the antrum/oocyte, and the peripheral 
granulosa cells, such as differences in proliferation capacity and steroidogenic activity 
(reviewed by Hirschfield, 1991; and Richards, 1994). 
During the first two to three weeks of postnatal development, AMH and AMHRII 
mRNA expression patterns differ slightly from the above described adult patterns. 
AMH mRNA is not expressed prior to birth, and becomes detectable after birth when 
the first preantral follicles have developed (Hi robe et al. 1992; and present results). 
Thereafter, AMH mRNA expression gradually increases in preantral follicles. When 
small antral follicles appear, these show low AMH mRNA expression. AMHRII mRNA 
expression is high in fetal ovaries (Baarends et al. 1994), and is expressed in an 
evenly distributed manner, covering the ovary, at postnatal day 5. From day 15 
onwards, AMHRII mRNA expression becomes restricted to granulosa cells, and is 
found in the follicle types that also express AMHRII mRNA in the adult ovary. 
Hirobe et al. (Hirobe et al. 1992) have also reported data conceming AMH 
mRNA expression data in 35-day-old rat ovaries, that are consistent with our findings. 
However, in a more recent report (Hirobe et al. 1994), Hirobe and co-workers show 
an intense hybridization signal representing AMH mRNA, in cumulus cells and luminal 
granulosa cells in follicles larger than 500 flm, which is lost just prior to ovulation. We 
also find that AMH mRNA, when its expression decreases, becomes restricted to 
luminal granulosa cells and the granulosa cells closest to the oocyte, but we observe 
that this signal is lost in follicles larger than 450 flm. Decreased AMH and AMHRII 
mRNA expression in large antral follicles compared to small antral follicles was also 
observed using RNase protection assay. Residual AMH and AMHRII mRNA 
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expression observed in large antral follicles and corpora lutea using RNase protection, 
may represent low levels of mRNA that are evenly distributed and therefore not 
detected using in situ hybridization. It is not clear what causes the disagreement 
concerning AMH mRNA expression in large follicles, although it cannot be excluded 
that a difference in the part of the AMH gene that was used as a probe, in the present 
experiments and by Hirobe et al. (Hirobe et al. 1994), may result in detection of 
different spliced forms of AMH mRNA. 
Based on the results presented in this paper, we conclude that both AMH and 
AMHRII mRNA expression are turned on in granulosa cells of small preantral follicles, 
increase to maximal levels in large preantral follicles, and decrease In small antral 
follicles. Subsequently, both AMH and AMHRII mRNA expression decrease to 
undetectable levels as the follicles develop a large antral cavity and start to undergo 
the final stages of follicular maturation. Using RNase protection, which is more 
sensitive than in situ hybridization, it was shown that the expression levels of AMH and 
AMHRII mRNAs in large antral follicles are approximately 2.5 and 3-fold lower, 
respectively, than in small antral follicles, and are even further reduced, but still 
detectable, in corpora lutea. 
Marked coregulation of AMH and AMHRII mRNAs is also observed in total RNA 
preparations from ovaries isolated from immature rats that were treated with PMSG 
and hCG. After PMSG treatment, the ovaries consist mainly of large antral follicles 
(at 24 h) and preovulatory follicles (at 48h), which results in relatively low levels of 
AMH and AMHRII mRNAs at these two time points. After ovulation (72h after PMSG), 
the signal decreases even further, reflecting the low levels of AMH and AMHRII 
mRNAs in corpora lutea. Total ovarian AMH and AMHRII mRNA expression have 
somewhat increased again after 7 days, which may reflect AMH and AMHRII mRNA 
expression in small preantral follicles that have started to grow. 
The expression of AMH and AMHRII mRNAs appears to be tightly coupled to 
follicle differentiation. This indicates that local changes in the environment surrounding 
the follicle, and/or in the responsiveness of granulosa cells to certain factors, may play 
a major role in the regulation of both AMH and AMHRII mRNA levels. During the 
estrous cycle, a change in the patterns of AMH and AMHRII mRNA expression is 
observed at estrus, when AMH and AMHRII mRNA expression is lost from several but 
not all preantral follicles. FSH has been reported to downregulate AMH mRNA 
expression in neonatal rat testis (Kuroda et al. 1990). Furthermore, results obtained 
in this report using GnRHant plus FSH-treated female rats, indicate that FSH may also 
downregulate ovarian AMH as well as AMHRII mRNA expression (see below). 
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Table 5.3: Expression of AMH and AMHRII mRNAs in ovaries from rats treated with GnRH antagonist in various combinations 
with FSH, estradiol benzoate (EB), and hCG. 
GnRHant GnRHant GnRHant GnRHant GnRHant 
+FSH +EB +FSH +hCG +FSH +EB 
0 AMH AMHRlI 0 AMH AMHRII 0 AMH AMHRI 0 AMH AMHRll 0 AMH AMHRII 
Healthy preantral (61) +1++ ±l+ (64) 0/+ 0/+ (52) 0/+ O/± (35) 0/+ 0/+ (20) 0/+ O/± 
small antral (5) ± ± (38) 0 O/± (8) 0 O/± (26) 0 0 (12) 0 0 
large antral (2) 0 0 (16) 0 0 (3) 0 0 
Atretic preantral (21) O/± O/± (18) 0 0 (14) 0 ± (5) 0 0 (3) 0 0 
small antral (4) O/± O/± (19) 0 0 (3) 0 0 (17) 0 0 (8) 0 0 
large antral (8) 0 0 (14) 0 0 (4) 0 0 
- '" folHele not present 
o = no silver grains above background, ± = moderate expression, + =: clear expression, ++ = highest expression 
Number of follicles (n) is given in parentheses 
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Thus, it could be postulated that the FSH surge on the morning of estrus may cause 
a decrease of ovarian AMH mRNA expression and perhaps also of AMHRII mRNA 
expression. Estrogens might also be involved in down regulation of AMH and/or 
AMHRII mRNA expression in the ovary. Estrogen is locally produced, and the results 
presented in this paper show that AMH and AMHRII mRNA levels during follicular 
development decrease at the time that follicular estrogen output increases (Uilenbroek 
and Richards, 1979). Furthermore, it has been reported that estrogens regulate AMH 
actions during sex differentiation in chickens (Hutson et al. 1982), and, mice treated 
with high doses of synthetic estrogens in utero develop abnormalities (Newbold et al. 
1984), that may be partly caused by impaired AMH function. Since AMH inhibits 
estrogen synthesis in cultured granulosa cells through inhibition of expression of 
aromatase mRNA and protein (di Clemente et al. 1994a), estrogenic regulation of 
AMH and/or AMHRII mRNA expression could be part of a feedback mechanism. 
The possible roles of estrogens and gonadotropins in regulation of AMH and 
AMHRII rnRNA expression in the ovary were investigated. For this, 30-day-old rats 
were treated with GnRHant to inhibit endogenous gonadotropin secretion 
(Meijs-Roelofs et al. 1990). Ovaries from these rats contain numerous preantral 
follicles; such follicles express high amounts of AMH and AMHRII mRNAs in control 
rat ovaries. In situ hybridization results showed that there was a small decrease of 
AMHRII mRNA expression in preantral follicles of GnRHanHreated rats, compared to 
control rats. This may indicate that gonadotropins are required for the maintenance 
of AMHRII mRNA expression in preantral follicles. Alternatively, the decreased 
AMHRII mRNA expression may be due to a direct action of GnRHant upon ovarian 
cells by blocking the GnRH receptor, which is expressed in the granulosa cells of most 
follicle types (Whitelaw et al. 1995). 
The results from combined treatment of GnRHant with FSH and/or EB, indicate 
that high doses of either FSH or EB are capable of inhibiting AMH and AMHRII mRNA 
expression in preantral and small antral follicles. Inhibition of AMH mRNA expression 
may result from a direct effect of estrogens on AMH gene transcription. The AMH 
promoter has been characterized in several species (Guerrier et al. 1990; Haqq et al. 
1992; Cate et al. 1986; Shen et al. 1994), and a number of possible regulatory 
sequence elements have been described (Haqq et al. 1993; Guerrier et al. 1990; Shen 
et al. 1994). The human AMH gene promoter contains a putative estrogen responsive 
element (Guerrier et al. 1990). When several copies of this 35 bp fragment are 
inserted in front of a basal promoter-reporter gene construct, the estrogen receptor 
binds to this construct, and activates transcription in vitro (Guerrier et al. 1990). 
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However, these results could not be obtained with a 182 bp fragment, containing the 
putative estrogen responsive element. Whether this element and surrounding 
sequences are involved in down regulation of AMH mRNA expression in vivo remains 
to be determined. No putative FSH-regulated AMH gene promoter elements have 
been described. 
The increased AMH and AMHRII mRNA levels in GnRHant-treated rats, as 
determined by RNase protection assay, are in accordance with the observed 
enrichment, when compared to control rat ovaries, in AMH and AMHRII mRNA positive 
follicles. Also, RNase protection assay results of the other hormonal treatment groups 
reflect the sum of the effects on follicle population and mRNA down regulation by FSH 
and EB. 
In adult ovaries, AMH and AMHRII mRNA expression decrease in granulosa 
cells of those follicles, which are at a decisive step of their development; many small 
antral follicles become atretic, and only a few survive and are selected to differentiate 
to the preovulatory stage. During this period, the sensitivity of the follicles to FSH 
increases (Richards, 1980), which results in increased aromatase activity and 
increased synthesis of estrogens. Based on the present results, it could be suggested 
that increased sensitivity of granulosa cells to FSH in small antral follicles, is the initial 
cause of downregulation of AMH and AMHRII mRNAs, resulting in a diminished 
inhibitory effect of AMH on aromatase activity. The subsequent increased estrogen 
production could then result in a further decrease of AMH and AMHRII mRNA 
expression. 
Total ovarian AMH mRNA expression increases during the first 15 days of 
postnatal development. Concomitantly, FSH levels increase to a high maximal level 
around day 15 (Meijs-Roelofs et al. 1973). Binding of FSH to granulosa cells is very 
low until day 17, and increases thereafter (Uilenbroek and van der Linden, 1983). 
Thus, it cannot be excluded that a low sensitivity of immature granulosa cells to FSH 
during the first two weeks of postnatal development allows AMH mRNA expression to 
increase. Between days 25 and 30, although FSH binding increases, FSH levels 
decrease, which might result in a further increase in AMH mRNA expression. The 
change in the pattern of AMHRII mRNA expression around postnatal day 15, from an 
evenly distributed pattern to a more restricted pattern, cannot be explained by changes 
in FSH and/or estrogen levels, or by known changes in the sensitivity of ovarian cells 
to these hormones, and is thus most likely caused by other factors. 
Recently, Behringer et al. (Behringer et al. 1994) have generated AMH knock-
out mice. Female AMH deficient mice develop normally, with ovaries that are 
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morphologically similar to the ovaries of control animals, and the mice are fertile and 
produce phenotypically normal progeny. Although this indicates that AMH may not be 
essential for ovarian function, functional redundancy between AMH and other 
members of the activin and TGFp family of growth and differentiation factors may 
mask some of the ovarian functions of AMH in the AMH knock-out mice. Indeed, 
follicular expression patterns of activins, inhibins, TGFps, and some of their receptor 
types, are partially overlapping with AMH and AMHRII mRNA expression (Meunier et 
al. 1988; Woodruff et al. 1988; Teerds and Dorrington, 1992; Cameron et al. 1994). 
Furthermore, detailed studies of multiple parameters related to ovarian function 
throughout the reproductive life-span of the AMH knock-out female mice, might provide 
some clues concerning long-term ovarian functions of AMH. 
The results presented herein provide evidence that granulosa cells of pre antral 
and small antral follicles are major target cells of AMH. Together with the reported 
inhibitory effects of AMH upon granulosa cell proliferation (Kim et al. 1992; Seifer et 
al. 1993), aromatase activity, and LH receptor expression (di Clemente et al. 1994a), 
it is an intriguing possibility that AMH is involved in preventing premature follicle 
maturation, rather than playing a direct role in oocyte meiotic maturation. It is also 
possible that AMH function involves a role in selection of follicles that do not undergo 
atresia. Little is known about the mechanism that determines whether a follicle will 
undergo atresia, or eventually ovulate (reviewed by Hsueh et aI., 1994). Many follicles 
become atretic when they reach the small antral stage, and the FSH-surge at estrus 
is thought to be essential for survival of those follicles at the large preantral/small 
antral stage which are destined to ovulate at the next proestrus. FSH-regulated 
survival of follicles may involve downregulation of AMH and AMHRII mRNA expression 
at estrus. In this respect, it is of interest to note that androgens are thought to be 
atretogenic, and that androgen receptor immunohistochemical staining data indicate 
that the ovarian androgen receptor expression pattern is markedly similar to the AMH 
and AMHRII mRNA expression patterns in adult rats (Tetsuka et al. 1995). Future 
experiments can be directed towards the study of functional interactions in the ovary, 
between AMH and other members of the activinlTGFp family, and between AMH, 
estrogens, and androgens. 
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Summary 
The androgen receptor (AR) is activated upon binding of testosterone or dihydrotestosterone and exerts 
regulatory effects on gene expression in androgen target cells. To study transcriptional regulation of the rat 
AR gene itself, the 5' genomic region of Ihis gene was cloned from a genomic library and the promoter 
was identified, SI-nuclease protection analysis showed two major transcription start sites, located between 
10to and 1023 bp upstream from the translation initiation codon, The area surrounding these start sites 
was cloned in both orientations in a CAT reporter plasmid, Upon transfection of the constructs into COS 
cells, part of the promoter stimulated transcription in an orientation-independent manner, but the full 
promoter showed a higher and unidirectional activity. In the promoter/ reporter gene constructs, transcrip-
tion initiated from the same positions as in the native gene, Sequence analysis showed that the promoter of 
the rat AR gene lacks typical TATA and CCAAT box elements, but one SPl site is located at about 60 bp 
upstream from the major start site of transcription, Other possible promoter elements are TGTYCT 
sequences at positions -174 to -179, -434 to - 439, -466 to - 471, and - 500 to - 505, resembling 
half-sites of the glucocorticoid-responsive element (GRE), Furthermore, a hOl1lopurine stretch containing a 
total of 8 GGGGA elements and similar to sequences that arc present in several other GC-rich promoters, 
is located between - 89 and -146 bp upstream from the major start site of transcription. 
Introduction 
Following differentiation of the testis, andro-
gen action is essential for development of the male 
reproductive tract, \'irilization and full initiation 
Address for correspondence: W.M. Daarends, Department 
of Biochemistry II, Medical Faculty, Era.smu~ University Rot· 
terdam, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands. 
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and maintenance of spermatogenesis (Griffin and 
Wilson, 1989). The androgenic hormones testos-
terone and dihydrotestosterone exert their effects 
on gene expression through binding to the andro-
gen receptor (AR). The AR helongs to the family 
of ligand-activated transcription factors that in-
cludes the' other steroid hormone receptors as well 
as the thyroid hormone, the retinoic acid and the 
vitamin D,l receptors. The progesterone and gluco-
corticoid receptor are structurally most closely 
related to the AR (Tilley et aI., 1989). 
Recently, the cDNAs encoding the human and 
rat AR have heen doned (Chang et aI., 1988; 
Lubahn et ai., 1988; Trapman et aI., 1988), The 
rat AR mRNA is approximately 10 kb, containing 
large 5' and 3' untranslated regions (UTRs) of 
approximately 1 and 7 kb respectively, The open 
reading frame encodes a protein with 902 amino 
acid residues. The rat and human AR mRNAs 
show a high degree of sequence similarity in the 
coding regions and the 5' UTRs, 
The regulation of AR protein levels may con-
stitute an important level of control at which the 
physiological effects of testosterone can be mod-
ulated. In the testis, AR protein is expressed in 
Sertoli celis, Leydig cells and peritubular celis, but 
not in the developing germ cells (Grootegoed et 
al., 1977; Buzek and Sanborn, 1988), Recently, it 
has been shown that both follicle-stimulating 
hormone (FSH) and testosterone can stimulate 
AR protein levels in cultured Sertoli cells from 
immature rats (Verhoeyen and Cailleau, 1988; DIok 
et al., 1989), However, only FSH stimulated the 
amount of AR mRNA, whereas testosterone had 
no effect on mRNA expression (Blok et aI., 1989), 
In other tissues, including prostate, kidney, brain 
and epididymis, the AR mRNA content is down-
regulated by testosterone (Quarmby et aI., 1990). 
The cellular amount of AR mRNA may be 
regulated at the level of transcription, but also 
through alteration of its stability, To study a pos-
sible regulatory effect of testosterone and FSH on 
the rate of AR gene transcription, the AR gene 
promoter should be defined. Here we report the 
identification and characterization of the rat AR 
gene promoter. 
Materials and methods 
Isolation 015' genomic rat AR clones 
A rat genomic library was constructed by clon-
ing rat DNA that had been partially digested with 
MboI into the BamHI site of AEMBLl This 
library (1.7 X 106 independent plaques) was 
screened using human AR probes corresponding 
to the 5' region of the human AR first exon 
(Faber et aL, 1989), Hybridization was carried out 
using standard methods (Maniatis ct aI., 1982) 
under conditions of low stringency. PositiYe clones 
were selected and rescreened to obtain purified 
rat androgen receptor gene promoter 
single plaques, Five independent clones were iso-
lated: GrAR2, 3, 4, 6, 7. 
Subdolling and sequencing 
Several restriction fragments derived from 
GrAR2 were subcloned into pGEM7 (Promega, 
Madison, WI, U.S.A.) using standard techniques 
(Maniatis et aL, 1982). Partial overlapping clones 
were sequenced by dideoxy-chain termination 
(Sanger et a1., 1977) in two orientations using 17 
polymerase (Pharmacia, Uppsala, Sweden), Dou-
ble-stranded plasmid DNA was used as a tem-
plate, The promoter/reporter gene constructs were 
prepared as follows: The genomic Hil/dIII frag-
ment (- 296/ + 120) was cloned in the HindIII 
site of the polylinker from the pCATENH vector 
(Promega) in the antisense direction (HASCAT). 
pGEM7H3.1, containing the HilldIII fragment 
(-296/+ 120}, was partially cut with NlleI, 
treated with Klenow enzyme and dNTPs to pre-
pare blunt ends, followed by a complete HilldIII 
digestion. Subsequently, the appropriate HindIII-
Nile! fragment (- 296/ + 97) was isolated from 
low-melting-point agarose, The fragment was 
ligated into pCATENH which had been cut with 
Xba I and blunt-ended with Klenow enzyme fol-
lowed by a second digestion with HilldIII 
(HSCAT). The PstI fragment (-507/+912) was 
cloned into the Pstl site from pCATENH in the 
antisense direction (PASCAT). pGEM7E3, con-
taining the EcoRI fragment (-570/ + 1005), was 
cut with KplI I, treated with T4 polymerase and 
dNTPs to create blunt ends, followed by digestion 
with Pstl. The KpIlI-PstI fragment was isolated 
from low-melting-point agarose and cloned into 
pCATENH (PSCAT), which had been cut with 
HindIII, blunt ended with Klenow and digested 
with PstL The insertion of the correct fragment in 
the desired orientation was checked by restriction 
enzyme digestion. 
RNA isolation 
Frozen tissues and cultured cells were lysed and 
homogenized in 3 M LiClj6 M ureum, and left on 
ice for several hours. The RNA was pelle ted 
through ultracentrifugation (25 X 103 rpm, 25 min, 
SW40 rotor), The pellet was dissolved in 0.1% 
(w/v) sodium dodecyl sulfate (SDS) and proteins 
were removed by repeated phenol extraction and a 
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single proteinase K treatment in 0.1% (w/v) SDS. 
After precipitation the RNA was dissolved in a 
small volume of watcr and the amount of RNA 
was determined by spectrophotometric optical 
density (OD) measurement at 260 run. RNA was 
stored in 0.3 M NaAc/70% ethanol at - 20°C. 
Sl-nuc/ease protection assay 
pGEMH3.1 was cut with HindIII, dephos-
phoryJated and end-labeled with T4 polynucleo-
tide kinase and [y. 32 PJATP according to Maniatis 
et al. (1982). TIle HindIII fragment was subse-
quently isolated from low-melting-point agarose 
and dissolved in 0.3 M NaAc (pH 5.2). Approxi-
mately 0.5-1 x 105 cpm were precipitated with the 
appropriate amount of total RNA. After centrifu-
gation, the pellet was dissolved in hybridization 
buffer containing 80% (v Iv) deionized formamide, 
40 mM Pipes (PH 6.3), 0.4 M NaCI and 1 mM 
EDTA according to Favaloro et al. (1980). The 
samples were denatured for 3 min at 90°C fol-
SE 
lowed by an overnight hybridization at 55 ° C. 
Sl-nuclease (Boehringer Mannheim, Mannheim, 
F.R.G.) digestions (Favaloro et ai., 1980) were 
carried out for 1 h at 37 ° C or for 3 h at 20°C, 
with similar results. The protected DNA frag-
ments were analyzed on a 6% or 8% polyacryl-
amide sequencing gel. 
Cell culture and lransiellilrans/eclion assays 
COS cells were grown in Dulbecco's modifica-
tion of Eagle's medium (Gibco BRL, Grand Is-
land, NY, U.S.A.), supplemented with 105 lUll 
of penicillin, 100 mg/l streptomycin and 5% fetal 
calf serum. All cultures were maintained at 3°C 
under an atmosphere of 5% CO2 in air. Before 
transfection, cells were plated in 6 cm diameter 
culture dishes (Nunclon, Roskilde, Denmark) at 
approximately 10% confluence and cultured for 24 
h. Transfections were carried out according to 
Graham and van der Eb (1973) using 10 p.g of 
plasmid DNA per dish. The cells were shocked 24 
, " 
GrAR3L!i! __ -" ______________ ~ ____ ~ ______ J 
S ( 
GrAR7L! __ ~~ __ ~ ____________ _" ______ "_J 
S ( 
GrAR6 L! ~! __ ~ __ LL __ L __________ _" 
s 
GrAR4)L-________ ~_i __ ~~ __ L ____ _" 
( ( S 
GrAR21"-____________ -" __ L-i)-"!~,c_~--~! 
, 
, 
, 
p,' 
, 
, 
, 
, 
, 
( "K H tI 
s· (I I I I 
100 hp 
end of published eDNA 
<------------
Fig. 1. s<:hematic representation of isolated lambda clones, wntaining genomic rat AR sequences (GrARl, J, 4, 6, 7). Part of GrAR2 
is shovm in more detaiL The 5' end of the published rat AR eDNA (Lubahn et aJ., 1988) is indicated. The horizontal arrov .. s show the 
sequence strategy. The horizontal line above the restriction map of GrAR2 represents the probe that was used for the Sl-nuclease 
protection assays. The asterisk indicates the site used for end.labeling by 1,,(· 3I p] ATP. A = Sal/JA, E = £CoRI, H = Hindlll, 
K=Kpnl, N = Nhel, P= Pstl, S= Sail. 
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h later for 2 min with 15% glycerol in phosphate-
buffered saline (PBS), and 48 h after transfection 
the cells \vere harvested and broken by three cycles 
of freezing and thawing. After centrifugation, su-
pernatants were assayed for CAT activity as de-
scribed by Gorman et at. (1982). A transfection 
with pSV2CAT was included in each experiment 
as a control to compare the transfection efficien· 
cies of the different experiments. 
of the AR mRNA. Five independent overlapping 
clones were isolated as presented in Fig. 1. GrAR2 
contained the farthest 5' extending sequences and 
this clone has been used for subsequent studies. 
Based upon hybridization results, we have sub· 
cloned and sequenced several restriction frag-
ments derived from GrAR2. The sequencing 
strategy is also shown in Fig. 1 and the obtained 
sequence is presented in Fig. 2. The 3' end of this 
sequence (117 bp) is identical to the published 5' 
end of the rat AR cDNA (Lubahn et al., 1988). Results 
/solation alld characterization of 5' genomiC rat AR 
clones 
Identification of the 5' end of the rat AR mRNA 
A rat liver genomic library was screened with 
human AR cDNA probes representing the 5' end 
In order to locate the cap site of the rat AR 
mRNA we have pcrformed SI·nuclease protection 
assays. A genomic HindlII fragment that suc-
-570 GAATl'CCCCATCl'ACGCTACIGGAGGATCI'CAAAGG'I'I'I'CI'GCAAGlIGTI"GCITIGGCIG 
-510 CAGe I iVIlClIIMTCTCI'IGGGACI'C1'CCC'lT~CcrGGGGA 
-450 GAGGGTACCT1'I1ioGAACM'ITGGTAGCCGGTACTTCTMTGCCccrTccrcCI'CGGAGMT 
-390 CI'GTlTI'GGGATIGGG'I'l'CAGGM'TGAAATCCGGCCTGTGCTMCCITITGAGGAGCCGG 
-330 TAGGCITGTCI'GTrMAAMTCGCTCCAAG'ITAAAGCI'I'CTGCI'I'I'GGAGTCTAMGCCC 
-270 GGTrCCGAMMCAAGTGGTATl'l'GGGGMllAGGGGTCITCAGAGGCTACAGGGAGTCCT 
-210 TCCAGCcrrcMCCATACTACGCCACGACTA'l'GTl'CTCTAAAGCCACCCIGCGCTAGCTl' 
HOMOFURINE-STRETCH 
-150 
GC-BOX 
-90 ~MGGCAGGGAOO<X!G':O ·»43<JCGGG.I>CCGACTCACAMCTGTl'G 
.. ------.. -----------------------
-)0 CATrI'GCI'I'I'l'CCAccrcCCAGCGCCCCCI'CGGAGATCCCTAGGAGCCAGCCTGcrGGGA 
+1 
'--
+31 GAACCAGAGGGTCCGGAGCAMCCIGGAGGCffiAGAGGGCATCAGAGGGGAAlIAGACTGA 
+91 GCTAGCCAcrccAGTGCCATACAGMGCTl' 
Fig. 2. Sequence of the 5' genomic region of the rat AR gene containing putative promoter e!ements. The + 1 position is defined at 
the major transcriptional start site. The asterisks aboye the sequence indicate the other start sites. Putati\'e promoter elements are 
bo!d-faced: TGrreT and AGAACA, the homopurine stretch and the GC box. The possib!e splice acceptor site is underlined and 
the transcribed sequence is overlined. 
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Fig. 3. SI·nuclease protection assay of the 5' genomic HindIII 
fragment. Protected fragments obtained v.ith 50 IlS of total 
testis RNA (lane 1), and 50 PS of total spl~n RNA (lane 2) 
are shown. The triangle indicates intact probe, and arrows 
indicate the major bands. The numbers on the right represent 
the lengths of the marker DNA in bp. 
rounds the 5' end of the eDNA was used as a 
probe (Fig. 1). Total RNA preparations from 21-
day-old rat testis or spleen were hybridized to the 
end-labeled DNA probe, and subsequently the 
SI-nuclease digestion was carried out; Fig. 3 shows 
the resulting protected DNA fragments after anal-
ysis on a denaturing polyacrylamide gel. 
Using total testis RNA, two pronounced bands 
were observed (Fig. 3; lane 1). The 5' ends of the 
two major bands map just upstream from the 5' 
end of the published rat AR cDNA which is 
located in Fig. 2 at position + 5. Using total RNA 
derived from spleen, an AR-negative tissue 
(Lubahn et al., 1988), no labeled DNA fragments 
protected from SI-nudease digestion were de-
tected. The SI-nudease digestion has been carried 
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out at 37 ° C as well as at 20°C, and similar results 
were obtained at both temperatures (not shown). 
We have also performed primer extension anal-
ysis as described by Krug and Berger (1987), to 
identify the transcription start sites using another 
method. HO\vever, this method did not yield re-
suits, most likely because the RNA was present in 
a conformation which interfered with AMV re-
verse transcriptase activity. 
Structure of the 5' genomic region of the rat AR 
gene 
The finding that different bands were obtained 
with the SI-nuclease protection assay strongly im-
plies the presence of multiple start sites of tran-
scription, a feature that is common to most pro-
moters that lack a TATA box. In concordance 
with this, sequence analysis of the 5' genomic 
region shows that no typical TATA or CCAAT 
box is present (Fig. 2). However, several structural 
elements indicative of a promoter can be indi-
cated. The genomic region from -1 to - 300 has 
an overall O/C content of 58%, and one SPI site 
(OGCGGO) is located ,around position - 60 
within an uninterrupted stretch of Ole residues. 
Furthermore, a homopurine streich contairung a 
total of eight GGOGA elements is located be-
tween -89 and -146 bp upstream from the major 
start site of transcription. These GGGGA se-
quences might represent promoter elements (see 
Discussion). 
Other possible promoter elements in this region 
are the TGTYCT consensus elements that are 
present at positions -174 to -179, -434 to 
-439, -466 to -471, and -500 to -505, and 
which can be considered as glucocorticoid-respon-
sive element (ORE) 'half sites'. The GRE consists 
of a palindromic pair of hexameric TOTYCT se-
quences separated by three nucleotides (Klock et 
aL, 1987). It should be noted that the 5' genomic 
region also contains a possible splice acceptor site 
(Fig" 2). 
Functional promoter aclivity in the 5' genomic re-
gion of the rat AR gene 
From the above described results, it is not clear 
whether the protected bands are derived from 
different start sites of transcription, or might re-
rat androgen receptor gene promoter 
100 ~p 
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Fig. 4. Promoter constructs cloned into the pCATENH y~tor. The promoter fragments and the genomic region from which they 
were derived Me shown. Arrows pointing to the right indicate the sense orientation. A schematic dra",ing of the pCATENH vector 
shows the relative positions of the polylinker (open box), the CAT gene, and the SV40 enhancer (closed boxes). Restriction enzyme 
ahbre\iations are as in Fig. 1. 
suit from the use of a splice acceptor site: TIle 
sequence 5'TITCCACCTCCAG3' is located in 
the area that contains the supposed start sites of 
transcription (Fig. 2) and is in accordance with a 
possible intronjexon splice acceptor site. Conse-
quently, further experimental evidence was needed 
2 3 4 5 6 
to determine that the region shown in Fig. 2 
indeed represents the rat AR gene promoter. 
Promoter trap constructs were used to test the 
functional capacity of the putative promoter. The 
cloning vector pCATENH (described in Materials 
and Methods) contains the CAT reporter gene and 
7 8 9 10 11 17 
M C CATENH fiSCAl HASCAT PSCAl PA';CM 
Fig. 5. Rat AR promoter activity in COS cells. CAT acthity in COS cells which were transfected \\ith: no DNA (M; lane 1), 
PSV2CAT (C; lane 2), pCATENH (lanes 3 and 4), HSCAT (lanes 5 and 6), HASCAT (lanes 7 and 8), PSCAT (lane 9 and 10), 
PASCAT(lanes 11 and 12). The S denotes the position of the substrates in the chromatogram, and the A is loc.1ted at the position of 
the acetylated products of the enzymatic reaction. 
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a SV40 enhancer sequence, but no promoter, Two 
types of constructs were made, which contained 
the putative promoter sequences and flanking re-
gions in either the sense or antisense orientation 
with fe,spect to the CAT reporter gene. A sche-
matic representation of the different constructs is 
shown in Fig. 4. After transfection into COS cells, 
the stimulatory effect of the different 5' genomic 
fragments on the rate of CAT gene transcription 
was determined by performing CAT assays (Fig. 
5). pSV2CAT, the positive control plasmid that 
contains a SV40 enhancer and promoter, showed a 
l 
[400 
I JOO 
t
i 200 
1')0 
f-l1.0 
f ~ 130 120 -110 100 
Fig. 6. Analysis of transcriptional start sites in promoter/ 
reporter gene constmcts. The probe shown in Fig. 1 was 
hybridized to RNA e:\;tracted from: COS cells transfected v.ith 
PSCAT (lane 1; 20 /lg), COS cells transfected with PASCAT 
(lane 2; 20 /1g), and total testis (lane 3; 60 /1g). The triangle 
points to the intact prohe and the arrows indicate the majDr 
protected fragments. The numbers on the right indicate the 
lengths of the marker DNA in bp. 
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high CAT activity as compared with pCATENH. 
The construct HSCAT as well as the antisense 
analogue HASCAT stimulated the transcription of 
the CAT gene several fold, as compared 
to the background activity of the parent vector 
pCATENH. These constructs contain about 300 
bp of possible promoter sequences and approxi-
mately 100 bp of the 5' UTR The larger con-
struct, PSCAT, that extends 150 bp further up-
stream and 850 bp further downstream than 
HSCAT and HASCAT, resulted in a somewhat 
higher CAT expression relative to HSCAT and 
HASCAT. In contrast, PASCAT, identical to 
PSCAT but containing the promoter in the anti-
sense orientation, did not show stimulation of 
CAT activity. 
To investigate whether transcription of the pro-
moter/CAT reporter gene constructs starts at the 
same sites as the transcription of the wild type AR 
promoter, we performed Sl·nuclease protection 
assays with RNA extracted from the transfected 
COS cells, using as a probe the genomic HindU! 
fragment that had also been used to locate the cap 
site in our previous experiment. The assay was 
performed on total cellular RNA derived from 
COS cells transfected with either the PSCAT 
(sense) or PASCAT (antisense) construct (Fig. 6). 
Using the sense and anti-sense rat AR genomic 
sequence constructs, stable transcripts were ob-
tained in both orientations, although CAT-gene 
derived sequences are only included in the PSCAT 
transcripts. This experiment was performed to 
show that the 5' ends of the protected fragments 
in RNA from the transfected cells mapped at 
exactly the same positions as those observed using 
RNA from rat testis (Fig. 6; lane C). It can be 
concluded, therefore, that the promoter ·region in 
PASCAT as weJl as PSCAT directs transcription 
from the correct initiation sites and on the correct 
DNA strand. 
Discussion 
Structflral features of the rat A R gene promoter 
From the present results it is concluded that 
the minimal promoter of the rat AR gene is located 
within the area from position + 100 to - 300 in 
the 5' genomic region of the rat AR gene. The 
sequence upstream of position + 1 is not effi-
ciently transcribed into mRNA as shown by SI~ 
nuclease protection analysis. A regulatory func-
tion of the largely untranscribed sequence -I to 
- 300 is reflected in the presence of known se-
quences in this area that have been proven to be 
functional elements of other promoters. 
First, a GC box (GGCGGG) is located around 
position -60. This sequence is identical to a re-
cognition site for the transcription factor SPI that 
has been shown to activate the transcription of 
several genes (Saffer and Singer, 1984). 
Second, a homopurine stretch of 67 bp, located 
between positions -79 and -146. Within this 
region a total of eight repeats of the sequence 
GGGGA is present. Several other genes also con-
tain purine-rich sequences in the promoter 
(Christophe et al., 1989; Claessens et aI., 1989; 
Watson and Milbrandt, 1989; Young et al., 1989), 
some including the GGGGA element (Watson 
and Milbrandt, 1989; Young et a1., 1989). No 
funclional role has yet been assigned to this se~ 
quence motive, although homopurine stretches are 
known to contain sites that are sensitive to Sl~ 
nuclease digestion indicating an irregular DNA 
structure (Claessens et al., 1989; Young et aI., 
1989). The GGGGA element could very well rep-
resent a regulatory protein binding site. For exam-
ple, the transcription factor ETF can bind to 
sequences that contain eccc or GGGG repeats 
separated by one nucleotide. Through binding to 
these consensus repeats, ETF specifically enhances 
transcription from promoters whieh do not con-
tain a TATA box (Kageyama et ai., 1989). The P2 
promoter of the c-myc gene also contains a GG-
GGA element which is involved in protein bind-
ing and promoter function. The sequence element 
GGGGAGGGA, located 48 bp upstream of the 
start sitc of transcription in the c-myc P2 promo-
ter, can be specifically bound by protein in a gel 
retardation assay and is capable of increasing the 
promoter activity (Hall, 1990). 
Finally, TGTYCT elements are present at four 
different positions between -174 and - 505 in 
the promoter region. A glucocorticoid responsive 
element (GRE) consists of a palindromic pair of 
the hexameric TGTYCT sequence, separated by 
three nucleotides (Klock et al., 1987). In a random 
distribution, the TGTYCT sequence would be ex-
pected to occur approximately once in every 103 
rat androgen receptor gene promoter 
bp. It might be suggested that this non-palindromic 
sequence, either as repe,lI, or together with flank-
ing sequences, might also have some function in 
steroid hormone responsive promoters in general. 
In this respect, it is of interest that TGTYCT 
sequences are present in the promoter of the 
androgen-dependent prostatic binding protein 
genes CI, C2 and C3 (Claessens et aI., 1989a). 
Furthermore, fragments from the promoter and 
first intron of the C3 gene that contain this con-
sensus sequence have been shown to bind AR~ 
steroid complex (Rushmcre et ai., 1987). Only the 
intron-derived sequence could confer androgen re-
sponsiveness to a heterologous promoter and this 
effect could be annulled by a single point muta-
tion in one of the two TGTYCT motives that were 
located in this area (Claessens et aI., 1989b). 
Recently, we have also cloned the human AR 
gene promoter (Faber et at, manuscript in prep-
aration). Comparison of the rat and human se-
quences indicates that the AR promoter shows a 
similar structural organization in these two species. 
The major start sites of transcription are located 
at the same positions within a region that shows a 
high degree of sequence similarity. The human AR 
gene promoter also contains one SPI site and a 
homopurine stretch, but no other conserved ele-
ments are located within 570 bp upstream from 
the major transcription start site. 
Two major s{ar{ sites of transcription alld a putative 
splice acceptor site are localed withill the same 
regioll 
The results of the Sl~nuclease protection assay 
indicated the presence of two major start sites of 
transcription between 10to and 1023 bp upstream 
from the translation initiation codon. However, it 
is important to exclude that the results reflect the 
presence of an intron/exon boundary (splice 
acceptor site), or that the results are derived from 
non-specific hybridization. This is indicated by the 
following. First, the two major bands were not 
found when spleen derived RNA was used. Sec-
ond, RNA from COS cells expressing the promo-
ter-lrap constructs PSCAT and PASCAT, resulted 
in the same Sl~nuclease protection pattern as that 
obtained using total testis RNA. In PSCAT and 
PASCAT, the possible splice acceptor site is sep-
arated from any possible splice donor site in the 
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genome. It can be concluded therefore, that the 
two double bands observed in the S1-nuclease 
assay are derived from hybridization of the probe 
to AR mRNAs, and represent two start sites of 
transcription. 
The mil/imal promoter 0/ the rat AR gelle is located 
wilh;Il the 5' genomic region between positions 
+lOOal1d -300 
Promoter tfap constructs were used to test the 
functional capacity of the DNA sequences sur-
rounding the start sites of transcription to act as a 
promoter. By cloning 5' genomic sequences in 
either the sense or antisense orientation, ad-
ditional information about the direction of tran-
scription initiation should be obtained. The frag-
ment that spans the region from - 296 to + 120 
(constructs HSCAT and HASCAT) activates Iran-
scription in an orientation-independent manner. 
Tltis is not surprising from what is currently known 
about the characteristics of promoters lacking 
typical T AT A or CCAAT box sequences, also 
called housekeeping or OC-rich promoters. The 
transcription factors SPl and ETF can activate 
transcription on both DNA strands (Saffer and 
Singer, 1984; Kageyama et aL, 1989) and the 
upstream half of the calcium-dependent protease 
(CANP) gene promoter shows activity in either 
orientation (Hata et ai., 1989). 
However, a larger construct of the rat AR 5' 
genontic region appears to function in one direc-
tion only. This can be concluded from the ob-
servation that the transcriptional activity is stimu-
lated by PSCAT that contains the promoter frag-
ment in the sense orientation, but not by the 
PASCAT antisense construct. PSCAT and 
PASCAT contain a promoter fragment which in-
cludes additional regulatory up- and downstream 
sequences as compared to the H(A)SCAT con-
structs. 
The start sites of transcription that were func-
tional in the promoter/reporter gene constructs in 
the transfected COS cells were found to map at 
exactly the same positions as the start sites that 
were identified using testis RNA. Hence, the pro-
tected DNA fragments that were obtained with 
RNA transcribed from both the sense and anti-
sense constmcts can only be the result of tran-
scription initiation. Intron/exon splicing could not 
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have resulted in the same protected fragments 
from either orientation of the promoter fragment, 
unless the splice donor site would be present in 
the genomic fragment. However, this is very un-
likely not only because we have shown that the 
different constructs resulted in transcription start-
ing at the rat AR gene promoter, but also because 
there is no splice donor consensus sequence pres-
ent in the tested promoter reporter gene con-
structs. 
No consensus cyclic AMP responsive element 
(eRE) is located within or near the AR gene 
promoter region. This may point to a complex and 
indirect regulatory mechanism for the effect of 
FSH on AR mRNA expression in Sertoli cells; the 
transcription of several CRE-containing genes in 
Sertoli cells is stimulated by FSH and/or dbcAMP 
(Hall et at, 1988; Klaij et aI., 1990). By transfec-
tion of AR promoter/reporter gene constructs 
into Sertoli cells, the upstream regions and possi-
ble regulatory elements of the rat AR promoter 
will be functionally analyzed. 
In conclusion, the rat AR gene promoter lacks 
TATA and CCAAT box elements, but it contains 
one SPI site and several other possible binding 
sites for tranSCription factors. Part of the promo-
ter can function in an orientation-independent 
manner, but the full promoter shows a higher and 
unidirectional activity. 
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Note added in proof 
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7.1 Introduction 
It was Jost who defined, almost 50 years ago, that two testicular hormones, viz. 
testosterone and another factor (now known as AMH), are required for sex 
differentiation during male fetal development (Jost 1947). The fetal functions of AMH 
and testosterone in sex differentiation, have been elegantly demonstrated using animal 
model systems and naturally occurring mutations in men. The phenotype that is 
caused by inactivating androgen receptor mutations has been analysed in the 
testicular-feminized mouse (He et al. 1991) and also in humans, where the condition 
is known as the (complete) androgen insensitivity syndrome (see also Chapter 2). 
Lack of AMH action leads to the persistent mOlierian duct syndrome, which is a rare 
cause of male pseudohermaphroditism. Overexpression of the human AMH gene in 
transgenic mice also generated much information about possible functions of AMH in 
males and females (Behringer et al. 1990; Lyet et al. 1995). More recently, Behringer 
et al. (Behringer et al. 1994), generated AMH knock-out mice, and mice that are both 
AMH and androgen receptor deficient. In the AMH knock-out mice, the mOlierian 
ducts persist not only in females but also in males. If, in addition, the androgen 
receptor is deficient, both XX and XY mice show persistent mOlierian ducts, and 
absence of wolffian ducts. Furthermore, through these experiments it was shown that 
correct and full differentiation of the wolffian and mOlierian ducts along the male or 
female pathway, requires complete regression of the mOlierian or wolffian ducts, 
respectively (Behringer et al. 1994). Thus, full development of either the wolffian or 
the mOlierian ducts are mutually exclusive processes, regulated by AMH and 
testosterone. 
There are several other observations that support a functional interaction 
between AMH and testosterone during sex differentiation (Heller et al. 1992; Ichas et 
al. 1994). However, little is known about possible postnatal interactions between AMH 
and testosterone. It is generally accepted that synthesis of androgens by Leydig cells 
of the testis and by theca cells of the ovary is essential for postnatal gonadal 
development and adult gonadal functions. However, the postnatal role of AMH in the 
gonads is not clear. 
Through the cloning of the anti·mOlierian hormone receptor type II (AMHRII) 
(Chapter 3), and subsequent study of the regulation of expression of AMH and this 
receptor (Chapters 4 and 5), results have been obtained that indicate that AMH may 
function in the gonads of both sexes after birth. The cloning of the androgen receptor 
promoter (Chapter 6) has generated information about the DNA regions that may be 
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important in the regulation of androgen receptor expression. 
This chapter aims to integrate the results which have been described in the 
previous chapters, with data from the literature, to define the putative mechanism of 
AMH/AMH receptor interaction and possible functions of AMH in the gonads. 
Furthermore, the roles of the principal regulators of gametogenesis, LH, FSH, 
testosterone and estrogen, in the regulation of AMH, AMHRII, and androgen receptor 
expression in the gonads will be discussed. Finally, aspects of AMH expression and 
function that may be of clinical significance are described. 
7.2 AMH and AMH receptor interaction 
The existence of AMH was first suggested by Jost (Jost, 1947), and the cloning 
of the cDNA in 1986 (Cate et al. 1986) revealed that AMH is a member of the 
activinlTGFp family. Initially it was thought that, in contrast to the other family 
members, AMH existed as a homodimer of two 70 kDa subunits which were not 
cleaved. Subsequently, Pepin sky et al. (1988) showed that 5-20% of recombinant 
human AMH expressed in COS cells was cleaved at 109 amino acids from the 
carboxyl terminus, generating a dimeric 110 kDa N-terminal fragment, and a dimeric 
25 kDa C-terminal fragment, that remain non-covalently associated. Plasmin treatment 
of purified recombinant human AMH generates the same cleavage products. The N-
and C-terminal fragments have to remain associated to obtain full bioactivity (Wilson 
et al. 1993). This is in contrast to the functional characteristics of TGFp, of which the 
C-terminal fragment is the active hormone. If associated, the N- and C-terminal TGFp 
fragments form a latent complex (Gentry and Nash, 1990). The dimeric C-terminal 
AMH fragment is capable of inducing mOlierian duct regression, and exhibits about half 
so-called maximal activity (activity observed with the combined N- and C-terminal 
fragments) in the fetal aromatase assay (Wilson et al. 1993). It has been suggested 
that in vivo, AMH is not cleaved until it binds to the receptor complex in the membrane 
(Wilson et al. 1993). In the past, these aberrant characteristics of AMH may have 
contributed to the difficulties that were observed when attempts were made to iodinate 
AMH in order to identify the AMH receptor type(s). Iodination of AMH resulted in loss 
of bioactivity of the hormone, indicating that the molecules were no longer intact (Lee 
and Donahoe, 1993). Olher strategies, involving the production of anti-idiotypic 
antibodies, or biotinylation of AMH, were reported to be unsuccessful with respect to 
binding to known AMH-target cells (Lefevre et al. 1989). Generation of AMH receptor 
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antibodies was hampered by difficulties in obtaining purified AMH receptor positive cell 
preparations (lefevre et al. t989). However, AMH binding to mammalian cells has 
been reported in several cases. Maclaughlin et al. (1992b), reported binding of an 
AMH anti-idiotypic antibody to tumor cell lines (including A431) which previously had 
been claimed to be AMH-responsive (Chin et al. 1991) (see also Paragraph 7.4). 
Maclaughlin et al. (1992b) also showed displacement of iodinated AMH binding to a 
200 kDa receptor on A431 cells with unlabelled AMH and with the anti-idiotypic 
antibody. Using a different technique, Catlin et al. (1992) showed binding of AMH to 
the mOlierian ducts in cultured rat urogenital ridges, and to cultured fetal rat lungs. 
More recently, this group (Catlin et al. 1993) used fluorescein isothiocyanate labelling 
of AMH to show binding of AMH to A431 cells, and iodinated C-terminal AMH to 
identify a 88 kDa receptor on A431 cells with a Kd of 5.8 nM. All these reports lacked 
data showing specificity of binding of AMH with respect to other members of the TGFp 
family. Thus, the specificity of AMH binding to these cells remains disputable. 
The cloning of a candidate AMH receptor as reported in this thesis (Chapter 3), 
and, more recently, also by di Clemente et al. (1994b), has provided a new tool to 
study AMH-receptor interaction. Based on the amino acid sequences of the rat and 
rabbit AMH receptors, the cDNAs most likely encode type II receptors. Binding of 
AMH to the type II receptor, independent of the presence or absence of a type I 
receptor, would be expected to be possible, if the known binding characteristics of the 
TGFp and activin type II and type I receptors (see Chapter 2) are generally applicable. 
Fig. 7.1. (Next page) Hypothetical evolutionary relationshIp dendrograms of several members of the 
activinITGFP family of growth and differentiation factors, and their type I and type If receptors. 
The dendrograms were constructed according to Fitch and Margoliash (Fitch and Margoflash, 1967) 
using the PHYLIP software package. 
A) Hypothetical evolutionary relationship dendrogram of the C-terminal mature fragments of human 
AMH (Cale el al. 1986), TGF]lI,2,3 (Derynck el al. 1985; de Martin el al. 1987; Derynck el al. 1988), 
inhlbino{J. (Inh),·pA (ActA),.pB (AcIB) and ·pC (AcIC) (Mason el al. 1986; Mason el al. 1989; Hotten el 
al. 1995), and bone morphogenetic prolelns 2,3,4,5,6,7 (BMP2·7) (Wozney el al. 1988; Celesle el al. 
1990) and D. melanogas/er Decapenlaplegic (DPP) (Padgett el al. 1987). 
B) Hypothetical evolutionary relationship dendrogram of the rat and rabbit AMH type II receptors 
(raIAMHRII and rabAMHRII) (Baarends el al. 1994; di Clemenle el al. 1994b), human TGF]l Iype II 
receplor (TGFBRII) (Lin el al. 1992) and activin receplor·like kinases 1,2,3,4,5,6 (Alkl·6) (Iype I 
receplors) (len Dijke el al. 1993), mouse activin receplor Iype II (AcIRII) (Malhews and Vale, 1991) and 
liB (AcIRIIB) (Allisano el al. 1992), C. elegans DAFI (type I receplor) (Georgi el al. 1990), and DAF4 
(Iype II receplor, binds bone morphogenetic proleins) (Eslevez el al. 1993) and D. melanogasler SAX 
and TKV (Iype I receplors for decapenlaplegic) (Nellen el al. 1994). 
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We have generated CHO cell lines expressing large amounts of rat AMH type 
II receptor mRNA, and used iodinated AMH (recombinant, plasmin-cleaved) in a 
routine binding assay. No specific binding of AMH could be detected using up to 1 nM 
of labelled AMH (non-specific binding was determined using a 1 DO-fold excess of non-
labelled AMH). Since we had no means to determine the bioactivity of the 
radiolabelled ligand, no definite conclusions could be drawn. Oi Clemente et al. 
(1994b) performed a similar experiment, on COS cells transiently expressing the rabbit 
AMH type II receptor, using iodinated AMH that still contained 70% of its ability to 
repress aromatase activity of fetal rat ovaries. A low level of specific binding of 
labelled AMH was observed at concentrations ranging from 0.5-2.0 nM. Saturation of 
binding was not obtained at reasonable ligand concentration, making meaningful 
estimates of binding parameters problematic. However, these data were sUbstantiated 
by showing that expression of a truncated receptor form, which lacked the ligand 
binding domain, did not result in binding. Furthermore, incubation of cells transienlly 
expressing rabbit AMHRII with iodinated AMH, followed by autoradiography, revealed 
specific binding. No AMH binding was observed in control cells, or when TGF~ type 
II receptor or truncated AMH type II receptor were used for transfection. Thus, 
although no normal binding curve of AMH to its type II receptor has been generated 
to date, the data of di Clemente et al. (1994b), together with the structural 
characteristics and the expression pallems of the rat and rabbit AMH type II receptor, 
indicate that this receptors is competent for AMH binding. 
The aberrant structural characteristics of AMH described herein, may result in 
a receptor binding mechanism that differs from TGF~ and activin. Binding of these 
laller two factors to their type II receptors can unequivocally be demonstrated with Kds 
ranging from 100-800 pM (Allisano et aI., 1992 and 1993). Aberrant characteristics 
of AMH and AMHRII may be deduced also from the relatively distant positions of AMH 
and AMHRII in hypothetical evolutionary relationship dendrograms (Fig. 7.1). 
II remains to be shown that an AMH type I receptor also exists. It has been 
suggested (He et al. 1993; Wang et al. 1994) that one of the activin type I receptors, 
Alk-2, might also function as an AMH type I receptor. This assumption is based upon 
the observation that Alk-2 mRNA is expressed in the mesenchymal cells that surround 
the mOlierian ducts in the rat, during the critical period of induction of mOlierian duct 
regression (He et al. 1993). Since Alk-2 can interact with activin as well as bone 
morphogenetic protein type II receptors in vivo (ten Oijke et al. 1994), it seems likely 
that this type I receptor may associate with different type II receptors, depending on 
the cell type in which it is expressed. However, postnatal expression of Alk-2 mRNA 
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in the rat ovary (specific expression in oocytes) (He et al. 1993) does not correlate 
with AMH type II receptor expression (specific expression in granulosa cells; Chapter 
5). Also, activin and AMH have opposite effects upon FSH-induced aromatase activity 
in granulosa cells (Hutchinson et al. 1987; di Clemente et al. 1994a), which makes it 
unlikely that they share the same type I receptor in this cell type, since it is the type 
I receptor that most likely determines the intracellular signal specificity (Wrana et al. 
1994). These data indicate that a separate AMH type I receptor most likely exists, 
although it cannot be excluded that Alk-2 may function as an AMH type I receptor 
during mOlierian duct regression. Candidate AMH type I receptors may be identified 
in AMH target cells (SertolVgranulosa cells) through PCR-based strategies using 
conserved sequences of the known type I receptors. The development of a bioassay 
to monitor AMH receptor complex activation is important for the subsequent 
identification of AMH type I receptors. Such a bioassay may be obtained by 
expressing a construct of an AMH responsive promoter linked to a reporter gene, in 
a cell line that also expresses the AMH type II receptor. Cotransfection of cDNAs 
encoding candidate type I receptors, followed by addition of AMH to the cells, could 
then lead to identification of possible AMH type I receptors. The aromatase gene or 
LH receptor gene promoters may be useful as AMH responsive promoters, since AMH 
inhibits mRNA expression of these two genes in cultured granulosa cells (di Clemente 
et al. 1994a). 
The present discussion of the possible mechanism of AMH receptor activation 
is based on current knowledge of activin and TGFp receptors. However, in view of 
the specific characteristics of AMH and its type II receptor (see above) unexpected 
findings conceming AMH receptor activation are anticipated. 
7.3 AMH and androgens in the gonads 
Gonadotropins and steroid hormones are principal regulators of gonadal functions. 
Apart from these hormones, a vast number of locally synthesized peptide 
growth/differentiation factors provide specific micro-environments, and probably allow 
differential effects of gonadotropins and steroids on gametogenesis depending on the 
stage of development or cyclic changes. Such a regulatory network may show much 
redundancy, resulting in compensation of the absence of a single factor by the 
establishment of a different balance between the actions of the remaining regulators, 
that still allows the formation of mature eggs and sperm. AMH may be one of the 
137 
Chapter 7 
growth/differentiation factors that contributes to the regulation of postnatal gonadal 
functions. The study of the regulation of AMH and AMHRII mRNA expression during 
postnatal gonadal development (Chapters 4 and 5) has revealed possible sites of 
gonadal actions of AMH. This paragraph compares the expression pattems of AMH, 
AMHRII, and the androgen receptor, in testis and ovary. Analogies in expression 
patterns may provide additional clues, not only about the targets of AMH, but also 
about the possible nature of AMH actions, and about functional interactions with 
androgens. Furthermore, the regulation of AMH, AMHRII and the androgen receptor 
by gonadotropins and steroids is discussed. 
7.3.1 Comparison of AMH, AMHRII, and androgen receptor expression In ovary 
and testis 
During fetal development in the rat, AMH mRNA expression is high in testis but absent 
from the ovary (Hirobe et al. 1992), whereas AMHRII mRNA is low in testis but high 
in ovary (Baarends et al. 1994). Although the presence of another AMH-like ligand 
that interacts with AMHRII in fetal ovaries cannot be excluded, it seems unlikely that 
the high fetal AMHRII mRNA expression in ovary has any functional significance. This 
may indicate that a common factor, present in both testis and ovary, initially stimulates 
fetal AMHRII mRNA expression, and that the fetal testicular AMHRII mRNA level is 
downregulated by a male specific factor. 
During early postnatal development in the rat, AMH mRNA expression is 
oppositely regulated in ovary versus testis, resulting in relatively high levels of AMH 
mRNA towards puberty in ovary and a low level in testis (Hirobe et al. 1992; Hirobe 
et a!. 1994) (Chapter 5) (Fig. 7.2). Total ovarian AMHRII mRNA expression remains 
similar during postnatal development (Chapter 5), whereas total testicular AMHRII 
mRNA levels markedly increase during the first three weeks of postnatal testis 
development (Chapters 3 and 4) (Fig. 7.2). Detailed observation of AMHRII mRNA 
expression in ovary and testis by means of in situ hybridization revealed that an even 
distribution of AMHRII mRNA expression during the first weeks of postnatal 
development, in granulosa and Sertoli cells, precedes a more restricted expression 
pattern in specific ovarian follicles and during specific stages of the spermatogenic 
cycle (Chapter 5, and unpublished results). A similar biphasic pattern has been 
described for expression of androgen receptor protein in testis (Bremner et al. 1994). 
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In the adult rat, there is a striking coregulation of AMH mRNA, AMHRII mRNA, 
and androgen receptor protein in both granulosa cells and Sertoli cells during follicle 
development and the spermatogenic cycle, respectively; although, the androgen 
receptor, is also expressed in other gonadal cell types (Chapters 4 and 5; Bremner et 
al. 1994; Tetsuka et al. 1995) . 
...... _-..., I 
/ \I 
I ) 
I ( 
I II 
I '1 
I I 
I I 
Qi I I I I 
> I ~ 2 ~ ..: l' z 
a: I I 
E I I 
<D I I 
> I I 
.;:; I I 
AMH ~ 
!! I I 
<D I I 
a: I I 
I \ 
I I 
I I 
I I 
I \ 
I I ,..------. 
I \ / \ / I I 
I \ I 
I \ I 
I \ / 
I \ / 
I / \ / I A 
/ 
AMHRII~ 
\ 
", AMHO 
~---------------. 
E14 BIRTH 7 14 21 28 35 
Days of age 
Fig. 7.2 Relative levels of AMH and AMHRII mRNA expression during gonadal development in the rat. 
The mRNA levels are estimated per constant amount of total ovarian (Indicated by ~) or testfcular 
(Indicated by cf) RNA The figure gives an Impression of data described In Chapters 3, 4 and 5, and 
of dala described by Kuroda el al. (1990), Haqq el al. (1992), and Hirobe el al. (1992). 
139 
Chapter 7 
7.3.2 Hormonal regulation of AMH, AMHRII, and androgen receptor expression 
in ovary and testis 
In the testis, the expression of a number of genes in Sertoli cells is known to be 
regulated by FSH and testosterone. Only a few genes, such as o:-inhibin, c-fos, jun-6, 
tissue plasminogen activator, and TSC-22, are known to be directly regulated by FSH 
at the transcriptional level (Hall et al. 1988; Klaij et al. 1990; Hamil et al. 1994; Hamil 
and Hall, 1994). c-Myc mRNA expression is induced by testosterone in immature rat 
Sertoli cells in vitro, and this induction also occurs when protein synthesis is inhibited 
(Lim et al. 1994), indicating that c-myc is a candidate androgen responsive gene in 
immature Sertoli cells. No other primary androgen responsive genes in the testis have 
been described. In order to get more insight in the mechanism by which FSH and 
testosterone regulate spermatogenesis, we have tried to isolate candidate androgen-
and/or FSH-regulated cDNAs from Sertoli cells, by using different molecular 
techniques, such as subtractive hybridization and differential screening. One FSH-
regulated cDNA (LRPR1) (Slegtenhorst-Eegdeman et al. 1995) was identified. The 
AMHRII cDNA was isolated as a candidate androgen-regulated gene (Chapter 3). The 
promoter of the androgen receptor was isolated to study genomic regions that might 
be responsible for regulation of androgen receptor mRNA by testosterone and FSH 
(Chapter 6). 
Regulation of AMH and AMHRII expression in the testis 
FSH injection decreases testicular AMH mRNA and protein levels in neonatal 
rats (Kuroda et al. 1990), indicating that FSH may, at least in part, be responsible for 
the postnatal decrease in testicular AMH. In adult rats, downregulation of AMH protein 
at defined stages of the spermatogenic cycle by FSH is compatible with expression 
pattems of AMH mRNA (Chapter 4) and FSH receptor mRNA (Heckert and Griswold, 
1991). The negative correlation between AMH and testosterone levels during human 
postnatal development (Rey et al. 1993), may lead to the suggestion that AMH 
production at puberty in boys is negatively regulated by testosterone also. 
Furthermore, in patients suffering from the androgen insensitivity syndrome (see also 
Chapter 2), AMH levels are elevated during the first postnatal year and after puberty 
(Rey et al. 1994). In testis of rats treated with testosterone at day 19 of fetal 
development, AMH mRNA levels were not changed when estimated two days later, 
and AMH immunohistochemical data indicated that testosterone may regulate AMH 
cleavage, rather than AMH synthesis (Kuroda et al. 1991). 
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No effects of testosterone on AMH mRNA or protein in adult animals or humans have 
been described. 
CCTTFFFTFT 
AMHRII 
GAPD 
Fig. 7,3 Regulation of AMHRII mRNA expressIon by FSH and testosterone in cultured immature SertoH 
celfs. 
Parfiafly purified Sertoli cells were isolated according to Themmen st al. (1991) from 14-day-ofd rats 
and cultured (or three days in Eagle's minimal essential medium (MEM) + 1% (v/v) fetal calf serum. 
Al day four, medium was changed into MEM, 0.1% (w/v) bovine serum albumin, insulin (5jJg/ml) and 
retinol (0.3/lM) (conlrol medium), wilh or wilhoul I/lM testosterone and/or 500 ng/ml FSH (NtH SI6), 
and the cells were kept in culture for an additional 24 h. Subsequent RNA isolation and RNase 
protection assay were performed as described in Chapter 3. RNase proteeffon was performed usIng 
total RNA from Sertoli cells cultured in control medium only (e), plus FSH (F), plus testosterone (T), 
and plus FSH and testosterone (FT). AMHRII and GAPD indicate the positions of the respective 
protected fragments, A GAPD probe was used to verify whether equal amounts of mRNA were used 
in each lane, 
The expression of AMHRII mRNA in cultured Sertoli cells, isolated from 21-day-
old rats, initially seemed to be androgen responsive, but this could not be confirmed 
in later experiments (Chapter 3). Also in vivo, depletion of testosterone through the 
use of the Leydig cell toxicant ethane dimethane sulfonate (EDS), did not result in any 
major change in total testicular level of AMHRII mRNA as compared to control adult 
rats, at three or five days after EDS administration (unpublished results). AMHRII 
mRNA expression in cullured Sertoli cells isolated from immature or adult rats rapidly 
decreases during the first few hours after isolation of the cells. After culturing testis 
tubules from 14-day-old rats for several days, AMHRII mRNA is still detectable, and 
stimulation with FSH for 24 h results in an increase in the AMHRII mRNA level. 
Again, no effect of testosterone was observed (Fig. 7.3). These results indicate that 
AMHRII mRNA expression is stimulated by FSH in vitro. Whether FSH also regulates 
testicular AMHRII mRNA expression in vivo, is not clear. During the prepubertal 
phase in male rats, FSH levels increase {de Jong and Sharpe, 1977; Ketelslegers et 
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al. 1978), concomitant with the most pronounced increase in AMHRII mRNA 
expression in Sertoli cells (Chapters 3 and 4). We also observed a normal pattern of 
AMHRII mRNA expression during the first three weeks of postnatal testis development 
in sterile (prenatally irradiated) rats (Chapter 4), that have been reported to have a 
normal pattern of FSH secretion during this period (Means et al. 1976). 
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P;g. 7.4 Effects of experimentally induced neonatal hypothyroidism and hyperthyroidism on the 
developmental express/on pattern of AMHRIf mRNA in rat testis. 
Hypothyroidism WaS induced through administration of 6-propyl-2-fhlouracif (PTU) from birth until 26 
days of age, as described by van Haasler ef al. (1992). To Induce hyperthyroidism, newborn rats were 
treated with T3 from birth to 16 days of age, as described by van Haasferet al. (1993). Total testicular 
RNA was isolaled al 3, 5, 7, 9, 12, 16,20,26, and 30 days after birth 01 conlrol and PTU·lrealed rals, 
and at 5, 7, 9, 12, and 16 days after birth of control and T3-treafed rats. A) RNase protection assay 
results from control and PTU-treated rat testes, B) RNAse protection results from control and T3-treated 
rat testes. The numbers above each lane correspond to the age In days of the rats. AMHRII and 
GAPD indicate the posWons of the respective protected fragments. A GAPD probe was used to verify 
whether equal amounts of mRNA were used in each lane. 
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Hypothyroidism, induced during the prepubertal period by administration of 6-
propyl-2-thiouracil (PTU), retards morphological differentiation of Sertoli cells, and 
prolongs the period of proliferation of these cells (van Haaster et al. 1992). The 
postnatal induction of total testicular AMHRII mRNA expression was delayed in PTU-
treated rats as compared to controls (Fig. 7.4a). Furthermore, in the opposite 
situation, when high neonatal triiodothyronine (T,) levels are present, Sertoli cell 
differentiation is advanced (van Haaster et al. 1993), and AMHRII mRNA expression 
reached its maximum at day 16, as compared to day 20 in control rats (Fig. 7.4b). 
The altered temporal AMHRII mRNA expression patterns after PTU and T, treatment 
are most likely not caused by actions of FSH, since a moderate reduction of the FSH 
level was observed, both after PTU and after T, treatment (van Haaster et al. 1992; 
van Haaster et al. 1993). However, FSH may be required to induce the expression 
of sufficient amounts of AMHRII mRNA. It will be of interest to study AMHRII mRNA 
expression in vivo, after FSH treatment of immature male rats, which are known to 
respond to an extra dose of FSH (Blok et al. 1992b; Slegtenhorst-Eegdeman et al. 
1995). In the adult rat testis, the situation is less clear. The stage specific expression 
of AMHRII mRNA during the spermatogenic cycle is at a maximum when FSH 
receptor expression is minimal, indicating an inhibitory rather than a stimulatory effect 
of FSH on AMHRII mRNA expression in adult rat Sertoli cells. 
Regulation of androgen receptor expression in the testis 
Although testosterone can down regulate transcription of the gene encoding its 
own receptor in a number of tissues (Shan et al. 1990; Quarmby et al. 1990; Blok et 
al. 1992a), it is not clear whether this also occurs in testis (see also Chapter 1). FSH 
stimulates the transcription of the androgen receptor gene in Sertoli cells in culture 
(Blok et al. 1989; Blok et al. 1992b), and high doses of forskolin or dibutyryl cAMP can 
stimUlate androgen receptor gene transcription in other cell lines (Mizokami et al. 
1994; Lindzey et al. 1993). The cloning of the rat (Chapter 6; Song et al. 1993) 
human (Tilley et al. 1990; Faber et al. 1991b) and mouse (Faber et al. 1991a) 
promoters of the respective androgen receptor genes has provided tools to study the 
mechanism of regulation of androgen receptor gene transcription in different animal 
species. The androgen receptor promoter contains two major transcriptional start sites 
in rat, mouse and human, that each require specific nearby sequence elements. 
Downregulation of androgen receptor transcription by testosterone in a number of 
human cell lines concerned both transcriptional start sites in a similar manner (Wolf 
et al. 1993). For each species, sequence elements that are essential for basal 
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transcription have been identified (Tilley et al. 1990; Faber et al. 1991a; Faber et al. 
1991b; Blok et al. 1992c; Song et al. 1993; Mizokami et al. 1994) (summarized in Fig. 
7.5). Furthermore, different sequence elements that are responsible for the stimulation 
of transcription by cAMP/FSH have been localized in the mouse, rat and human 
androgen receptor promoters (Blok et al. 1992c; Lindzey et al. 1993; Mizokami et al. 
1994). No consensus CRE sequences are present in any of the studied promoters, 
but the human and mouse promoters contain sequences that are very similar to the 
consensus CRE, and those sequences are thought to mediate at least part of the 
stimulatory effects of cAMP (Mizokami et al. 1994; Lindzey et al. 1993). However, 
these elements are not conserved between the mouse, rat, and/or human androgen 
receptor promoters (Fig. 7.5). 
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CRE lort+=J 
·2327 
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Hg, 7.5. Comparison between the androgen receptor gene promoters of human, mouse and rat. 
The promoters of the human (Tilley et al. 1990; Faber et al. 1991b), mouse (Faber et al. 1991a) and 
rat (Chapter 6; Song ef af. 1993) androgen receptor genes are shown. The arrows indicate that aft 
three promoters contain fWD major transcriptional start sites. Each of these promoters contains several 
GGGGA repeats (IndIcated by the black boxes; the function of these repeats is unknown). The SPI 
binding-site, indIcated by open bars, is thought to be an important element of the basal promoter. 
Other elements that have been shown to stimulate (box marked +) or inhibit (box marked -) the basal 
level of transcription are indicated. Some of the identified cAMPIFSH response elements resemble the 
consensus CRE (TGACGTCA) (indicated by CRE), and other DNA regions that are also involved in 
mediating (part of) the response to FSH and!or cAMP are indicated by "eRE". 
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Little is known about the regions of the androgen receptor promoter that are 
responsible for the downregulatory action of testosterone in certain tissues. 
Transfection of a rat androgen receptor promoter-reporter construct, comprising 
approximately 8 kb of promoter sequence and almost the complete 5' UTR, into the 
human prostate cancer cell line LNCaP, followed by addition of testosterone, did not 
result in any changes in reporter gene expression (Blok et al. 1992c). However, 
cotransfection experiments of a mouse androgen receptor promoter-reporter construct 
and a mouse androgen receptor expression vector in a quait cell line, showed that 
dihydrotestosterone could reduce basal and forskolin-induced expression of the mouse 
androgen receptor (Lindzey et al. 1993). Deletion of a putative androgen response 
element had no effect on this suppression. Thus, it is unclear which regions in the 
androgen receptor promoter of the different species confer androgen-mediated 
transcriptional downregulation. 
The above described functional analysis of the androgen receptor promoter 
indicates that the postnatal increase in testicular AR mRNA level may be an FSH 
regulated event. In contrast, the expression patterns of the FSH receptor and the 
androgen receptor in adult Sertoli cells are negatively correlated during the 
spermatogenic cycle (Kangasniemi et al. 1990; Heckert and Griswold, 1991), 
suggesting that stimulatory effects of FSH on androgen receptor expression in adult 
rat Sertoli cells might be unlikely. With respect to the in vivo regulation of testicular 
androgen receptor mRNA expression by androgens, the situation is also complicated. 
In adult rats, testosterone withdrawal through the use of EDS does not affect testicular 
androgen receptor mRNA levels and total androgen binding (Blok et al. 1992a), but 
androgen receptor immunostaining is reduced (Bremner et al. 1994). 
Regulation of AMH, AMHRII, and androgen receptor expression in the ovary 
Since manipulation of the levels of gonadotropins and steroids in the ovary often 
results in rapid changes in follicle development, it is difficult to decide whether changes 
in ovarian levels of gene products are due to direct hormonal effects, or to a change 
in the numbers of follicle types that are present. Therefore, in situ hybridization and 
immunohistochemistry are of great importance to study effects of hormones on 
follicular development and gene expression. The expression patterns of AMH, 
AMHRII, and androgen receptor in granulosa cells during follicular development 
(Chapter 5; Tetsuka et al. 1995) are consistent with a role of these gene products 
during the follicular phase that precedes the FSH-induced follicular maturation. For 
AMH and AMHRII mRNAs, we have shown that their expression can be 
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downregulated by FSH and estradiol benzoate in large preantral follicles (Chapter 5). 
Fig. 7.6 illustrates possible interactions between AMH and FSH, that could be involved 
in regulation of aromatase and LH receptor expression during different phases of 
follicular development. This model is based on the observation that the FSH-
sensitivity of granulosa cells increases as a follicle starts to develop a large antrum 
(reviewed by Richards, 1994). Little is known about the significance of androgen 
receptor expression in the ovary, and no effects of androgens on the ovarian 
expression of androgen receptor, or any other gene, have been described. 
Future studies of the AMHRII gene promoter (Visser et aI., personal communication) 
may provide additional insight into the mechanism of regulation of AMHRII gene 
transcription in ovary and testis. Comparison between the AMH, AMHRII, and 
androgen receptor gene promoters may reveal possible common regulatory sequences 
that are responsible for the unique coregulation of these three genes (see 7.3.1) in 
adult Sertoli and granulosa cells. 
7.3.3 Possible functional significance of AMH expression in the gonads, and 
Interactions between AMH and androgens 
Granulosa and Sertoli cells are thought to be derived from a common precursor cell 
(Chapter 1). In this respect, it is not surprising that there are a number of analogies 
in the expression of AMH, AMHRII, and androgen receptor in these two cell types. 
Whether the analogies also extend to the functions of the genes in these cells, 
remains a matter of speculation. The fact that the three genes are coregulated in 
adult Sertoli and granulosa cells, indicates that the functions of AMH and testosterone 
may be interdependent and may even overlap. The developmental change in the 
AMHRII mRNA expression pattern from an even distribution to a more specific pattem 
in both ovary and testis, may indicate separate functions of AMH during the 
prepubertal and adult phases. The same suggestion can be made with respect to 
distinct functions of the androgen receptor, since this gene displays a similar biphasic 
developmental expression pattern in rat testis (Bremner et al. 1994). 
AMH may be involved in regulation of Leydig cell proliferation, through an effect 
on Sertoli cells, possibly involving the extracellular matrix (Chapter 4). There are two 
distinct growth phases of Leydig cells, leading to two different Leydig cell populations, 
termed fetal and adult Leydig cells (reviewed by Huhtaniemi, 1994). Fetal Leydig cell 
prOliferation is maximal between E17.5-E19.5 (Tapanainen et al. 1984) in the rat. 
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From postnatal day 15 onwards, the adult Leydig cell population is fonmed and Leydig 
cell numbers increase steadily until 60 days after birth (Tapanainen et al. 1984). An 
inhibitory effect of AMH on the adult number of Leydig cells, is exemplified by the 
Leydig cell hyperplasia in AMH knock-out mice (Behringer et al. 1994), and by the 
severely decreased androgen production by Leydig cells of adult transgenic mice 
expressing a relatively high level of human AMH (Lyet et al. 1995). Whether these 
effects reflect a function of AMH during the immature or the adult phase, remains to 
be established. 
In the adult testis, maximal levels of AMH mRNA, AMHRII mRNA, and 
androgen receptor protein during the spermatogenic cycle are found at the stages that 
have been defined as being androgen dependent (reviewed by Sharpe, 1994). 
Possibly, AMH contributes to one of the Sertoli cell functions that depend on 
androgen. 
In the adult ovary, there might be a role for AMH in the inhibition of follicular 
maturation or in follicle selection, through autocrine mechanisms. This assumption is 
based on the expression patterns of AMH and AMHRII mRNAs, and on the in vitro 
effects of AMH on granulosa cells (Chapter 5) (Fig. 7.6). It is not known whether AMH 
has effects on the number of theca cells during follicle development in the ovary, 
analogous to the possible effects of AMH on Leydig cell numbers in the testis. The 
expression pattern of the androgen receptor in granulosa cells during follicular 
development indicates that any effect of androgens on granulosa cell functions also 
would take place prior to final follicle maturation. 
In order to gain more insight into the possible effects of AMH on Leydig cell 
and/or theca cell development, the ontogeny of these cell numbers in AMH 
overexpressing and AMH knock-out mice should be studied, to detenmine during which 
phase of postnatal testis and/or ovary development AMH may influence Leydig and/or 
theca cell numbers. Indications about possible effects of AMH on adult Leydig cell 
numbers may be obtained through study of long-term AMHRII mRNA expression using 
in situ hybridization, or observation of the effect of manipulation of AMH action, during 
Leydig cell regeneration in EDS-treated adult rats. 
Manipulation of the levels of AMH and/or AMHRII at precise time points during 
postnatal gonad development may provide additional infonmation about effects of AMH 
on Leydig or theca cells. Furthermore, other genes that are involved in gonadal 
function, such as androgen receptor, FSH receptor, LH receptor, activin, inhibin, and 
aromatase, may be affected by AMH, and must be studied as well. 
147 
Chapter 7 
SA 
FSH- - ,-,I FSHR E 
1'-----'1 - -- - Q---I'---A_M_H-----'~ 1 AMHR I_,~---_-_-_-_-------'O» :_A_R9t'yS_E_: 
LH ~ - :::::,...1 LH R \ A 
• 1 _____ J 
LA -----~ -----~ 
1 AMH I--~ .... I AMHR I 1 _____ ~ • 1 _____ J 
-
-
FSH~I FSHR 
LH ----;,.1 LHR A 
Fig. 7.6 Schematic illustration of hypothetical regulatory interactions between AMH, FSH, and 
estrogens in granulosa cells during follicle development, 
In thIs hypothetical mode', the following processes may occur: 
SA: In large preanlral and small anlral (SA) lollicles, bOlh AMH and AMHRII mRNAs are expressed al 
a high level. The AMHRII partiCipates in repressing aromatase activity and LH receptor expression 
during these stages of folHele development. 
LA: The granulosa celfs of large antral (LA) fOllicles have become more sensitive to FSH, thus allowing 
downregufation of AMH and AMHRIf mRNA expression by FSH. Aromatase activity and LH receptor 
expression are no longer downregulafed, and FSH stimulates both aromatase and LH receptor 
expression. Furthermore, androgen synthesis by the theca celfs has Increased. Together this results 
in an increased estrogen output, whIch leads to a further downregulafion of AMH and AMHRII mRNA 
expression via an autocrine effect of estrogens on the granulosa cells. 
Granulosa cefl·derived proteins are boxed, stippled lines indicate that the amount of protein is relatively 
low. ., +, negative, positive regulation of the factor indicated by arrow,' arrows also indicate 
hormonelreceptor interaction; stipled arrow, hormone sigr,·~, is not (or not efficiently) transduced; open 
arrow, enzymatic conversion of androgen (A) into estrogen (E); AMH, anti·mOllerian hormone; AMHR, 
AMH Iype Illype /I receplor complex; FSH, folllcle-slimulating hormone; FSHR, FSH receplor; LH, 
luteInizing 'Jormone; LHR, LH receptor. 
148 
Discussion 
The possible role of the extracellular matrix in AMH action deserves further 
study. It is known that the basement membrane (composed of extracellular matrix 
components) that surrounds the spermatogenic epithelium plays an important role in 
maintenance of the differentiated function of Sertoli cells. Furthermore, a number of 
growth factors are sequestered in basement membranes, and their action may be 
dependent on interaction with extracellular matrix components (reviewed by Dym, 
1994). Our observation that cultured Sertoli cells rapidly lose AMHRII mRNA, 
indicates that the expression of this gene may be dependent on the maintenance of 
the columnar shape and polarity of the Sertoli cell, and/or the presence of an 
extracellular matrix. The production rate of several Sertoli cell gene products is known 
to be increased when the cells are cultured in the presence of extracellular matrix 
(reviewed by Dym, 1994). Immature or adult Sertoli cells cultured on top of 
reconstituted basement membrane may provide an adequate model system to 
investigate the interaction between the extracellular matrix and AMH action. 
The extracellular matrix may also affect local concentrations of AMH. The 
concentration of AMH in small bovine follicles is 0.29 nM (Vigier et at. 1984), whereas 
the ED,o of AMH effects on aromatase activity and LH receptor expression in vitro is 
7 nM (Wilson et at. 1993; di Clemente et at. 1994a). In this respect, it will be of 
interest to study whether local accumulation of AMH occurs, and whether the presence 
of extracellular matrix can influence AMH dose-response curves for cultured cells. 
7.4 Clinical applications of AMH and AMHRII 
Mutations in the gene encoding AMH are an important cause of the persistent 
mOlierian duct syndrome (PMDS) (Chapter 2). It will be of interest to study whether 
any of the AMH positive cases of PMDS are due to mutations in the human AMHRII 
gene. 
The development of sensitive immunocytochemical techniques has allowed 
detailed measurements of normal levels of AMH between birth and adulthood in 
humans (Baker et at. 1990; Josso et at. 1990; Hudson et at. 1990; Baker and Hutson, 
1993). Between 4 and 12 months of age, relatively high serum AMH levels are 
detected in boys. The levels gradually decrease during childhood and become very 
low around puberty in males. In girls, AMH becomes first detectable around puberty, 
but the serum AMH concentrations remain low during the reproductive years in 
females, and are comparable to those observed in the adult male (Hudson et at. 
1990). Measurement of serum AMH levels can be helpful in the diagnosis and 
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management of intersex and gonadal abnormalities (Gustafson et al. 1993). For 
example, serum AMH concentrations can be used to confirm the presence of testicular 
tissue in patients with anorchia and/or intersex anomalies (Josso et al. 1991; 
Gustafson et al. 1993). Also, elevation of serum AMH appears to be a marker of 
androgen resistance in sexually ambiguous genetic male infants (Rey et al. 1994). In 
cases of certain gonadal tumors, such as AMH secreting granulosa cell tumors, it has 
been shown that serum AMH concentrations decrease after surgical removal of tumor 
tissue, and if tumor recurrence occurs AMH levels rise correspondingly (Gustafson et 
al. 1992). Thus, AMH measurements may serve as a predictive marker of persistent 
or recurrent disease. AMHRII mRNA is expressed at a high level in the mesenchyme 
surrounding the mOlierian duct during fetal development and in fetal and adult ovaries 
and testes (Chapters 3-5). Study of the expression of AMHRII mRNA or protein in 
gonadal tumors, or in tumors from mOlierian duct derived tissues, may provide 
information about the possibilities to use AMHRII expression to identify the cellular 
origin of a tumor, and may help to select tumors that might be responsive to growth 
inhibitory actions of AMH. 
AMH has been reported to act as an antitumorigenic agent. Partially purified 
bovine AMH inhibited the growth of certain cancer cells in vivo and in vitro (Donahoe 
et al. 1981; Fuller Jr et al. 1982; Fuller Jr et al. 1985). However, when purified 
recombinant AMH became available, these results could not be reproduced, and only 
minimal antiproliferative effects were observed (Wallen et al. 1989). Subsequently, it 
was reported (Chin et al. 1991; Ragin et al. 1992) that modification of the purification 
protocol of the recombinant AMH resulted in the elimination of factors produced by the 
AMH expressing CHO cells that stimUlate tumor growth, and that recombinant AMH 
purified in this manner inhibited growth of a number of tumor cell lines of mOlierian 
duct/coelomic epithelium origin (Chin et al. 1991) and ocular melanoma cell lines 
(Parry et al. 1992). However, partially purified recombinant AMH is generally a more 
potent inhibitor (Chin et al. 1991), and the antiproliferative activity of AMH remains 
preparation dependent. Maclaughlin et al. (1992a) suggest that this may be due to 
the fact that the tumor cell lines lack the ability to cleave AMH to a biologically active 
conformation (see Paragraph 7.2). These authors report that the purified 25 kDa C-
terminal AMH dimer induces reproducible dose-dependent inhibilion of the growth of 
A431 cells (derived from a squamous cell carcinoma of the vulva) (Maclaughlin et al. 
1992a), but extremely high concentrations (1 ~lg/ml-40IlM) of the C-terminal AMH 
were used in these experiments. Thus, consistent inhibition of tumor growth by 
purified recombinant AMH at concentrations comparable to those needed for mOlierian 
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duct regression has not been shown. Recently, di Clemente et al. (1994b) have 
reported that A431 cells do not express the human homologue of the rabbit and rat 
AMHRII. It will be of interest to study whether any of the other tumor cell lines that 
have been reported to be AMH-responsive, express AMHRII. If such cell lines exist, 
it will be possible to study whether the antiproliferative effects of the AMH-preparations 
are mediated via the AMHRII, or whether cross-reaction with another receptor is 
involved. 
The possible implications of the postnatal AMH and AMHRII mRNA expression data, 
as discussed in this chapter, support the concept that AMH functions not only during 
fetal sexual differentiation, but also during postnatal gonad development. This should 
stimulate research that aims to define the exact nature of these functions, and to 
identify regulatory interactions between AMH and FSH, LH, testosterone, and/or 
estrogens. 
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The fetal testes produce two hormones that are essential for correct male sex 
differentiation. The first hormone, anti-mOlierian hormone (AMH), is a dimeric 
glycoprotein, which induces the regression of the mOlierian ducts (the anlagen of the 
fallopian tubes, the uterus and upper part of the vagina). The other hormone, the 
steroid hormone testosterone, stimulates development of the wolffian ducts into 
epididymides, vasa deferens and seminal vesicles. The situation is reversed in 
females: ovaries develop instead of testes, and the absence of AMH and testosterone 
leads to mOlierian duct development and wolffian duct regression. The principal 
regulators of postnatal gonadal development are follicle-stimulating hormone (FSH) 
and luteinizing hormone (LH). LH stimulates the gonadal synthesis of androgen 
(testosterone) which is converted to estrogen in the ovary. The gonadal actions of 
gonadotropins (FSH, LH) and steroid hormones (androgen, estrogen) are modulated 
by a vast number of locally acting factors. Members of the activinlTGF(l family of 
growth and differentiation factors, including AMH, are probably some of the most 
important local factors. This thesis focuses on structural and regulatory aspects of the 
receptors for AMH and testosterone. 
In the General Introduction (Chapter 1) the regulation of sex determination, sex 
differentiation, and pre- and postnatal gonadal development are described, with 
emphasis on the roles of testosterone and AMH in these processes. Chapter 2 gives 
an overview of the receptor mechanisms that are used by gonadotropins, steroid 
hormones, and members of the activinlTGFp family of growth and differentiation 
factors. Furthermore, some naturally occurring, or experimentally induced mutations 
in the genes encoding these hormones or their receptors are described, to illustrate 
their importance in sex differentiation and gonadal development. 
The cloning of a candidate rat AMH type II receptor (AMHRII, initially named 
C14) is described in Chapter 3. This receptor is a member of the family of 
transmembrane serine/threonine kinase receptors, and is specifically expressed from 
embryonic day 14 in the rat in the gonads and in the mesenchymal cells surrounding 
the mOlierian duct. Thereafter, the expression gradually disappears from the male 
urogenital ridge, and persists in the female. After birth, expression of AMHRII is 
mainly confined to ovary and testis. The structure of the receptor, and its specific 
expression in AMH target cells, strongly suggest that AMH is the ligand. 
In Chapters 4 and 5, the postnatal expression patterns of AMH and AMHRII 
mRNA in the gonads are studied in detail, using RNase protection assays and in situ 
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hybridization. In the male, AMH and AMHRII mRNA are specifically expressed in the 
Sertoli cells of the testis. The total testicular AMHRII mRNA expression level 
increases during the first three weeks of postnatal development, whereas during the 
first week of this period, there is a sharp decline in the amount of AMH mRNA. This 
leads to an AMHRII mRNA level in the adult testis that is much higher than that of 
AMH mRNA. However, the expression pattern of both genes in Sertoli cells during the 
spermatogenic cycle shows a maximum at Stage VII. Thus, autocrine actions of AMH 
on Sertoli cells may be of particular importance during Stage VII. Depletion of specific 
groups of germ cell types, ranging from intermediate spermatogonia to mature sperm, 
does not affect the total testicular level of AMHRII mRNA expression. However, 
AMHRII mRNA levels are decreased in testes from adult prenatally irradiated adult 
rats, and also in experimentally cryptorchid rat testes. This indicates that a 
combination of spermatogenic cycle events, possibly involving changes of Sertoli cell 
structure and/or Sertoli cell· basal membrane interactions, regulate autocrine AMH 
action on adult rat Sertoli cells. 
In the ovary (Chapter 5), AMH and AMHRII mRNA expression is found to be 
mainly restricted to the granulosa cells of preantral and small antral healthy follicles, 
except during the first two weeks of postnatal ovary development, when AMHRII 
mRNA is expressed in an evenly distributed manner, and AMH mRNA expression is 
lower than in adult rat ovary. Estrogen and FSH can downregulate AMH and AMHRII 
mRNA expression in granulosa cells of gonadotropin·releasing hormone antagonist-
treated immature rat ovaries. The results suggest that, similar to the above described 
autocrine action of AMH on Sertoli cells of the testis, AMH acts in an autocrine manner 
on granulosa cells of the ovary. The pattern of AMH and AMHRIt mRNA expression 
during follicular development may be regulated in part by the combined action of FSH 
and estrogen. As follicles reach the small antral stage, the sensitivity of granulosa 
cells to FSH and estrogen production increase, which subsequently may result in 
downregulation of AMH and AMHRII mRNA expression. The function of AMH in 
preantral and small antral follicles may involve inhibition of follicle maturation, and/or 
AMH may playa role in follicle selection. 
Chapter 6 describes the isolation of the rat androgen receptor promoter. This 
promoter contains two major transcriptional start sites, separated by 11 bp, which are 
preceded by an SPI site located approximately 60 bp upstream. Androgen can 
downregulate androgen receptor gene transcription in several tissues, and FSH can 
stimulate androgen receptor gene transcription in immature rat Sertoli cells. However, 
no consensus androgen/glucocorticoid response elements or cyclic AMP-response 
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elements are present. The possible localization and functional significance of 
promoter elements that may confer androgen or cAMP/FSH regulation on the 
androgen receptor gene is discussed in Chapter 7. 
Chapter 7 also describes the possible mechanism of action of AMH, based on 
the results described in this thesis, and the current knowledge about the mechanism 
of action of other members of the activinlTGF~ family of growth and differentiation 
factors. Furthermore, the expression pattems of AMH, AMHRII and the androgen 
receptor in the gonads are compared and discussed in the light of regulatory 
interactions between AMH, gonadotropins, androgen and estrogen. Suggestions about 
the possible postnatal functions of AMH are given. Finally, the possible clinical 
significance of AMHRII and AMH is discussed. 
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Samenvatting 
Tijdens de ontwikkeling van een zoogdier-embryo worden structuren gevormd waaruit 
in een latere fase de geslachtsorganen ontstaan. Esn van deze structuren is de 
ongedifferentieerde gonade, het orgaan waaruit een eierstok (ovarium) of een zaadbal 
(testis) wordt gevormd. De geslachtsbepaling vindt in deze ongedifferentieerde 
gonaden plaats: wanneer de cellen een X en een Y chromosoom bevatten, zal zich 
een testis ontwikkelen. Echter, wanneer het Y chromosoom afwezig is, wordt uit de 
ongedifferentieerde gonade een ovarium gevormd. Esn gen op het Y chromosoom 
is verantwoordelijk voor het in gang zetten van testisdifferentiatie. Vervolgens 
produceren de foetale testes in mannelijke embryo's twee hormonen waarvan de 
werking essentieel is voor een juist verloop van de mannelijke geslachtsdifferentiatie. 
Het eerste hormoon, het anti-mOlierse gang hormoon (AMH), is een eiwithormoon dat 
zorgt voor het ten gronde gaan van de mOlierse gangen. In het vrouwelijke embryo 
wordt geen AMH gevormd, en daar ontwikkelen de mOlierse gang en zich tot de 
eileiders, de baarmoeder, en het bovenste deel van de vagina. Het tweede hormoon 
uit de testis, testosteron (een steroidhormoon), bewerkstelligt de vorming van de 
bijballen, de zaadleiders en de zaadblazen, uit structuren die de wolffse gang en 
genoemd worden. De wolffse gangen degenereren in de vrouwelijke embryo's, omdat 
daar vrijwel geen testosteron aanwezig is. 
De verdere ontwikkeling van ovarium en testis na de geboorte is ook afhankelijk 
van hormonen. In de hypofyse, een aanhangsel van de hersenen, worden de 
gonadotropin en follikel-stimulerend hormoon (FSH) en lute'inizerend hormoon (LH) 
gevormd. Via de bloedbaan bereiken deze hormonen de testes of ova ria (de 
gonaden). FSH en LH oefenen hun werking uit op specifieke cellen in de gonaden. 
FSH stimuleert de Sertoli cellen in de testis en de granulosa cellen in het ovarium. 
Sertoli cellen ondersteunen en reguleren de vorming van zaadcellen, terwijl granulosa 
cellen een groot deel van de follikel vormen waarin de eicel zich bevindl. LH is 
belangrijk voor de ontwikkeling van de steroidhormoon producerende cellen; de Leydig 
cellen in de testis en de theca cellen in het ovarium. LH stimuleert deze celtypen tot 
het maken van androgenen, waaronder testosteron. In het ovarium worden 
androgenen omgezet in oestrogenen. De werking van LH en FSH wordt waarschijnlijk 
be'invloed door een aantal lokaal werkende stoffen, zoals AMH en soortgelijke 
groeifactoren (leden van de activinefTGF~ familie van groei- en differentiatiefactoren). 
Het in dit proefschrift beschreven onderzoek omvat studies naar de regulatie 
van de werking van AMH en testosteron in de gonaden na de geboorte. Hierbij is 
vooral onderzoek gedaan aan de structuur en regulatie van de receptoren voor deze 
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hormonen. Receptoren zijn eiwitmoleculen die zich op of in een lichaamscel bevinden 
en het hormonale signaal in een cellulaire respons vertalen. 
De Aigemene Introductie (Hoofdstuk 1) omvat een beschrijving van de regulatie van 
geslachtsbepaling, geslachtsdifferentiatie, en de ontwikkeling van de gonaden, zowel 
voor als na de geboorte. Hierbij is extra aandacht geschonken aan de rol van AMH 
en testosteron bij deze processen. In Hoofdstuk 2 worden de verschillende 
mechanismen beschreven waarvan de hierboven beschreven hormonen gebruik 
maken om signaal·overdracht in cellen te bewerkstelligen. Het belang van elk van de 
hormonen en/of hun receptoren wordt ge'illustreerd door het feit dat verandering 
(mutatie) in een van de genen die coderen voor deze hormonen of hun receptoren kan 
leiden tot ernstige verstoringen van de gonadeontwikkeling en/of 
geslachtsdifferentiatie. 
Hoofdstuk 3 beschrijft de clonering van een stukje DNA (cDNA) dat codeert 
voor een kandidaat AMH type II receptor (AMHRII) in de rat. De structuur van deze 
receptor en de specifieke aanwezigheid van het boodschapper RNA (mRNA) dat 
codeert voor het AMHRII eiwit in de cellen rondom de mOlierse gang en in de foetale 
gonaden, geven sterke aanwijzingen dat AMH inderdaad de belangrijkste activator van 
deze receptor is. 
De aanwezigheid (expressie) van AMH en AMHRII mRNA in ovaria en testes 
van de rat na de geboorte is nader onderzocht in experimenten beschreven in de 
Hoofdstukken 4 en 5. Hierbij werd gebruik gemaakt van technieken zoals RNase 
protectie en in situ hybridizatie. In de testis komen het AMH en AMHRII mRNA 
specifiek tot expressie in Sertoli cellen. Dit wijst op een mogelijk autocriene werking 
van AMH. Kort na de geboorte neemt de hoeveelheid AMH mRNA in de testis af, 
terwijl de AMHRII mRNA expressie toeneemt. Dit leidt tot een hoog AMHRII mRNA 
niveau en een laag AMH mRNA niveau in testes van een volwassen rat. De 
expressie van beide genen is echter niet constant, maar hangt af van de aanwezigheid 
van bepaalde met de Sertoli cel geassocieerde spermatogene cellen, tijdens de 
spermatogenese. Veranderingen in de associatie tussen Sertoli cellen en 
spermatogene cellen zijn cyclisch, en er zijn 14 (I-XIV) verschillende stadia 
gedefinieerd in deze zogenoemde spermatogenetische cyclus. AMH en AMHRII 
mRNAs zijn beiden maximaal tijdens Stadium VII. Alhoewel totale afwezigheid van 
spermatogene cellen leidt tot een verlaging van de AMH en AMHRII mRNA expressie 
in de volwassen testis, bleek het niet mogelijk om een specifieke groep spermatogene 
celtypen te definieren die betrokken is bij de (cyclische) regulatie van AMH en AMHRII 
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mRNA expressie. Mogelijk zijn vooral de structuur van Sertoli cellen en de interactie 
met de bas ale membraan, regulerende factoren voor AMH en AMHRII mRNA 
expressie in de Sertoli cellen. 
In het ovarium van de rat komen AMH en AMHRII mRNAs voornamelijk tot 
expressie in de granulosa cellen in bepaalde stadia van follikelontwikkeling, in 
preantrale en kleine antrale follikels (Hoofdstuk 5). Tijdens de eerste twee weken na 
de geboorte is het expressiepatroon iets afwijkend: AMHRII mRNA is over het gehele 
ovarium aanwezig, terwijl de AMH mRNA expressie van zeer laag stijgt to een hoog 
niveau in het ovarium van een volwassen rat. Overeenkomstig met de werking in de 
testis, oefent AMH mogelijk ook in het ovarium een autocriene functie uit, in dit geval 
op de granulosa cellen. Twee hormonen, FSH en oestrogenen, bleken de expressie 
van AMH en AMHRII mRNAs te kunnen verlagen in ovaria van immature ratten die 
behandeld waren met een antagonist van het luteiniserend hormoon-releasing 
hormoon. Deze antagonist verlaagt de endogene FSH en LH niveaus en daardoor 
ook de produktie van oestrogenen. Deze resullaten suggereren dat FSH en 
oestrogenen mogelijk betrokken zijn bij de regulatie van AMH en AMHRII mRNA 
expressie in ovaria van normale ratten. Functies van AMH in het ovarium kunnen 
betrekking hebben op processen zoals follikelselectie en de remming van 
follikelmaturatie. 
Hoofdstuk 6 beschrijft de clone ring van de promotor van het androgeen receptor 
gen. De plaatsen in het DNA van de promotor waar transcriptie kan opstarten zijn 
vastgesteld, en tevens werd het functioneren van de promotor in vitro bepaald. Verder 
is op basis van de DNA base volgorde van de promotor onderzocht, welke gebieden 
betrokken zouden kunnen zijn bij de regulatie van transcriptie van het androgeen 
receptor gen door androgenen en door FSH. 
In de Aigemene Discussie (Hoofdstuk 7) wordt het mogelijke 
werkingsmechanisme van AMH beschreven, op basis van gegevens uit dit proefschrift 
en gegevens uit de literatuur omtrent het moleculaire werkingsmechanisme van andere 
led en van de activine/TGFp familie van groei- en differentiatiefactoren. Verder worden 
de expressiepatronen van AMH, AMHRII en de androgeen receptor in de gonaden 
vergeleken, en besproken in het kader van regulerende interacties tussen AMH, 
gonadotropinen, androgenen en oestrogenen. Er worden enkele suggesties gedaan 
omtrent de mogelijke postnatale functies van AMH. Tot slot wordt de klinische 
relevantie bediscussieerd van AMH en de AMHRII. 
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